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Abstract 
 
 
Objectives: Acquired demyelinating syndromes (ADS) are rare childhood central nervous 
system disorders. In this thesis I aimed to describe the UK incidence, clinical features, MRI 
characteristics and prognostic features of childhood ADS. 
Methods: I describe the first UK population active surveillance and one year follow up study 
which features multiple source ascertainment, MRI review, and blinded clinical expert panel 
diagnostic review. I also describe: 4 longitudinal retrospective case series delineating 
prognostic risk factors; outline the setup of a longitudinal cohort; and describe 
methodological concepts important for the design of the future clinical trials in ADS.  
Results: The incidence of first onset ADS in children aged 1-15 years old was 9.83 per million 
children per year; the highest surveillance rate reported to date. The female-to-male ratio in 
children older than 10 years was 1.52:1. A trend towards higher incidence rates of ADS in 
children of South Asian and Black ethnicity was observed compared with White children. A 
number of MRI characteristics distinguished acute disseminated encephalomyelitis cases 
(1/3 of cohort) from clinically isolated syndrome (CIS) cases (2/3 of cohort). Of CIS cases with 
contrast imaging, 26% fulfilled McDonald 2010 MS diagnostic criteria. Predictive risk factors 
for MS diagnosis included: CIS presentation; presence of periventricular lesions on MRI brain 
scan; and age> 8 years. 
Conclusions: The detailed study of ADS presented in this work will help to inform future 
clinical service delivery and clinical trial design.  
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CHAPTER 1: BACKGROUND  
In this chapter, I will introduce the monophasic and relapsing acquired demyelinating 
syndromes (ADS) and their accepted definitions. I will then describe current knowledge at 
the time of writing on the incidence of ADS, their demographics, and clinical features. I will 
then examine the MRI characteristics and diagnostic criteria of paediatric onset multiple 
sclerosis, the most common relapsing acquired demyelinating syndrome, in relation to adult 
onset multiple sclerosis. I will go on discuss the immunological and investigative features in 
ADS. I will illustrate the current knowledge on the genetic and environmental influences on 
these autoimmune conditions with a focus on multiple sclerosis. I will then consider the 
differential diagnoses, treatments, outcomes, natural history and implications for every day 
functioning after ADS onset. I will conclude by highlighting the need for further studies and 
more detailed investigation of the incidence, clinical features, MRI characteristics and 
prognosis of the acquired demyelinating syndromes. 
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1.1 Introduction 
 
Acquired demyelinating syndromes (ADS) are rare childhood disorders which may result in 
physical and cognitive disability, or ultimately be diagnosed as multiple sclerosis (MS). MS, 
the most common relapsing acquired demyelinating disorder in children and adults, is a 
chronic autoimmune inflammatory demyelinating disease of the central nervous system 
(CNS). MS is characterized by myelin loss, axonal degeneration and, progressive neurological 
dysfunction, that is usually relapsing and remitting in nature. It is often difficult to predict at 
ADS onset as to whether the disease will have a monophasic or relapsing course.  
Multiple sclerosis is a chronic and costly neurodegenerative disease, with onset 
predominantly in young adulthood (late 20s- to late 40’s), and is characterised by usually 
recurrent demyelinating inflammatory attacks to different regions of the central nervous 
system (brain, spinal cord) at different time points. MS is a disease with variable 
presentation and prognosis, and its aetiology is as yet undetermined, with current research 
focussing on gene-environment interactions with the immune system and MS risk (1, 2). 
Incidence of MS appears to be increasing worldwide with a rising female to male sex ratio (2-
4) and with up to 10% of adults who develop MS having first symptoms in childhood (4-7). 
There is evidence that Indian and Pakistani immigrants who entered England younger than 
15 years of age have a higher risk of developing MS than those that entered after this age(1). 
Previous MS studies have shown that adolescent females are over-represented compared to 
males with ratios of up to 3:1 (5-7). Adult MS studies have also shown a consistent increase 
in female MS incidence, compared to males, as well as a higher risk ratio of females 
developing CIS,(8) the first presentation of MS. Adult MS studies have also shown higher 
incidence and prevalence of multiple sclerosis in less deprived populations  (9, 10). 
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Epidemiological evidence suggests early environmental exposures may influence MS risk (1, 
2). Hence any epidemiological change in MS may be evident first in a paediatric population.  
In children, MS is largely relapsing-remitting at onset (in more than 95%), with secondary 
progression and an Expanded Disability Status Score (EDSS) disability score of 6 (requires a 
walking aid- to walk about 100m) occurring at a median of 28 years after disease onset (11). 
Although there are some similarities in terms of disease presentation, especially in 
adolescence, differences are more apparent in younger children who more commonly 
present with an acute disseminated encephalomyelitis (ADEM) which may indeed be 
relapsing (although usually monophasic). In addition, clinical outcomes observed in 
childhood onset and adult onset MS share similarities; however, the severity and course 
differs somewhat between both groups as will be later expanded on.  
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1.2 Definitions of ADS and MS 
 
The International Paediatric MS Study Group (IPMSSG), have published consensus definitions 
(Table 1) of paediatric acquired demyelinating disorders (ADS) and multiple sclerosis (MS) to 
help facilitate uniformity in clinical practice and future research (12).  Encephalopathy 
(behavioural change or altered consciousness) distinguishes polyfocal CIS from ADEM in the 
definitions. 
 
Diagnosis of MS in children, as in adults, is first heralded by onset of a clinically isolated 
syndrome (CIS), or more rarely acute disseminated encephalomyelitis (ADEM). Children 
ultimately diagnosed with relapsing-remitting MS present with an ADS followed by a second 
event usually within two years (12). Childhood CIS presentations with abnormal Magnetic 
Resonance Imaging (MRI) of the brain (i.e. more than one high T2 signal) compared to ADEM 
are much more likely to have relapsing disease (5, 13-21).     
 
Recently, the new MRI McDonald 2010 MS criteria have been recommended for use in 
children presenting with a CIS (22), potentially allowing for MS diagnosis at first presentation 
of a CIS (7). There is no biomarker that differentiates between monophasic ADEM, 
monophasic CIS, or MS, hence a combination of clinical, cerebrospinal fluid (CSF) positive 
oligoclonal bands and MRI features is often used (23-25).  MRI differences, in particular 
between ADEM and polyfocal CIS, are also not well recognised (26). The differential 
diagnosis of ADSs is complex and wide, especially so in childhood (27, 28) . MS (defined 
inTable 2) is characterized by relapses of neurological dysfunction and MRI evidence of 
inflammatory white matter lesions. 
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Table 1: Summarised IPMSSG definitions (12) for CNS Inflammatory Demyelinating Disease (2007)  
 
 
 
Condition Definition 
Acute 
Disseminated 
Encephalo-
myelitis 
(ADEM)  
A polysymptomatic clinical event with acute/subacute onset that must include encephalopathy (behavioural change or 
altered consciousness). (2) MRI Brain shows multifocal (usually diffuse bilateral lesions), predominantly involving white 
matter. 
 
• Relapsing ADEM: symptoms or signs within 3 months of initial onset of ADEM. 
IF a new event occurs ≥3 months later and ≥1 month after completing steroid treatment, it is defined as: 
• Recurrent ADEM: recurrence of initial symptoms without involvement of new clinical areas. 
• Multiphasic ADEM: New event, but involving new anatomical areas of the CNS. 
 
Clinically Isolated 
Syndrome 
(CIS)  
A first acute-clinical episode of CNS symptoms which may either be monofocal or multifocal, but does not include 
encephalopathy (except in brainstem syndromes). The MRI will show area of white matter demyelination. These include: 
Transverse myelitis: weakness and/or numbness of both legs +/- arms, usually with maximal deficits 1 week after symptom 
onset supported by demyelination on MRI spine. 
Brainstem, cerebellar, and/or hemispheric dysfunction, supported by demyelination on MRI. 
 
Optic Neuritis 
(ON) 
Acute or subacute loss of vision and ≥1 of: relative afferent pupillary defect (unilateral cases), visual field deficit or scotoma, 
impaired colour vision, optic disc oedema, or abnormal visual evoked potentials. MRI is not necessary for diagnosis. 
 
Neuro-myelitis 
Optica (NMO)  
Must have: i. Optic neuritis and ii. Acute myelitis iii.  
Must have: Spinal MRI lesion extends over three or more segments OR iv. NMO antibody testing is positive. 
The brain MRI must not meet Multiple Sclerosis diagnosis criteria 
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Table 2: IPMSSG Multiple Sclerosis definition 
Multiple 
Sclerosis 
(MS)  
 
- Two or more non ADEM episodes of CNS demyelination separated in time (4 
weeks) and space. For children aged >12 years:  
 
- Dissemination in space can be met if: MRI shows three of: 1) ≥ 9 white matter 
lesions or 1 gadolinium enhancing lesion, 2) ≥3  periventricular lesions, 3) One 
juxtacortical lesion, 4) an infratentorial lesion. 
  
OR abnormal CSF (oligoclonal bands or elevated IgG index) with 2 lesions on the 
MRI (one in the brain). 
 
- Dissemination in time can be met if: MRI shows new T2 or gadolinium 
enhancing lesions developing ≥3 months after initial event. 
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1.3 Incidence 
 
Introduction 
Ideally an epidemiological study in children should: ascertain children at first onset of ADS; 
be a large prospective surveillance and population based study;  have multi-source active 
case ascertainment (29); consider and if possible estimate the impact of missed cases; report 
clinical, demographic, and investigative features; have independent review  of MRI;  have 
expert panel case review;  and utilise internationally accepted definitions (30). To date, there 
are no studies in children of first onset ADS or MS which fulfil all these criteria.  
It cannot be assumed that the risk of relapse in children and hence the risk of developing MS 
is the same as in adults, and MS risk may be geographically different in children (6). There is 
hence an urgent need for prospective population based studies to further understand 
clinical, radiological, and pathobiological features as well as outcome of childhood onset 
acquired demyelinating syndromes. 
 
A diagnosis of paediatric MS is currently based on consensus definitions by the International 
Paediatric MS Study Group (IPMSSG) (12). Current information on incidence is derived from 
a few studies in Europe and North America. As reported in studies of MS in adults, 
prevalence of paediatric MS seems to differ amongst countries, with a higher incidence 
reported in Northern Europe and Canada, lower in southern Europe and very low in African 
countries with relatively few cases reported from Japan, China or India. It is unclear whether 
this represents a true geographic bias, or whether the disease is under-recognized or under-
reported in some areas. Two previous epidemiological surveillance studies using a single 
surveillance system with no MRI or post reporting verification of diagnosis by expert panel 
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revealed an incidence of ADS ranging from 3.7 (31) to 9.0 per million children per year (32). 
Furthermore, both studies predated the aforementioned consensus definitions(12).  
 
At least 20% of children presenting with an ADS will display accepted diagnostic criteria of 
MS after 2 years of follow-up, suggesting an incidence of 1.8 per million children with MS. In 
the U.S.A a study using a large California-based database reports an incidence of ADS as 1.66 
per 100,000 children per year and the incidence of paediatric MS as 0.51/100,000 (33). The 
median age at onset of paediatric MS in different cohorts is 11 to 12 years, with 20 to 30% 
being younger than 10 years, the youngest patients being less than two years. 
 
A systematic review of the epidemiology of adult onset MS in England & Wales (34) have 
given a range of prevalence estimates, with average estimated at about 110 patients per 
100,000 population across the adult age range. There is good international evidence of 
geographical variation in prevalence, best described by increasing prevalence with latitude 
(both north and south of the equator). This is not seen however within the data on MS in 
adults for England and Wales, which may be due to other causes of variation masking any 
trend in the limited data.  
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Literature search strategy 
I searched the medical literature for estimates of the incidence of acquired demyelinating 
syndromes. I searched PubMed (Table 3) for articles published between 1st January 1980, 
and 1st December 2011. The search terms for the childhood central nervous system acquired 
demyelinating disorders were “incidence or epidemiology” and “childhood or paediatric or 
pediatric or children” and “demyelination or demyelinating or acute disseminated 
encephalomyelitis or transverse myelitis or optic neuritis or neuromyelitis or multiple 
sclerosis.” Only original reports reporting the incidence of any or all of the ADSs were 
included. Review articles were not included, but their references screened for any relevant 
articles. For each study included, I summarised the design, incidence rates and demographic 
characteristics (Table 5).  
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Table 3: Literature search strategy for the incidence of childhood acquired demyelinating 
syndromes  
Literature search date: 26th November 2011; Pubmed 
Keywords used (using The MeSH® Database, www.ncbi.nlm.nih.gov/mesh ): 
Incidence; MeSH heading 
Epidemiology; MeSH heading 
Children; synonym for MeSH heading ”child” 
Paediatric; MeSH heading 
Pediatric; MeSH heading 
Childhood; MeSH text word 
Demyelination; synonym for MeSH heading “demyelinating diseases” 
Demyelinating; MeSH text word 
acute disseminated encephalomyelitis; MeSH heading 
transverse myelitis; MeSH heading 
optic neuritis; MeSH heading 
neuromyelitis; MeSH heading 
multiple sclerosis; MeSH heading 
 
Pubmed Search: ((incidence[Title/Abstract]) OR (epidemiology[Title/Abstract])) AND 
((childhood[Title/Abstract]) OR (children[Title/Abstract]) OR 
(paediatric[Title/Abstract]) OR (pediatric[Title/Abstract])) AND 
((demyelination[Title/Abstract]) OR (demyelinating[Title/Abstract]) OR (acute 
disseminated encephalomyelitis[Title/Abstract]) OR (transverse 
myelitis[Title/Abstract]) OR (optic neuritis[Title/Abstract]) OR 
(neuromyelitis[Title/Abstract])OR (multiple sclerosis[Title/Abstract])) 
 
Limits: Human, 1/1/1990- 25/11/2011 
N=129 (reviews=45) 
Five studies selected 
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Classification of evidence for diagnostic and population screening studies was described 
using terminology (Table 4) adapted from the American Academy of Neurology (AAN) 2011 
Guideline Process Recommendations (www.aan.com/globals/axon/assets/9023.pdf 
accessed 29th March 2012). 
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Table 4: The American Academy of Neurology (AAN) 2011 Guideline Process 
Recommendations 
Criteria for diagnostic studies: 
 
Class I: A cohort study with prospective data collection of a broad spectrum of persons with 
the suspected condition, using an acceptable reference standard for case definition. The 
diagnostic test is objective or performed and interpreted without knowledge of the patient’s 
clinical status. Study results allow calculation of measures of diagnostic accuracy. 
 
Class II: A case control study of a broad spectrum of persons with the condition established by 
an acceptable reference standard compared to a broad spectrum of controls or a cohort study 
where a broad spectrum of persons with the suspected condition where the data was 
collected retrospectively. The diagnostic test is objective or performed and interpreted 
without knowledge of disease status. Study results allow calculation of measures of diagnostic 
accuracy. 
 
Class III: A case control study or cohort study where either persons with the condition or 
controls are of a narrow spectrum. The condition is established by an acceptable reference 
standard. The reference standard and diagnostic test are objective or performed and 
interpreted by different observers. Study results allow calculation of measures of diagnostic 
accuracy. 
 
Class IV: Studies not meeting Class I, II or III criteria including consensus, expert opinion or a 
case report. 
 
Criteria for population Screening: 
 
Class I 
-  Study of a cohort of patients at risk for the outcome from a defined geographic area (i.e., 
population based) 
-  The outcome is objective 
-  Also required: 
a. Inclusion criteria defined 
b. At least 80% of patients undergo the screening of interest  
 
Class II 
-  A non–population-based nonclinical cohort (e.g., mailing list, volunteer panel) or a general 
medical, neurology clinic/centre without a specialized interest in the outcome. Study meets 
criteria a and b (see Class I) 
-  The outcome is objective 
 
Class III 
-  A referral cohort from a centre with a potential specialized interest in the outcome 
 
Class IV 
-  Did not include persons at risk for the outcome 
- Did not statistically sample patients or patients specifically selected for inclusion by outcome 
-  Undefined or unaccepted screening procedure or outcome measure 
-  No measure of frequency or statistical precision calculable 
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Literature search Findings: 
Published studies reporting on the incidence of childhood ADSs (summarised in Table 5) 
included one retrospective analysis of a patient database, a multicentre retrospective study, 
a single centre prospective study, and two prospective population based surveillance 
studies.  The surveillance studies however predated IPMSSG consensus diagnostic definitions 
and did not include independent MRI and expert panel review.  To date, there have been 
two surveillance studies studying ADSs.  A Canadian surveillance study (2004-2007) 
estimated the incidence of childhood ADSs to be 9.0 per million (32), with 22% classified as 
ADEM and 78% as CIS. This study however used a single surveillance system with a card 
return rate of 80%; did not have MRI available or have expert panel review; included 
adolescents up to the age of 18; did not include neuromyelitis optica; and commenced 
before IPMSSG definitions were published.  An earlier surveillance study from Germany 
(1997-1999) estimated the incidence of MS in children <16 years as 3·0 per million children, 
and that of ADEM as only 0.7 per year per million children (31). This study also used only one 
source with ascertainment from paediatric departments; did not have MRI available or 
expert review; and did not include other ADSs.  Diagnosis of MS depends on clinical 
definitions and MRI criteria used. Hence, reliable ascertainment requires expert review and 
up to date clear definitions. 
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Table 5: Summary of studies investigating the incidence of first onset childhood Central Nervous System Inflammatory Demyelinating 
Diseases (ADSs) 
Author 
(Year) 
Study 
period & 
sample 
size 
Study Design 
and setting/ 
AAN evidence 
classification 
Conditions 
Studied 
Incidence 
of ADS 
Demographics i. Surveillance 
unit used/ ii. 
Expert panel 
used 
Sources of 
ascertainment 
IPMSSG 
consensus 
definitions 
used 
Additional
/ other 
criteria or 
definitions 
used  
MRI scan 
review & 
reported 
Methodology 
considering 
impact of 
missed cases 
 
Langer-
Gould 
et 
al(33) 
2011 
 
01/2004 
– 
12/2009; 
n= 81 
 
Retrospective; 
Southern 
California, 
USA (latitudes 
33-34°N). 
 
Class II 
 
ADEM, ON, 
TM, other 
CIS, NMO  
 
15·6 per 
million 
children 
≤18 yrs/ 
year 
 
56·8% female; 
49% Hispanic, 
19% white, 20% 
black; mean age= 
12·6 yrs (range 
0·7-18·0). 
 
i. No 
 
ii. No 
 
electronic 
database 
searches using 
ICD-9 codes, 
Kaiser 
Permanente 
members, 
medical 
records 
review.  
 
Yes 
 
No 
 
No 
 
No 
 
Parvon
e et 
al(35) 
2010 
 
1992 –
2009; 
n=17 
 
Prospective, 
one 
institution; 
Catania, Italy 
(latitudes 37-
38°N). 
Class III 
 
ADEM 
 
11 per 
million 
children 
(<10 
years)/ 
year 
 
 
41·2% female; 
median age= 3·1 
yrs (range 1·5- 8·0 
yrs). 
 
 
 
 
 
 
i. No 
 
ii. No 
 
One paediatric 
neurology 
department 
 
Yes (after 
2007) 
 
No 
 
Yes 
10/17 
 
No 
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AAN= American Academy of Neurology; ADEM = acute disseminated encephalomyelitis; BOSU = British Ophthalmological Surveillance Unit; BSPU= British Paediatric 
Surveillance Unit; ADS; F= female; M= male; MRI= magnetic resonance imaging; MS= multiple sclerosis; NMO = Neuromyelitis optica; ON= optic neuritis; TM= transverse 
myelitis; yrs= years 
 
Author 
(Year) 
 
Study 
period & 
sample 
size 
 
Study Design 
and setting 
 
Conditions 
Studied 
 
Incidence 
of ADS 
 
Demographics 
 
i. Surveillance 
unit used/ ii. 
Expert panel 
used 
 
 
Sources of 
ascertainment 
 
PMSSG 
consensus 
definitions 
used 
 
Additional
/ other 
criteria or 
definitions 
used  
 
MRI scan 
review & 
reported 
 
Methodology 
considering 
impact of 
missed cases 
 
Toriso 
et 
al(36) 
2010 
 
09/1998 
– 
08/2003; 
n=30 
 
Retrospective 
multicentre; 
Fukuoka, 
Japan 
(latitudes 33-
34°N). 
Class II 
 
ADEM, TM 
 
7·4 per 
million 
children 
<15 yrs/ 
year 
 
36·.7% female; 
mean age= 5.8 yrs 
(range 0-15.0). 
 
i. No 
 
ii. No 
 
Five major 
medical 
centres, 
questionnaire 
based. 
 
No 
 
Own 
criteria 
 
Yes 
 
No 
Banwel
l et 
al(32) 
2009 
 
 
 
04/ 2004 
– 
03/2007; 
n=219 
Prospective, 
surveillance; 
Canada 
(latitudes 42-
80°N). 
 
Class I. 
ADEM, ON, 
TM, other 
CIS. 
9·0 per 
million 
children 
<18 yrs/ 
year 
52·1% female; 
mean age= 10·5 
yrs (range 0·66–
18·0 years); sex 
ratio consistent 
when 
evaluated as a 
function of age. 
 
i. One unit 
used (80% 
card return 
rate) 
 
ii. No 
Paediatricians, 
paediatric 
neurologists 
and paediatric 
ophthalmologi
sts 
No  Own 
criteria 
likely to 
not have 
changed 
classificati
on as per 
IPMSSG 
No No 
Pohl et 
al(31) 
2007 
 
 
 
 
01/ 1997 
– 
12/1999;
n= 28 
Prospective, 
surveillance; 
Germany 
(latitudes 47-
55°N). 
Class I 
ADEM 
(n=28), 
MS 
(n=132) 
0.7 per 
million 
ADEM; 3.0 
per mill; 
MS;  <16 
yrs/ year 
42.8% female; 
median age= 6.0 
yrs (range 1-14 
yrs). 
i. One Unit 
used (94% 
card return 
rate) 
 
ii. No 
Paediatric 
departments 
in Germany 
No No No No 
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1.4 Demographic & Clinical features of ADS 
Multiple sclerosis in adults is most commonly a disease of individuals of white ethnicity and 
of Northern European ancestry (37). A recent retrospective study from the USA (Kaiser 
Permanente members, medical records review) showed the incidence of childhood ADSs and 
MS to be higher in black children compared with white and Hispanic children (33). A 
Japanese retrospective multicenter study showed the male to female ratio of ADEM to be 
2.3:1, and that ADEM was three times more common than MS (36). These observations 
regarding the demographics of childhood ADSs support the hypothesis that environmental 
influences (which might include vitamin D) may indeed be acting as early as in childhood. 
The first attack of demyelination is characterized by a constellation of neurological deficits 
(Table 6), occasionally accompanied by systemic features, with acute or subacute onset in a 
previously healthy child. In one large cohort study of childhood ADS, long-tract signs (motor, 
sensory, or sphincter dysfunction) was the most common finding (76%), followed by 
symptoms localised to the brainstem (41%), optic neuritis (22%), and transverse myelitis 
(14%).  Monofocal presentation was more common in adolescents. CISs are more common 
than ADEM in children. CIS is a clinically heterogeneous entity and has a higher incidence of 
subsequent MS diagnosis than ADEM. CIS can be monofocal affecting a localised part of the 
CNS (optic neuritis, transverse myelitis, brainstem syndrome, hemispheric syndrome) or 
multifocal, affecting multiple parts of the CNS but must not include encephalopathy. A high 
index of suspicion for ADS is required in children presenting with neurological deficits, 
encephalopathy, and first onset status epilepticus.  
In this next section I will discuss the demographic, clinical, and neuroimaging features of the 
monophasic and relapsing ADS phenotypes.  
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Table 6: Presenting symptoms and signs in CNS inflammatory demyelination 
 
 Bilateral visual loss (involvement of both eyes within 30 days of each other 
 Unilateral visual loss (one eye only) 
 Double vision 
 Intranuclear ophthalmoplegia 
 Facial pain and numbness 
 Loss of sensation (one side of face) 
 Weakness (one side of face only) 
 Other brainstem signs 
 Loss of sensation (one sided, involving face, arm and leg) 
 Weakness (arm and leg ± face, all on same side of body) 
 Loss of sensation (both legs and/or both arms at the same time) 
 Weakness (both legs and/or both arms) 
 Sphincter disturbance (bladder retention ±  bowel dysfunction) 
 Loss of balance (gait ataxia) 
 Impaired co-ordination of arms/legs (limb ataxia) 
 Confusion or impaired alertness (encephalopathy) 
 Fever 
 Neck stiffness 
 Headache 
 Seizures 
 Vertigo 
 Fatigue 
 L’Hermitte’s symptom (electrical sensation down the back produced by bending the neck 
forward). 
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1.4.1. Acute Disseminated Encephalomyelitis  
 
Acute   disseminated   encephalomyelitis   (ADEM)   is defined as an episode of inflammatory 
central nervous system (CNS) demyelination with acute/subacute onset, polyfocal 
neurological  deficits  accompanied  by  encephalopathy  (behavioural  change  or  altered  
consciousness)(12). There is often a wide variation in the severity of the illness. Occasionally, 
ADEM can present as a subtle disease, with nonspecific irritability, headache and 
somnolence.  However, ADEM can present with a rapid progression of symptoms and signs 
to coma and decerebrate rigidity requiring admission to the Paediatric Intensive Care Unit 
(PICU), and may result in death (18). The recent International definitions (see Table 1) 
emphasises that encephalopathy must be present for the term ‘ADEM’ to be used in a child 
with acute demyelination accompanied by multifocal MRI lesions. In the absence of clear 
evidence of an infectious cause, the MRI findings should define the distribution of the CNS 
demyelinating inflammatory process. Brain MRI changes in ADEM are supportive but not 
diagnostic and often reveal multifocal, diffuse and hyperintense T2 white matter lesions. The 
grey matter (especially basal ganglia and thalamus) is frequently involved, and the spinal 
cord MRI may also show intramedullary lesions (Figure 1). The MRI brain changes in ADEM 
however have not been well characterised and as such further studies are required to better 
understand the MRI changes in ADEM compared to polyfocal clinically isolated syndromes.  
 
ADEM is more common in children than adults, although there are no adult epidemiological 
studies. Available population based incidence data of ADEM in childhood have reported an 
incidence of 0.7–4 per million children/year (31, 32, 38). ADEM occurs more commonly in 
young children less than 10 years of age (equal male: female ratio). ADEM may be preceded 
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by infectious symptoms, although a specific pathogen is rarely implicated.  Meningism, fever, 
and seizures are more commonly seen in ADEM as compared to clinically isolated 
syndromes. Outcome after ADEM is often good with a complete recovery expected in 
approximately 70% within a few weeks. However, ADEM may result in varying levels of 
neurodisability (physical, cognitive, neuropsychiatric) or very rarely death (18, 39).   
 
ADEM is classically described as an acute, monophasic illness. Prospective studies 
internationally are underway to establish more detailed outcome measures in this group of 
patients. New deficits within 3 months of onset are currently considered to be part of the 
same acute episode.  Further  ADEM  episodes  occur  rarely  and happen  in  two  main  
situations:  recurrent  ADEM  and multiphasic  ADEM (Table 1). In up to 20% of patients 
ADEM may also be the first attack of MS. The diagnosis of MS should be considered in cases 
of recurrent demyelination.  
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Figure 1: MRI brain changes in a child with ADEM demonstrating diffuse bilateral white 
matter, cerebellar, basal ganglia lesions and a spinal lesion. 
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1.4.2 Clinically Isolated Syndromes 
A clinically isolated syndrome (CIS) is a first acute-clinical episode of CNS symptoms (Table 6) 
which may either be monofocal or polyfocal (Table 1), but does not include encephalopathy 
(except in brainstem syndromes). The MRI shows areas of inflammatory demyelination 
which may be symptomatic or silent. 
A Clinically Isolated Syndrome is a clinically diverse entity with a higher risk of subsequent 
MS diagnosis than ADEM (5, 40). Clinically Isolated Syndrome have recently been usefully 
classified into 5 different types to aid clarity in phenotypic descriptions (27): 
Type 1 CIS: clinically monofocal, at least one asymptomatic MRI lesion 
Type 2 CIS: clinically multifocal, at least one asymptomatic MRI lesion 
Type 3 CIS: clinically monofocal, MRI may appear normal; no asymptomatic MRI lesions 
Type 4 CIS: clinically multifocal, MRI may appear normal; no asymptomatic MRI lesions 
Type 5 CIS: no clinical presentation to suggest demyelinating disease, but MRI is suggestive.   
Examples of monofocal syndromes include: 
- Transverse myelitis 
- Optic neuritis; unilateral or bilateral. 
- Brainstem, cerebellar, or hemispheric dysfunction. 
In this next segment, I will describe the two most common childhood syndromes, transverse 
myelitis and optic neuritis (subject to a more detailed study and review in Chapter 3.1). 
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Acute Transverse Myelitis 
 
Childhood transverse myelitis (TM) is an inflammatory disorder of the spine (41). It is a 
potentially devastating condition with variable outcome (42). TM has been more commonly 
reported in adults, but occurs in children in approximately 20% of all cases (43). The majority 
of published studies on TM are retrospective case series reviews. Two prospective TM 
surveillance paediatric studies in Canada (32) and UK neurology centres  (44) showed the 
incidence of TM to be 2 per million   and 1.7 per million children respectively. In recent 
literature (2007-2010), there is a trend that male children were more likely to present with 
TM with ratios of 1.04-1.6:1 reported (32, 43-46). There appears to be a bimodal distribution 
with children predominantly affected under 5 years and older than 10 years of age (43, 44). 
In the Canadian and UK population studies, mean ages were 11.0 years (range 0.66–17.35) 
and median 9 years (0.5-15.9) respectively. The adult literature has also reported another 
peak between 30-39 years of age (47). Idiopathic TM represents approximately 14-22% of all 
first CNS Inflammatory Demyelination syndromes (15, 32) and there appears to be no 
seasonal influence, or difference in ethnicity prevalence. 
 
Definitions of TM 
Although reports of TM date back to 1882 (48, 49) there has been a recent effort in 
classifying and defining TM in order to facilitate biomarker discovery and clinical trials. In 
2002 the Transverse Myelitis Consortium Working Group (TMCWG) published criteria for 
idiopathic TM (41). These criteria have to include all of the following: 
1. Development of sensory, motor, or autonomic dysfunction attributable to the spinal 
cord. 
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2. Bilateral signs and/or symptoms (though not necessarily symmetric). 
3. Clearly defined sensory level. 
4. Inflammation within the spinal cord demonstrated by CSF pleocytosis or elevated IgG 
index or gadolinium enhancement.  
5. If none of the inflammatory criteria are met at symptom onset, repeat MRI and lumbar 
puncture evaluation between days 2 and 7 following symptom onset may be used to 
meet criteria. 
6. Progression to nadir between 4 hours and 21 days following the onset of symptoms (if 
patient awakens with symptoms, symptoms must become more pronounced from point 
of awakening). 
7.  (i) Exclusion of extra-axial compressive aetiology by neuroimaging (MRI; CT of spine not 
adequate). 
(ii) Other presentations to be excluded: 
- History of previous radiation to the spine within the last 10 years 
- Clear arterial distribution clinical deficit consistent with thrombosis of the anterior 
spinal artery 
- Abnormal flow voids on the surface of the spinal cord consistent with arterio-venous 
malformation. 
 
In 2007, The International Paediatric MS Study Group (IPMSSG) classified TM as in adult 
literature as a subtype of clinically isolated syndrome (CIS) (12). Since the publication of the 
TM criteria (41), seven paediatric case series (Table 7) have been published with a total of 
190 cases. Five studies are retrospective, and hence subject to confounding factors and 
selection bias to the more severe cases. Two studies were prospective in nature and 
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included ascertainment from neurology centres only (where milder cases may not be seen) 
with relatively short follow up. None of the studies used similar criteria, investigative 
procedures, or outcome measures at the outset. There is hence a need for standardising 
core outcome measurement, and for prospective longitudinal large population based study 
designs. Nevertheless, data derived from these studies are informative and reviewed in the 
subsequent sections. 
 
Clinical Features of TM 
The clinical features of TM depend on the location and extent of the spinal cord lesion. The 
spinal cord dysfunction presents with motor (weakness of the limbs), sensory, and sphincter 
disturbance which may be asymmetric with varied presentation and severity. Clinically, 
neurological signs are caused by interruption of neuroanatomical pathways in the transverse 
plane of the cord, and a resulting sensory level is also characteristic (50). MRI lesions do not 
always result in a corresponding clinical sensory level (45). When myelitis also occurs in the 
context of encephalopathy, and polyfocal neurological symptoms with inflammatory 
demyelinating lesions in the brain, Acute Disseminated Encephalomyelitis (ADEM) is 
diagnosed. The differential diagnosis is wide, and in Figure 2, I devise an algorithm on how to 
approach non-compressive myelopathy presentation.  Table 7 summarises the recent case 
series in children with TM highlighting the cardinal clinical features. Most children reach a 
nadir within the first 1-2 weeks of presentation (most common symptoms being pain, lower 
limb weakness and bladder dysfunction). In the majority of children a sensory level was 
detectable (75-95%). More than half of patients have a thoracic clinical sensory level, and 
the rest have a cervical or lumbosacral level. A ‘plateau’ typically lasts for approximately one 
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week before ongoing recovery begins.  The recovery period may extend to several years 
after the initial insult. Motor deficits tend to recover before bladder dysfunction. 
In adults the American Spinal Injury Association (ASIA) scale of myelopathy, rates patients 
according to severity: 
A = Complete: No motor or sensory function is preserved in the sacral segments S4-S5 
B = Incomplete: Sensory but not motor function is preserved below the neurological level 
and includes the sacral segments S4-S5. 
C = Incomplete: Motor function is preserved below the neurological level, and more than 
half of key muscles below the neurological level have a muscle grade less than 3. 
D = Incomplete: Motor function is preserved below the neurological level, and at least half of 
key muscles below the neurological level have a muscle grade of 3 or more. 
E = Normal: Motor and sensory function are normal. 
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Table 7: Summary of recent largest case series of clinical features for TM in children (43-46, 51-53) 
Ref Alper 2010 DeGoede 2010 Kalra 2009 Yiu 2008 DaJusta 2008 Pidcock 2007 Defresne 2003 
Setting, 
Design & 
Follow up 
USA, Pittsburgh; 
1 centre 
retrospective MRI 
study review; 
 
1985-2008;  
 5.2yrs mean 
follow up 0.04-
13.1) 
UK, 14 regional 
Paediatric 
Neurology centres; 
Prospective 
surveillance ;  
 
2002-2004;  
0.5 yr follow up 
India; prospective 
Case-control 
One centre 
 
2003-2007 
1 yr follow up 
Australia; 
1 centre 
retrospective 
comparison to 
ADEM 
 
1997-2004 
1.0 yr median 
follow up (0.3- 
8.5 yrs) 
USA; New Jersey; 
Retrospective 
review 
 
 
1995-2004 
Mean follow up 
2.3 yrs 
USA, Baltimore; 
1 centre 
retrospective review- 
idiopathic TM; 
 
2000–2004 
3.2 yr median follow 
up  
France; 
retrospective 
review; single 
centre 
 
 
1965–1995 
 6.5 yr median 
follow up (1-20 
yrs) 
Demo-
graphics 
27 cases; 
Mean age 9.5yrs 
yrs (0.5-16.9); 
 
 M:F= 1.07  
41 cases ;  
Median age 9yrs 
(0.5-15.9);   
 
M:F= 1.56 
15 cases; 
Mean age 7.9 yrs 
(3.5-14 yrs). 
 
M: F= 1.5:1. 
22 cases; 
Median age 7.5 
yrs (0.3-15 yrs) 
 
M:F= 1.6:1 
14 cases; 
Mean age 
11.2yrs (0.7-18) 
 
M:F= 1.3:1 
47 cases; 
Mean age 8.3 yrs, 
clustering 0-3, 5-17 
yrs 
M:F = 1.04   
24 cases; 
Mean age=8 (2-14) 
 
 
M:F= 0.85 
TMCWG 
Criteria 
used/ 
exclusions 
Yes ; 14 definite 
TM, and 13 
probable 
 
2 excluded with 
NMO none MS 
No- All probable 
TM except 2: 
vascular 
myelopathy. 
No relapse at 6 
months  
 
 
 
 
 
 
 
 
No- but all 
probable TM; 
Yes 
 
Excluded:  
1NMO, 1 CTD, 1 
radiation myelitis 
Yes Yes 
 
2 had recurrent TM, 1 
NMO, 1 MS, 1 ADEM 
No- but all 
probable TM 
 
None developed 
MS;  
27 
 
Ref Alper 2010 DeGoede 2010 Kalra 2009 Yiu 2008 DaJusta 2008 Pidcock 2007 Defresne 2003 
Clinical 
features 
4 monoparesis, 
20 paraparesis, 3 
tetraparesis 
27 sensory (22 
with level), 34 
motor (15 flaccid 
legs, 13 arms + 
legs involved), 26 
sphincter; 6 
cerebral 
involvement;  
 
1 had ON + TM. 
 
Mean time to 
nadir 3.9 days 
(0.5-14 days).  
2 required 
mechanical 
ventilation. 
Motor improved 
before sphincter. 
At 3 months, 8 
ambulatory (4 
with support) 
weakness limbs- 
lower 100%, 
upper 41% 
 
68% Bladder 
disturbance  
 
55% Sensory  
 
64% Pain 
All lower limb 
motor deficits & 
bladder 
dysfunction 
 
Sensory; 35% 
cervical, 65% 
thoracic 
At nadir (mean 2 
days): 89% couldn’t 
walk ± ventilated; 
85% sphincter 
dysfunction;  
sensory level cervical 
25%, thoracic 53%, 
lumbar 5%, sacral 3% 
(1/36), unclear in 14%  
Nadir of 5 days. 
Pain (88%), motor 
loss (1/2 bilateral, 
lower limbs ± 
upper) preceded 
sphincter 
dysfunction 
(15/24)  
  
12% cervical, 88% 
thoracic. 
 
Treatment n/a 30/36 high dose 
steroids 
All received high 
dose IV steroids 
for 5 days 
21/22 High dose 
IV steroids mean 
5 days 
& tapering oral 
prednisolone 4 
weeks 
All high dose IV 
steroids ± IVIG 
70 % IV steroids 
33%, IVIG 
15% PLEX 
 
High dose 
steroids, 6 not 
received 
treatment 
Outcome/ 
disability 
n/a 80% started 
recovery<2 weeks; 
19 complete /8 
good/ 3 fair /6 
poor*; 17 had 
continuing bladder 
problems  
8 full recovery, 3 
non-ambulatory, 
7 Bladder 
disturbances.  
 
*1 deaths 
61%  complete 
/21%  good/ 6% 
fair /6% poor1 
 
Bladder 
dysfunction (14% 
moderate/ 
severe) 
4/14 full motor & 
bladder recovery  
 
4/14 non-
ambulant bound 
& Intermittent 
catheterisation 
(cervical levels) 
At median 3.2 yrs: 
43% were unable to 
walk 30 feet and 21% 
required a walker or 
other support,  
50% required bladder 
catheterisation 
 
*2 deaths 
2/16 (13%) 
children had 
severe motor 
sequelae 
 
5/15 had severe 
sphincter 
dysfunction 
 
*1 death 
*: Normal= complete recovery; good= insignificant sequelae; fair= sequelae but not interfering with daily life; poor= sequelae interfering with daily life. 
TM= acute transverse myelitis ADEM= Acute Disseminated Encephalomyelitis; CTD= connective tissue disease; IV= steroids; IVIG= Intravenous 
immunoglobulin; M: F= male to female; MS= multiple sclerosis; NMO= Neuromyelitis Optica; ON= optic neuritis; PLEX= plasmapharesis; yr= year 
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Figure 2: Algorithm for non-compressive transverse myelopathy (non trauma/ tumour) 
 
  
                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- Compressive myelopathy (e.g. 
tumour, haematoma): 
Appropriate management (see 
chapters XX) 
Serologic or clinical evidence of 
systemic inflammatory/ 
connective tissue disease: 
SLE, 
 sarcoidosis, 
 Behcet’s disease, 
 Sjogren’s syndrome, 
 mixed connective tissue disorder 
 
CNS manifestations of 
infection:  
Mycoplasma pneumonia,  
Lyme disease,  
Tuberculosis 
viral infection (e.g. HTLV-1; 
HIV; HSV; enteroviruses; 
VZV; EBV; CMV; HHV). 
 
 
CNS Inflammatory 
Demyelination: 
- Brain MRI abnormalities 
meeting MS diagnostic criteria 
for dissemination in space 
- Presentation (polyfocal 
neurological deficits and 
encephalopathy) and MRI 
findings consistent with 
ADEM. 
- Criteria for NMO diagnosis 
met  
 
Non Inflammatory causes: 
- Spinal cord ischaemia/ vascular 
- Radiation myelitis 
- Neurodegenerative disorders 
(e.g. X linked adrenoleukodystrophy, 
Krabbe disease, HSP) 
- Metabolic/nutritional deficiencies  
(e.g. Arginase, Vitamin B12, Folate, 
Copper, biotidinase, and 
abetalipoproteinaemia and Vitamin E 
deficiencies) 
 
Idiopathic Acute 
Transverse 
Myelitis 
(TMCWG criteria) 
 
 
CMV: cytomegalovirus; CNS: Central Nervous System; EBV: Epstein–Barr virus; HIV: human immunodeficiency virus; HSV: herpes simplex virus; HHV: HSP; Hereditary spastic 
paraplegias; human herpes virus; HTLV-1: human T-cell lymphotropic virus-1; IgG: Immunoglobulin G; MRI: Magnetic Resonance Imaging; NMO: neuromyelitis optica; SLE: 
Systemic lupus erythematosus; TMCWG: Transverse Myelitis Consortium Working Group; VZV: varicella zoster virus;  
- MRI spine and brain with Gadolinium contrast 
- Non- compressive myelopathy: 
Lumbar puncture for CSF pleocytosis or 
raised IgG index 
- Confirm myelopathy; symptoms, signs, and time course 
- Elicit on history and examination features suggestive of: infection; systemic inflammatory disease; CNS 
inflammatory demyelination; vascular/ischemia; trauma; exposure to radiation; tumour 
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Optic Neuritis 
Childhood optic neuritis (ON) due to demyelination is one of the most common CIS events in 
children, and is a potentially treatable condition that may lead to visual impairment. Optic 
neuritis is clinically defined as: Acute or subacute loss of vision and ≥1 of: relative afferent 
pupillary defect (unilateral cases), visual field deficit or scotoma, impaired colour vision, 
optic disc oedema, or abnormal visual evoked potentials. MRI is not necessary for diagnosis 
(see Table 1). 
A recent Canadian surveillance study showed an incidence of 0.2 per 100,000 children (32). 
However, incidence rates are likely to be geographically different and more studies are 
needed. Isolated ON may also be the first manifestation of Multiple Sclerosis (MS) or 
Neuromyelitis Optica (NMO). The natural history of childhood optic neuritis (ON) remains 
relatively unreported. Case series reported in the literature have tended to be single centre 
studies, not included NMO as an outcome and some have included cases of 
polysymptomatic clinically isolated syndromes (CIS) at presentation (54-59).  
Bilateral  optic  neuritis  is  more  common  in children  than  adults  (approximately  half  of  
childhood optic neuritis is bilateral). Despite severe acute visual loss, approximately 70-80% 
of children will recover visual acuity (snellen of 6/9 or better). Both unilateral and bilateral 
optic neuritis can be the first manifestations of MS or Neuromyelitis Optica. In recent studies 
of children with optic neuritis , 20-45% experienced further demyelinating attacks leading to 
a diagnosis of MS after follow-up periods of approximately two years. Recurrent optic 
neuritis and the presence of  MRI  brain  lesions  extrinsic  to  the  optic  nerves has been  
associated  with  an  increased  likelihood  of  MS after ON onset. 
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1.4.3 Neuromyelitis Optica (NMO) 
 
Neuromyelitis Optica (NMO) is a severe immune mediated inflammatory demyelinating 
condition characterised by the presence of both optic neuritis and transverse myelitis 
occurring simultaneously or separated in time and distinct from multiple sclerosis. 
Neuromyelitis optica (NMO) is also characterised by the presence of the NMO-IgG antibody 
directed against the astrocytic water channel protein Aquaporin-4 (60); and this discovery 
has broadened the disease spectrum. NMO-IgG appears to be a specific test as it is invariably 
negative in paediatric MS (61, 62). NMO may initially present as an isolated optic neuritis 
(with abnormal visual evoked potentials) in adults (63) and also in childhood  (64) or as TM 
before further relapses reveal the underlying diagnosis (63). It can be a monophasic illness 
but is usually a relapsing remitting disorder in the paediatric population. NMO is a very rare 
disorder comprising 3-8% of the childhood Acquired demyelinating syndromes (61). LETM is 
a feature of NMO but can also occur in monophasic TM and paediatric multiple sclerosis (43, 
61, 65). 
In 2007, The International Paediatric MS Study Group (IPMSSG) defined NMO as having all of 
the following criteria: 
1- Optic neuritis and acute myelitis. 
2- Either a spinal MRI lesion extending over three or more segments or be NMO positive on 
antibody testing. 
Two recent adult diagnostic criteria were developed on the basis of the most recent clinical, 
MRI and AQP4 antibody results:  
A. Revised diagnostic criteria (66); two absolute criteria: 
(i) optic neuritis, (ii) myelitis.  
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And at least two of three supportive criteria: 
(i) Spinal cord MRI lesion extending >2 vertebral segments, 
(ii) MRI criteria not satisfying the revised McDonald diagnostic criteria (67) for MS, 
(iii) AQP4 antibody in serum. 
 
B. The National MS Society task force on differential diagnosis of MS, (27); major criteria (all 
are required, but may be separated by an unspecified interval): 
(i) Optic neuritis in one or two eyes 
(ii) Transverse myelitis, clinically complete or incomplete, but associated with MRI evidence 
of spinal cord lesion extending >2 spinal segments on T2-weighted MRI images and 
hypointensities on T1-weighted images when obtained during acute episode of myelitis, and 
(iii) no evidence for sarcoidosis, vasculitis, clinically manifest systemic lupus erythematosus 
(SLE) or Sjogrens syndrome (SS), or other explanation of the syndrome. 
 
Minor criteria, from which at least one must be fulfilled: 
1. Most recent brain MRI scan of the head must be normal or may show abnormalities not 
fulfilling the Barkhof criteria used for McDonald diagnostic criteria including: 
(i) Non-specific brain T2-signal abnormalities not satisfying the Barkhof criteria for 
dissemination in space used in the revised McDonald criteria, 
(ii) lesions in the dorsal medulla, either in contiguity or not in contiguity with a spinal cord 
lesion, 
(iii) hypothalamic and/or brainstem lesions, 
(iv) linear periventricular/corpus callosum signal abnormality, but not ovoid, not extending 
into the parenchyma of the cerebral hemispheres in Dawson finger configuration. 
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2. Positive test in serum or CSF for NMO-IgG/aquaporin-4 antibodies 
 
Table 8 summarises the clinical features in the three recent case series of paediatric NMO 
using diagnostic criteria. Although the current diagnostic criteria are as recommended by the 
IPMSSG, it is likely that modifications need to be considered with evolution of new evolving 
MRI criteria such as in Miller et al., 2008. Further prospective studies are needed to clarify 
the spectrum of these diseases. 
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 Table 8: Summary of recently described paediatric NMO case series (61, 68, 69)  
Ref Setting, Design & 
Criteria Used 
Demo-
graphics 
NMO-IgG & CSF OGB First attack & course/  
Time to first relapse/ 
Annualised relapse 
rate (ARR) 
 
MRI Brain  
features 
Disease Modifying 
Treatment 
Outcome/ 
disability 
Collongues 
2010 
Multicentre (mainly 
adult); retrospective;  
France; 
Follow up mean 19.3 
yrs; 
Wingerchuk  2006 
criteria 
12 cases 
 
Age: 14.5 
yrs median 
(4.1-17.9) 
3F:1M 
8/12 NMO-IgG 
positive 
First attack: 
6ON/5SC/1OS 
All relapsing-
remitting; 
 
first attack interval 17 
months (7–154) 
6/12 MRI brain 
abnormal (1-10 
lesions) 
 
3 MS 
radiological 
criteria positive 
(2MS/1ADEM) 0 
Barkhof 
All treatments used: 
Azathioprine; 
cyclophosphamide; 
glatiramer acetate; 
IVIG; interferon; 
mitoxantrone; MMF; 
rituximab 
Median time to EDSS 4= 20.7 
yrs 
 
Vision: residual visual loss  +1  
logMAR or 20/200 
Snellen=1.3 yrs. 
Lotze 
2008 
Retrospective single 
centre; USA;  
Follow up 4 yrs 
median (0.6-9); 
Wingerchuk  2006 
criteria 
9 cases 
 
Age: 14yrs 
median 
(1.9-16);  
All female  
6/9 NMO-IgG  positive 
(1 had recurrent TM 
only) 
First attack: 5 
OS/1TM/2ON 
 
All relapsing 
 
ARR=2.6 
 
9/9 MRI brain 
abnormal (5 
symptomatic) 
All treatments used: 
6 steroids + MMF  
5 rituximab  
1 monthly IVIG  
1had  azathioprine, 
glatiramer, and 
monthly PLEX.  
Median EDSS=3 (range 0-8) 
Banwell 
2008 
Selected prospective 
cohort; Canada & 
Argentina; 
Follow up 36 months 
median (1.2-126 
months); 
Wingerchuk  1999 
17 cases 
 
Age: 10.4 
yrs median 
(4.4–15.2) 
3.2F:1M 
 8/17 NMO-IgG 
positive  
 
13 CSG OGB negative 
 
(1 recurrent ON, and 
1 recurrent TM NMO-
IgG positive; 68 other 
CNS inflammatory 
demyelination were 
negative) 
9 relapsing (NMO-IgG 
pos)  
 
8 monophasic (NMO-
IgG pos)  
 
 
9/17 MRI brain 
abnormal 
At time of serum: 
7 prednisone,  
1 glatiramer acetate, 
1 interferon-1a, 
2 monthly IV 
cyclophosphamide 
 
1 non-ambulant, 1 gait 
limited aid not required; 
 
Vision: 12/18 decreased 
visual acuity or severe visual 
impairment (4/18) 
ADEM= Acute Disseminated Encephalomyelitis; ARR= annualised relapse rate; EDSS= Expanded Disability Status Scale; IVIG= intravenous immunoglobulin; MMF= mycophenolate 
mofetil; MRI= Magnetic Resonance Imaging; MS= Multiple Sclerosis; NMO-IgG= Neuromyelitis Optica antibodies; ON= Optic Neuritis; OS= Optico-spinal; PLEX= plasmapharesis; SC= 
Spinal Cord; yrs= Years 
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Paediatric NMO-spectrum disorders 
Cases which are NMO-IgG positive but not fulfilling current criteria have been described as 
NMO spectrum disorders in the literature, and the spectrum of these disorders is expanding 
both in adults and also in childhood (70).  
The largest series on paediatric NMO spectrum disorders involved a cross-sectional study 
from one lab (USA), where 88 consecutive NMO-IgG seropositive paediatric patients were 
ascertained and followed up for a median of one year (71). Clinical information was available 
for 58 (66%) children with 88% being girls and nearly three-quarters non-white, hence 
highlighting the female predominance and ethnic variation. The median age at symptom 
onset was 12 years (range 4–18). Presenting symptoms involved the brain in 9 patients 
(16%). Median duration between attacks was 3 months (range 1– 87 months). All but one 
(98%) had at least one attack of optic neuritis (78%) or transverse myelitis (78%). Other 
attack-related symptoms involved the brain or brainstem in 26 patients (45%). Thirty-eight 
(66%) cases fulfilled NMO diagnostic criteria (66) at follow up. The median longitudinal 
extent of attack-related spinal cord MRI abnormalities was 10 vertebral segments. Thirty-
eight (68%) had brain MRI abnormalities, predominantly involving periventricular areas and 
(in descending order of frequency) -the medulla, supratentorial and infratentorial white 
matter, midbrain, cerebellum, thalamus, and hypothalamus. Surprisingly, additional 
autoantibodies were detected in 57/75 patients (76%), and 16/ 38 (42%) had a coexisting 
autoimmune disorder recorded (SLE, Sjogren syndrome, juvenile rheumatoid arthritis, 
Graves disease). Although this study provides useful information, conclusions cannot be 
universally extrapolated given the many limitations including that the lack of information on 
a third of patients (possibly because of a milder course), the relatively short follow up 
period, and the referral centre-based retrospective lab ascertainment. 
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MRI brain abnormalities in NMO 
In children in particular the presence of brain lesions should not exclude NMO as a diagnosis 
as lesion located in the hypothalamus, brainstem, or cerebral white matter, have been 
described in children who have typical features of NMO (as defined in Wingerchuk et al., 
2006) (Figure 3). Brain lesions in paediatric NMO hence appear to occur more commonly 
(50-100%) when compared with adult NMO (25%) (63).  A recent case series (69) showed 
that the first brain MRI in paediatric NMO (as defined in Wingerchuk et al., 2006) can show a 
diffuse inflammatory process, such as MS-like (2 patients) or acute disseminated 
encephalomyelitis-like lesions (1 patient). Brain lesions in another series (68) also confirm 
this observation and demonstrated that MRI brain changes in paediatric NMO frequently 
involve the diencephalon. In another series (61) 9/17 children with NMO (Wingerchuk et al., 
2006) had brain lesions. It is important to recognise the spectrum of brain abnormalities in 
NMO as the occurrence of such lesions and sometimes the presence of encephalopathy and 
polyfocal neurological deficits may resemble ADEM, with misleading implications as to 
prognosis and therapy. 
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Figure 3: MRI brain FLAIR sequences in a five year old child with relapsing NMO showing 
from left to right multiple large, diffuse juxtacortical and deep white matter lesions. There is 
also a left internal capsule lesion with restricted diffusion. This relapse was characterised by 
acute onset encephalopathy and right sided hemiplegia. The case was treated with plasma 
exchange and on recovery was ambulatory with mild residual motor deficits.   The patient 
has severe visual impairment from previous attacks of optic neuritis with onset at 3 years of 
age and persistently high NMO-IgG levels. 
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1.4.4 Multiple sclerosis: children compared to adults 
Multiple sclerosis (MS) is a disabling and chronic neurodegenerative central nervous system 
inflammatory demyelinating disease (ADS), affecting cognition, motor abilities, and quality of 
life. It is characterized by progressive neurological dysfunction and multiple symptoms, 
which are difficult to manage(72). Diagnosis of MS in children, as in adults(40), is first 
heralded by onset of a clinically isolated syndrome (CIS) such as optic neuritis, or more rarely 
acute disseminated encephalomyelitis (ADEM) (13, 15, 20, 21, 23). Recently, the new MRI 
McDonald 2010 MS criteria have been recommended for use in children presenting with a 
CIS(22), potentially allowing for MS diagnosis at first presentation of a CIS(7). There is as yet 
no biomarker that accurately differentiates between ADEM, monophasic CIS, or MS (23, 25).   
 
Clinical Presentation of MS in children compared to adults 
The International Paediatric Multiple Sclerosis Study Group (IPMSSG) have published 
consensus definitions for paediatric acquired demyelinating disorders (ADS[s]) and MS to 
facilitate uniformity in clinical practice and epidemiological research (12). This definition 
states that children ultimately diagnosed with relapsing-remitting MS present with an ADS 
followed by a second event usually within two years (12). Childhood CIS presentations with 
an abnormal Magnetic Resonance Imaging (MRI) of the brain (i.e. more than one high T2 
signal) compared to ADEM are much more likely to have relapsing disease (13, 15, 20, 21, 
23). Recently, the new MRI McDonald 2010 MS criteria have been recommended for use in 
children presenting with a CIS (22), hence potentially allowing for MS diagnosis at first 
presentation of a CIS (7). There is no biomarker that differentiates between monophasic 
ADEM, monophasic CIS, or MS, hence a combination of clinical, cerebrospinal fluid (CSF) 
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positive oligoclonal bands and MRI features is suggested to support clinician decision making 
(23, 25).   
There is general consensus that MS in adolescents is probably similar to that in adults both in 
terms of both underlying pathophysiology and evolution. The slower onset of progression to 
irreversible disability in younger patients compared to older adults may be attributable to 
the fact that onset of the disease is closer to the true biological onset compared to adult 
onset disease who may indeed have an apparently clinically silent phase with brain white 
matter lesions. It is likely that the biological processes are hence indeed the same but with 
variation in the initial clinical phase (symptomatic vs silent) of the disease hence suggesting a 
continuum (73, 74). There are most likely more differences between MS in younger children 
and adults. In a study analysing cerebrospinal fluid response in children with very early onset 
MS (n =4-; mean age= 7.2 years ± 2.7) compared to later onset (mean 15.1 years ± 1.7 years)- 
fewer patients had an elevated IgG index suggesting a more immature immune response. In 
an MRI brain study by the same group 13 children with early onset MS (median age 8.9 
years) compared to 18 with late onset MS (median age 14.47 years, range [11.78-18.00], 
61% girls) had: fewer well-defined ovoid T2-bright lesions; and more often had confluent 
lesions on their first MRI (also 92% vs 29% had a reduction in the number of T2-bright lesions 
on a subsequent scan). These observations add weight to the fact that younger patients with 
ADS and MS may have differences with regards biological processes and clinical progression 
(75, 76).  
 
Difficulty occurs in children compared to adults, as the first onset of an inflammatory 
demyelinating event may be an acute disseminated encephalomyelitis in approximately 1/3 
of patients. In adults, ADEM is a very rare presentation. ADEM is likely to have a monophasic 
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course, compared to CIS presentations with abnormal MRI scans. Studies in both children 
and adult have shown that it often difficult to distinguish between ADEM, polyfocal CIS and 
MS (25, 77-79). ADEM, polyfocal CIS and MS MRI changes often overlap, and children with 
MS have been reported to present with encephalopathy. In addition the term 
encephalopathy is loosely defined and often difficult to apply consistently amongst cohorts 
(20). In Chapter 2.5 I describe a study which describes the MRI differences between ADEM 
and CIS with abnormal MRI scans. 
 
The majority of childhood MS has a relapsing remitting onset at initial progress (more than 
95%), whilst approximately 15% of adult onset MS has been described as primary 
progressive (Figure 4) at onset (5, 37). 
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Figure 4: Usually course of multiple sclerosis in childhood 
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MS Relapse rates 
Studies following children within the first 2-5 years of disease onset have shown a higher 
frequency of clinical relapses (80) (annualized relapse rate [ARR] 0.9-1.1) (Table 9) compared 
to adults, as opposed to those with longer follow-up times (ARR 0.5-1). In adults, relapse 
frequency in the first two years after onset appears to have some association with long term 
outcome and disability (81). Despite this adult participants in the trials of interferon and 
glatiramer acetate and the recent new oral drug therapies, already had disease duration of 
several years. There have been no paediatric studies as yet examining early relapse rates and 
correlation with longer term neurodisability outcome. 
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Table 9: Annualized relapse rates (ARR) in paediatric MS (not including first attack) 
Study Study 
duration 
Study type Sample 
Size 
ARR 
(82) Ghezzi 
2002 
First 2 years Prospective cohort 5 
centres 
n=54 1.3 
(11)   Renoux  
2007 
First 2 years Data from database 
registry from 13 adult 
centres 
n=394 1.9 
(80) Gorman 
2009 
First 3.7 years  Single centre; 
prospective follow up 
n=21 1.1 
(82) Ghezzi 
2002 
First 5 years Prospective cohort 5 
centres 
n=54 1.0 
(83) Boiko A 
2002 
16.3 years  Single centre 
database registry 
n=116 0.54 
(84) Deryck 
2006 
28.7 years Single centre 
retrospective study 
N=49 0.47 
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Diagnosis of paediatric MS compared to adult MS 
The diagnosis of paediatric MS, like adult MS, has relied on clinical and supportive MRI 
criteria showing lesion dissemination in time (DIT) and dissemination in space (DIS), after 
exclusion of alternative causes. Adult MRI criteria, since their first introduction (McDonald 
2001) have continually continued to be redefined with the introduction of the McDonald 
2005 and 2010 criteria. For the first time, the McDonald 2010 criteria have included children 
(only presenting with CIS, not ADEM). 
 
History of the development of McDonald magnetic resonance imaging (MRI) criteria in 
adults 
In 1997, Barkhof et al (85) developed a model consisting of 4 MRI parameters (sample size, 
n= 74 patients) — the presence of ≥1 gadolinium-enhancing, ≥1 juxtacortical, ≥1 
infratentorial, and  ≥3 periventricular lesions. In 1999, Tintore et al (86) adapted these 
criteria by allowing the gadolinium enhancing lesion to be replaced by 9 T2 lesions and 
introduced the model of having at least 3 of the 4 Barkhof parameters to achieve a higher 
diagnostic accuracy and an improved balance between sensitivity and specificity for 
predicting conversion from CIS to clinically definite MS (CDMS). 
 
In 2001, the 2001 McDonald et al (87) diagnostic criteria were published (Table 10).  The MRI 
criteria chosen by an expert panel approved the models developed by Barkhof et al. and 
Tintore et al. with some modifications and additions. The 2001 McDonald criteria were 
retrospectively evaluated in CIS adult cohorts showing high specificity (83-86%) for clinically 
definite MS (CDMS) (88, 89) but limited sensitivity (49%)(90). In 2005, the McDonald DIS and 
DIT criteria(67) were then revised (Table 10). The 2005 McDonald criteria were compared to 
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the 2001 criteria in adults and showed an improvement of sensitivity (60% vs 47%) while 
retaining a good specificity (88% vs 91%) (91). In 2010, The European Magnetic Imaging in 
MS (MAGNIMS) multicenter research network (92) compared the McDonald 2005 DIS 
criteria with simplified criteria developed by Swanton et al (91). In the Swanton model, DIS 
can be met with at least 1 T2 lesion in at least 2 of 4 locations (juxtacortical, periventricular,   
infratentorial,   and   spinal   cord),   with lesions   within   the   symptomatic   region   
excluded   in patients with brainstem or spinal cord syndromes. In 282 CIS patients, the 
Swanton-based DIS criteria were slightly more sensitive than the original McDonald Criteria 
for DIS, without sacrificing specificity and accuracy (91). For DIT, it was shown that disposing 
of the requirement for an extra reference MRI after 1 month did not compromise specificity 
(93). In addition, MAGNIMS  group  (92) showed that in CIS patients, a single brain MRI study 
that demonstrates DIS and both asymptomatic gadolinium-enhancing and non-enhancing  
lesions  is  highly  specific  for  predicting  early development of clinically CDMS and reliably  
substitutes  for  prior  imaging  criteria  for  DIT (92, 94).  Importantly, the revised criteria 
allow for MRI diagnosis of MS on a first gadolinium enhanced scan. 
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Table 10: McDonald MRI criteria adults 
 McDonald 2001 (87) McDonald 2005 (67) McDonald 2010 (22) 
DIS 3 or more of (a-d): 
a. ≥9 T2 lesions or 1 Gadolinium enhancing 
b. ≥3 periventricular lesion(s)   
c. ≥1 juxtacortical lesion(s) 
2 or more of: 
≥1 periventricular 
≥1 juxtacortical 
≥1 infratentorial§ 
≥ 1 spinal cord§ d. ≥ 1 infrantentorial 
brain lesion(s)* 
d. ≥ 1 infrantentorial 
brain lesion(s) OR ≥1 
spinal cord lesion(s)* 
OR the presence of 2 or more T2 lesions plus CSF 
oligoclonal bands 
DIT 1 Gadolinium  enhancing lesion at least 3 months 
after CIS onset OR A new T2 lesion with reference 
to a prior scan obtained: 
>1 new lesion when compared 
to a previous scan (irrespective 
of timing).  
 
>3 months after CIS 
onset 
>1 month after CIS onset Or presence of asymptomatic 
enhancing lesion and a non-
enhancing T2 bright lesion on 
any one scan  
DIS= dissemination in space; DIT=dissemination in time. 
*In McDonald 2001 1 cord lesion can replace 1 brain lesion; In McDonald 2005 any number 
of cord lesions can be included in total lesion count; AND spinal lesions equivalent to 
infratentorial lesions.  
§ All lesions in symptomatic regions excluded in Brainstem and spinal cord syndromes. 
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History of the development of childhood MRI multiple sclerosis criteria 
Different combinations of MRI characteristics have been proposed to aid in establishing the 
diagnosis of paediatric MS or to assess the risk of relapse after an initial event (Table 11 and 
Table 12). These MRI criteria were dissimilar to those used in adults, reflecting the 
differences in presentation of ADS and MS in children, and were developed for somewhat 
different purposes (95) and in different populations.  The Kids With Multiple Sclerosis 
(KIDMUS) criteria (77), and criteria from a prospective Canadian cohort (96) aim to 
differentiate monophasic from relapsing disease at the time of the first clinical presentation 
of CNS demyelination from the baseline MRI (77, 85, 96). The Callen MS-ADEM criteria were 
developed to distinguish ADEM from MS (25). The Callen paediatric MS criteria were 
developed to distinguish MS from other neurological disorders, such as migraine, but 
excluding ADEM (97). Dissemination in time criteria have not been developed for children 
until the incorporation of the McDonald 2010 criteria. 
Compared to adults, children with MS appear to have an increased T2 lesion load on MRI at 
disease onset (24, 98). The information obtained through cohort based natural history 
studies, suggests a higher level of inflammation in children (Figure 5). Data obtained through 
controlled trials might however be different than that through natural history control studies 
or registries, as there one may expect recruiting individuals with fewer less relapses and 
lower MRI T2 lesion. 
  
Currently, conventional MRI is not a useful surrogate outcome marker for disease relapse or 
disability. Advanced neuroimaging methods have shown that injury begins earlier than 
previously believed (99-108).  These techniques have started to be implemented in adult 
clinical trials (Barkhof et al., 2009), although standardising approaches has been challenging 
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and slower than desired. In parallel with an increasing use of advanced (quantitative) 
techniques, adult studies are also moving towards higher field strength, while  the few 
paediatric studies to date (sample sizes n=20—46) have been carried out on 1.5T scanners 
(109-113).  
 
 Advanced neuroimaging methods are increasingly used to understand disease processes in 
children (114, 115). One advanced technique, magnetization transfer ratio (MTR), reflects 
tissue integrity, which, in the context of MS white matter, is related to myelination (116) 
(not as yet assessed in paediatric MS). Combining techniques may provide synergistic 
information, hence better identifying the extent of disease and providing better biomarkers 
that one technique alone. 
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Table 11:  Paediatric ADS and MS MRI diagnostic criteria 
KIDMUS (77) Callen MS vs. 
ADEM (25) 
Callen Diagnostic 
MS  (97)  
Verhey Model 
(96) 
McDonald 2010 
(22) 
1 of 2:  
   
Lesions 
perpendicular 
to long axis of 
the corpus 
callosum 
 
Sole presence 
of well 
defined 
lesions 
2 out of 3: 
 
Absence of a 
diffuse bilateral 
lesion pattern 
 
 
Presence of 
black holes 
 
Greater or equal 
to 2 
periventricular 
lesions 
2 out of 3: 
 
≥5 lesions on T2 
weighted images 
 
 
 
≥2 periventricular 
lesions 
 
≥1 brain stem 
lesion(s) 
2 of 2: 
 
≥ 1 
periventricular 
lesion(s) 
 
 
≥1 hypointense 
lesion(s) on T1 
images 
 
 
 
2 or more of: 
≥1 periventricular 
≥1 juxtacortical 
≥1 infratentorial 
≥ 1 spinal cord 
 
AND 
≥1 new lesion 
compared to 
previous scan,  
OR presence of 
asymptomatic 
enhancing lesion 
and a non-
enhancing T2 
lesion on any scan 
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Table 12: Paediatric ADS and MS MRI diagnostic criteria; sensitivity and specificity 
KIDMUS (77) Callen MS vs. 
ADEM (25) 
Callen Diagnostic 
MS  (97)  
Verhey Model 
(96, 117) 
McDonald 2012 
(117) 
Compared to 
Barkhof space 
criteria 
 
Specificity: 
100% vs 63% 
 
Sensitivity 
21% vs 52% 
Compared to 
McDonald 2005 
space criteria 
 
Specificity: 95% 
vs 30% 
 
Sensitivity 81% 
vs 68%  
Compared to 
McDonald 2005 
space criteria 
 
Specificity: 98% 
vs 100% 
 
Sensitivity 85% vs 
76% 
Compared to 
McDonald 2005 
space criteria 
 
Specificity: 90% 
vs 100% 
 
Sensitivity: 70% 
vs 74% 
Compared to 
McDonald 2005 
space criteria 
 
Specificity: 80% 
vs 100% 
 
Sensitivity: 85% 
vs 74% 
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 Figure 5: MRI brain and spine of a 15 year old adolescent female with clinically relapsing 
remitting Multiple Sclerosis (positive oligoclonal bands). There are multiple T2-weighted and 
FLAIR lesions; periventricular (A, D, F), juxtacortical (E), gadolinium enhancing on T1 (C), 
infratentorial spinal lesion spanning 2 vertebral cervical segments (B) hence fulfilling 
McDonald criteria. 
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1.5 Immunological features, and investigative features in ADS and MS 
Immunological Features 
There is a paucity of information with regards the immunopathology of paediatric MS and 
the consequences of ongoing neurodevelopment and changing immune systems which may 
contribute to differing natural history than adult onset MS. Mounting information regarding 
risk factors for both adult and paediatric MS point to similar influences; however, the timing 
of exposures, particularly infectious exposures, and the extent of effect may be different.  
 
The cause of CNS Inflammatory demyelination is still unknown, and no biomarker has been 
established for ADEM or MS diagnosis.  
 
Pathologically, ADEM is characterized by perivenular infiltrates of macrophages, 
lymphocytes, and plasma cells with demyelinated and oedematous neighbouring white 
matter. Lesions are multifocal and usually diffuse being found in predominantly white 
matter of brain, optic nerves, and spinal cord. Deep grey nuclei are sometimes affected. 
Typically, and differently to MS, lesions are of the same age, and there is usually minimal 
axonal injury (118). 
 
Multiple Sclerosis is a chronic inflammatory demyelinating disease of the CNS characterized 
by myelin loss, axonal degeneration and, often, progressive neurological dysfunction.  
 
Idiopathic TM is an inflammatory demyelinating condition with immune mediated 
mechanisms implicated. Numerous case series have reported a large number of patients 
having CSF pleocytosis and raised CSF proteins (43, 44, 46, 51, 52). Histopathological studies  
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have demonstrated focal infiltration of the spinal cord by monocytes and lymphocytes as 
well as astroglial activation (49). Grey and white matter have been observed to be equally 
affected,  confirming recent MRI observations (46).  
Several immune mechanisms have been postulated. In healthy CNS, immune surveillance 
involves both immune cells entering and possibly leaving the CNS, and antigen draining from 
the CNS in to the periphery [reviewed in (119, 120)]. Activated T cells can migrate across the 
blood brain barrier (BBB), facilitated by a host of endothelial and local factors (121).  Under 
normal conditions this lymphocyte surveillance activity does not lead to inflammation or 
alter BBB integrity (119, 122). However, when patrolling lymphocytes, in the context of local 
infection or autoimmune disease, re-encounter their specific antigens in the CNS (presented 
via perivascular antigen presenting cells), they may initiate a classical “auto-inflammatory” 
response. The response promotes BBB disruption and invasion of high numbers of activated 
lymphocytes into CNS parenchyma (123). These mechanisms form the cornerstone of our 
current thinking on the induction of disease in CNS autoimmune disorders [reviewed in 
(124)]. 
Additionally, although many reports have quoted childhood infections and immunisations as 
temporal associations, studies have not included an appropriate design such as large case 
control studies. If these associations are confirmed, it remains uncertain whether the link 
with TM is a result of molecular mimicry (immune targeting of infection/ vaccine related 
proteins that bear molecular similarity to neuronal proteins), or whether the heightened 
immunity increases the pool of T or B cells clones which possess the ability to recognise 
neuronal proteins (42) or a combination of the two. 
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Immune system: possible insights from studying ADS in children 
In a recurrent form of demyelination, neuromyelitis optica (NMO), the antibody to 
aquaporin 4 (AQP4) has recently been demonstrated to be a disease specific biomarker and 
to be pathogenic in animal models (125). The work on NMO raises the possibility that other 
autoantibody biomarkers may be present in other childhood demyelinating diseases. 
Antibodies to native myelin oligodendrocytes glycoprotein (MOG), uncommon amongst 
adult-onset patients (126), have been found in 38% of paediatric-onset MS patients and also 
in a cohort of patients with ADEM (127). These and other CNS directed antibodies may be 
determinants of childhood demyelinating disorders and that their identification may prove 
helpful in diagnosis and management. 
 
Specific Investigations  
Many inflammatory and non-inflammatory disorders may have a similar clinical and 
radiologic presentation and should be considered in the differential diagnosis as above. 
There are no formal guidelines as yet with regards the investigation of a suspected 
inflammatory CNS presentation. Investigations are tailored according to the clinical 
presentation and progress, consideration of differential diagnosis (see chapter 1.7), and MRI 
appearances. 
CSF Oligoclonal bands represent intrathecal synthesis of IgG. Although they are not specific 
for inflammatory demyelination as they can be positive in other disorders, they are useful in 
supporting diagnoses. 
Visual Evoked Potentials (VEPs) are useful in the assessment of demyelination of the optic 
pathways. 
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The presence in serum of antibodies directed against aquaporin 4 (NMO- IgG) appears to be 
sensitive and specific to paediatric NMO. 
 
Approximately half children presenting with TM (a monofocal CIS) reported in the literature 
have CSF pleocytosis and/or raised protein levels. In isolated monophasic TM, CSF 
oligoclonal bands are normally absent (Table 13).  In children, the TMCWG criteria may be 
too stringent, repeat investigations to confirm inflammatory criteria may not be appropriate 
and hence a diagnosis of probable TM may be made based on clinical presentation, 
investigation and MRI findings. Testing for NMO-IgG antibodies should also be considered at 
the outset for all children presenting with TM (see NMO sections in chapters 1.4 and 3.4). 
 
In chapters 2, 3, and 4 and I will further explore in more detail the utility of investigative 
features to help characterise ADEM, CIS, NMO and MS. 
.
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Table 13: Summary of investigative and MRI features of TM 
Ref Alper 2010 DeGoede 2010 Kalra 2009 DaJusta 2008 Yiu 2008 Pidcock 2007 Defresne 2003 
CSF pleocytosis/  
raised protein 
10/27 (37%) 16/36 pleocytosis 
(44%), 
 11/36 protein 
>0.4g/L 
3/6 pleocytosis, 
4/6  raised proteins  
n/a CSF (in 74%): 
67% pleocytosis  
38% raised protein 
50% pleocytosis  
(17/34) 
raised protein in 48% 
(14/29) 
15/24 pleocytosis 
3/14 raised protein;  
CSF OGB positive/ 
IgG index 
0/22 OGB positive, 
2/21 IgG index raised 
4/27 OGB positive, n/a n/a n/a OGB positive or 
raised IgG index in 
<5% 
0/14 OGB positive 
NMO-IgG/ other 
antibody tests 
0/5 positive n/a Anti-GM1 Abs in 46% 
with TM vs 6.6% 
control (P= 0.035) 
n/a n/a n/a n/a 
MRI spine; segment 
lengths affected  
segs (mean 6.4) 
 
7/39 >6 segments  13/15 had >3 segs (2 
entire cord) 
n/a 68% had ≥3 segs 
 (mean 8segs)   
Mean segs=6  
(1 multifocal, 1 
entire cord) 
4/6 had >2segs 
 
 
MRI spine; regions 
affected 
10 cervical ± 
thoracic, 6 thoracic, 
1 lumbar, 4  
14 cervical, 19 
thoracic, 7 
lumbrosacral; 
thoracic cord most 
common; 1 
multiregional 
Cervical 57% 
Thoracic 43% 
n/a cervical 19/38, 
thoracic 15/38 , 
lumbar/conus 2/38 , 
2/38 normal. 
 
2/6 normal 
MRI spine; GAD 
enhancement 
4/21  n/a 2/4 n/a n/a 74% (26/35)  
 
3/6 
MRI brain features 1/25 patchy T2 
hyperintensity 
17/26 abnormalities 
(6 symptomatic) 
n/a n/a 3/10 abnormal (2 
asymptomatic, 1 
brainstem extension) 
n/a 1of 4 multiple T2 
lesions in cortex and 
basal ganglia 
 
Anti-GM1 Abs= Anti-GM1 antiganglioside immunoglobulin G antibodies; CSF= cerebrospinal fluid; GAD= gadolinium enhancement; IV= steroids; Neuromyelitis Optica; OGB= oligoclonal band; 
segs= segments;  
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1.6 Genetic-environmental associations in multiple sclerosis 
Genetic and environmental risk factors are likely to be operating in ADS and MS 
immunopathology. Adult MS prevalence varies from very low rates in peri-equatorial 
regions, to over 100 per 100,000 population in temperate regions distant from the equator, 
hence prompting consideration of limited sunlight and vitamin D insufficiency as potential 
risk factors for MS. These features are yet to be shown in childhood ADS. 
 
Genetic influence is childhood acquired demyelinating disorders compared to adults 
There is increasing awareness of the importance of genetic factors that determine the host 
response to likely environmentally triggered childhood CNS immunological diseases (128).  In 
adults the most important component of MS hereditability is situated in the Major 
Histocompatibility Complex (MHC). Recently, in a Canadian Paediatric study, HLA-DRB1*15 
was shown to be significant (OR=3.3 p<0.001) for the development of MS (129). In adult 
onset MS, interactions between HLA haplotypes are key to determining MS risk, for example 
HLA-DRB1*08 has been shown to more than double the risk of MS associated with a single 
copy of HLA-DRB1*15 (130-133). Recent identification of mutations of RANBP2 gene 
(encodes protein part of the nuclear pore complex) (134), thiamine transporter gene 
SLC19A3 (135) and polymorphisms in the carnitine palmitoyl transferase II gene (136) in 
children with acute subtypes of recurrent encephalopathy raises the possibility of these or 
other genes being involved in pathobiology of ADEM and MS. These mutations may indeed 
contribute to a subgroup of children with demyelination.  
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Geographic Distribution pointing towards environmental influences 
MS has long been believed to be a disease with rates rising with increased distance from the 
equator in both northern and southern hemispheres (137). However, data on the geographic 
distribution of MS in children are lacking, and it is yet to be determined whether paediatric 
cases of MS follow the same pattern. Preliminary data suggest that non-Caucasian ancestry 
may play a role in paediatric MS. Childhood populations in the United States and Canada 
have a higher than expected number of MS patients under age 18 who are first generation 
North Americans with parents born in either Latin or Caribbean countries, where MS is 
usually less common (138, 139). Migration studies hence imply that puberty is a decisive 
stage for changing the risk of developing MS (140).There is evidence that Indian and 
Pakistani immigrants who entered England younger than 15 years of age had a higher risk of 
developing MS than those that entered after this age (141).  
 
Vitamin D  
Vitamin D has become increasingly topical and one interesting factor appears to involve 
sunlight and vitamin D (142, 143).  
 
The amount of winter sunlight parallels the range of MS prevalence, and high sunlight 
exposure is associated with low disease prevalence [69]. Sunlight, through its responsibility 
in generating active vitamin D, has hence been proposed as a potential significant 
environmental factor for the disease. Recently, sequence analysis found a single MHC 
vitamin D response element (VDRE) to the promoter region of HLA-DRB1, which was 
conserved in HLA-DRB1*15 haplotypes but variant to some extent in all others (144). 
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Vitamin D has also been postulated to be important in early brain development (145). There 
has hence been increasing speculation that gene-environment interactions could lead to 
preventive interventions in at risk individuals (146, 147). For example, a Norwegian study 
demonstrated reduced risk for MS in adults reporting an increased amount of childhood 
outdoor activities (148).  
 
Infectious Agents and vaccination 
Ebstein-Barr Virus (EBV) has been implicated to have a role in increased MS susceptibility. A 
case control study in Toronto showed that 83% of 30 paediatric MS patients had serologic 
evidence for remote Epstein-Barr virus (EBV) infection, compared with 42% of 90 controls, 
suggesting a potential increased risk of paediatric MS being associated with EBV infection 
(149). These findings have been confirmed in a German (150) and in a multinational cohort 
(151).  A large population-based study, showed the rate of previous infection with infectious 
mononucleosis at approximately 50% of MS cases compared to 20% (p<0.001) of controls 
(152). Similarly the group have also shown that historically reported measles, mumps, 
rubella, varicella and vaccination for hepatitis B, influenza, measles, mumps and rubella are 
not associated with increased risk of MS later in life. A recent large cohort study also showed 
no correlation between hepatitis B vaccination and paediatric MS(153). Chlamydia 
pneumoniae antibodies have been detected in CSF of paediatric (154) and adult MS patients 
(155) but the significance of these findings is uncertain (156). 
 
Epidemiological studies have shown that exposure to siblings in the first 6 years was 
associated with a reduced risk of MS, possibly due to altered developmental immune 
responses(157).  
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1.7 Differential Diagnosis 
 
The differential diagnosis of multiple sclerosis is wide and even more so in children 
compared to adults. Two relatively recent review articles have reviewed the issue in both 
children (28) and adults (27), although the likely diagnoses in children with white matter 
abnormalities is likely to be even wider. 
Many inflammatory and non-inflammatory disorders may have a similar clinical and 
radiologic presentation and should be considered (guided by clinical presentation and MRI 
findings) in the differential diagnosis as highlighted in Table 14.  
When  the  MRI  shows large  focal  tumour-like  lesions,  one  should  consider brain  
tumours, brain abscesses, and variants  of ADEM/MS. An  MRI  pattern  with symmetric  
bithalamic  involvement  may  be  seen  in children  with  acute  necrotizing  encephalopathy, 
deep  cerebral  venous  thrombosis,  hypernatremia, and extrapontine myelinolysis. Basal  
ganglia  involvement  may  be consistent  with  organic  aciduria,  poststreptococcal 
infection,  or  infantile  bilateral  striatal  necrosis. The presence of complete ring-enhanced 
lesions in the cerebral white matter is unusual in ADEM, and brain abscess, tuberculomas, 
neurocysticercosis, toxoplasmosis, and histoplasmosis should be excluded. Vasculitic lesions 
may also mimic inflammatory demyelination. 
In Chapters 2 and 3 I further explore the differential diagnoses of ADS in a prospective 
cohort. 
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Table 14: Diagnoses to consider exclusion depending on presentation in children presenting 
with CIS or MS like phenotypes 
 
System Disorders 
Endocrine 
 
Inflammatory 
 
 
Mitochondrial 
 
Leukodystrophy 
 
Genetic/metabolic 
 
Infectious  
 
 
Vascular/thrombotic 
disorders 
 
Nutritional 
 
Neoplastic 
 
Haematological 
 
Other 
 
Thyroid disorder, diabetes mellitus 
 
Systemic lupus erythematosus, neurosarcoidosis, antiphospholipid 
antibody syndrome 
 
MERRF, MELAS, LHON 
 
Metachromatic leukodystrophy, adrenoleukodystrophy 
 
Inborn errors of metabolism, amino acidurias 
 
Herpes simplex encephalitis, post streptococcal infection, HIV, lyme 
disease, neurocysticercosis, Neuroborreliosis, brain abscess 
 
CADASIL, Moyamoya disease, carotid dissection, Cerebral venous 
sinus thrombosis, other vasculitis or vasculopathies 
 
B12 or folate deficiency 
 
Lymphoma, astrocytoma 
 
Hemophagocytic lymphohistiocytosis 
 
hypernatremia, extrapontine myelinolysis 
 
MERRF:  myoclonic epilepsy with ragged red fibers;  MELAS: mitochondrial encephalopathy with lactic acidosis 
and stroke-like episodes;  LHON:  Leber hereditary optic neuropathy; CADASIL: cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy 
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1.8 Treatment 
 
Acute demyelination 
There are no controlled trials for the treatment of ADS in childhood. Most recommendations 
are mainly extrapolated from case series or data from clinical trials for the treatment of 
exacerbations of adult MS (41, 50, 158). In adults, treatment of relapses with IV 
methylprednisolone (IVMP) shortened relapse duration and sped up recovery. High doses of 
IVMP (more than 500 mg/day for at least 3 days in adults) are superior to lower doses (159).  
Children are usually treated with high dose intravenous steroids for 3-5 days to attenuate 
inflammation. There is consensus that intravenous corticosteroids should be administered in 
order to shorten the acute inflammatory process and hasten recovery. Subsequent oral 
steroid taper with a duration of 2–6 weeks is recommended for ADEM. In children who do 
not respond to steroids, intravenous immunoglobulin is often used, although the data to 
support this is limited to small case series and single case reports (5). Intravenous 
immunoglobulin (IVIg) is used at doses of up to 2 g/kg administered over 2–5 consecutive 
days.  In children with severe symptoms not responding sufficiently to  a first course  of high-
dose  corticosteroids, a second pulse might be warranted , and in case of severe or  life-
threatening  acute  demyelination,  plasma exchange should be considered. Plasmapharesis 
is increasingly used as rescue therapy based on its efficacy in a small randomised controlled 
trial in adults with acute CNS demyelination  (160). 
 
Disease Modifying Treatment in MS; children vs adults 
Early initiation of “disease modifying agents”, such as beta interferon and glatiramer acetate 
appears to be of benefit in adults. Thus, it is more critical than ever to accurately diagnose 
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MS as early as possible. However, very little is published on the use of interferon in children 
(161-165). 
 
There have been no randomised controlled trials in ADS or MS conducted in children. 
Treatments are currently based on clinical experience and consensus.  Differences in 
pharmacodynamics pharmacokinetics and of disease modifying treatments in younger 
patients are likely to be present, although there is little information available for the 
different drugs used in treatment of MS in children. 
 
 
In the UK, it often difficult to obtain funding for traditional MS disease modifying drugs 
(Absoud et al; abstract presentation- “Immunomodulatory drug treatment in childhood MS: 
Experience from the UK.” Eur J Paediatr Neurol 13:0; S103 (2009). I reviewed cases in 3 UK 
tertiary Centres to evaluate efficacy, safety and tolerability of immune modulating therapies 
(IMT) in childhood MS. In a retrospective UK audit survey from 3 UK paediatric 
demyelination clinics (2004-2008), 28 relapsing-remitting MS cases (22 female) with a mean 
age of 11 yr9m (SD 3yr6m) were ascertained. On presentation 50% had polyfocal clinically 
isolated episodes (CIS), 39% monofocal CIS and 11% acute disseminated encephalomyelitis 
(ADEM).  Twenty-six were treated with interferon beta 1a or 1b 
(Rebif/Avonex/BetaInterferon) and 2 with glatiramer acetate (Copaxone). One patient 
stopped shortly afterwards (poor compliance). In one centre (12 cases) time from “decision 
to treat” to administering IMT averaged 5 months, and was due to delays in specific drug 
approval, and nursing support. These treatments are generally well tolerated There were no 
serious side effects. 29% reported flu-like symptoms, 25% fatigue, 18% transient 
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lymphopaenia, and 11% transient transaminasemia. Disease modifying treatments in 
childhood MS in this cohort appeared safe, well tolerated, as comparable to other childhood 
surveys and adult data (5). There is no European and indeed international consensus that 
recommends the use of first line treatments for paediatric MS and there is a need for future 
randomised clinical trials in children (166, 167). 
 
Early referral to a specialist is essential for consideration of treatment in recurrent 
demyelination. Although recent research in adults suggests that early disease modifying 
treatment (DMT) of MS (such as such as with beta interferon and glatiramer acetate) may be 
beneficial, current criteria from the UK National Institute of Clinical excellence (NICE) do not 
support treatment for patients younger than 18 years of age  as there are no large 
randomised trials in children.  Observational case series suggest that DMTs in childhood MS 
appears safe, well tolerated, and efficacious (by reducing relapse rate) as compared to adult 
data. Neuromyelitis Optica is often treated with other DMTs (azathioprine, Rituximab) and 
hence the importance of early diagnosis.   
 
It is beyond the scope of this thesis to detail current and future therapies in the pipeline, and 
referral should be made to the Paediatric Neurologist for consideration of these therapies. 
 
Treatment of NMO 
It is important to recognise NMO early in the course of the disease as permanent disability is 
more attack-related in NMO than in MS (168). Hence, early and aggressive intensive 
treatment with disease modifying treatment may be beneficial in reducing the disability and 
ameliorating the course of disease in children (27, 61, 68, 69, 168). There have been no large 
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randomised trials in children or adults and current practice is based on case series and 
expert opinion. Recent adult European consensus guidelines have been published (168). In 
children, acute exacerbations are usually treated with 5 days of intravenous steroids ± 
intravenous immunoglobulin. Severe exacerbations are treated with plasmapheresis. A wide 
variety of disease modifying drugs have recently been used but recent reports show that 
drugs used to treat multiple sclerosis (interferons, glatiramer) may exacerbate NMO (169). 
Future clinical trials incorporating children are needed in this condition.   
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1.9 Outcome, MS & Risk of Relapse  
 
The first episode of CNS Inflammatory Demyelination may occur as an isolated monophasic 
illness or may represent the first attack of MS (Figure 6). Several studies have been 
conducted to establish clinical and radiological risk factors for MS development after a fist 
attack of CNS inflammatory demyelination (Table 15). Most of these studies although 
longitudinal, were conducted before international definitions (2007), and had a 
retrospective case ascertainment from tertiary centres and hence subject to bias. Hence the 
risk factors currently reported in the literature and summarized here need to be interpreted 
with caution. No clinical features, radiological, serum, or cerebrospinal fluid (CSF) 
biomarkers absolutely distinguish ADEM or isolated CIS form MS and further research in this 
area is ongoing. Radiological MRI criteria have also been suggested for children which are 
yet to be established in longitudinal prospective studies. The majority of paediatric onset MS 
is characterised by a relapsing remitting course (figure 3) and later into adulthood becomes 
secondary progressive. 
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Table 15: Risk Factors of Multiple Sclerosis after a first CNS inflammatory demyelinating 
event. 
 
Increased Relapse risk Decreased relapse risk 
>10 years of age 
CIS- polyfocal 
Optic neuritis 
No encephalopathy 
CSF oligoclonal band positive 
MRI brain showing asymptomatic lesions 
<10 years of age 
ADEM 
Isolated Transverse Myelitis 
Encephalopathy 
Presentation with meningism, fever, seizures 
MRI brain without symptomatic lesions 
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Risk of MS in ON 
Optic neuritis (ON) is one of the most common CIS events in children.  Bilateral  optic  
neuritis  is  more  common  in children  than  adults  (approximately  half  of  childhood optic 
neuritis is bilateral). Despite severe acute visual loss, approximately 70-80% of children will 
recover visual acuity (snellen of 6/9 or better). Both unilateral and bilateral optic neuritis can 
be the first manifestations of MS or Neuromyelitis Optica. In  recent studies of children with 
optic neuritis , 20-45% experienced further demyelinating attacks leading to a diagnosis of 
MS after follow-up periods of approximately two years. Recurrent optic neuritis and the 
presence of  MRI  brain  lesions  extrinsic  to  the  optic  nerves has been  associated  with  an  
increased  likelihood  of  MS after ON onset. 
 
Outcome of TM 
Children are thought to have a better outcome than in adults (44, 51, 170) with 
approximately half making a complete recovery. However, a group of children have severe 
disabilities. Additionally deaths have been reported mainly due to respiratory failure 
associated with a high cervical cord lesion (43, 51, 53). The most common sequelae affecting 
children are sensory disturbances and bladder dysfunction (15-50%). Approximately one 
quarter are wheelchair-bound or require an aid for walking. A group of children never regain 
mobility or bladder function (10-20%). Several studies have attempted to correlate 
presenting clinical and laboratory features with clinical outcome (Table 16).  A higher spinal 
level is the only consistent poor prognostic feature across these studies. An identifiable 
trigger (intercurrent illness or vaccination) does not appear to predict clinical outcome. The 
influence of age, rapidity to nadir of symptoms and late start of recovery in predicting 
clinical outcome appear to vary between studies.   
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TM may be isolated or part of a polyfocal clinically isolated syndrome (CIS). It can be 
monophasic, or later relapse and hence be the first presentation of a relapsing NMO 
spectrum (Figure 1) disorder or Multiple Sclerosis (Figure 2). Patients with TM should be 
followed up longitudinally irrespective of initial outcome, in part to clarify the diagnosis and 
to provide ongoing multidisciplinary support into ongoing rehabilitation (motor, sphincter, 
psychological, and schooling support). 
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Table 16: Summary of poor prognostic factors reported in recent case series for paediatric TM (43, 44, 51, 52, 171) 
 
 
Ref older 
age 
(>10) 
rapid 
onset to 
nadir<1day 
late start of 
recovery>1 
week 
higher  
spinal 
levels 
Sphincter 
involvement 
flaccid legs 
at 
presentation 
many 
spinal 
segments 
CSF 
pleocytosis 
intercurrent 
illness/ 
vaccination 
DeGoede 
2010 
yes Yes yes Yes Yes Yes n/a n/a No 
Yiu 
2009 
No- 
younger 
age 
No n/a Respiratory 
failure 
requiring 
ventilation 
n/a Yes No 
 
n/a n/a 
Pidcock 
2007 
No- 
younger 
age 
No n/a Yes n/a n/a yes yes No 
Defresne 
2003 
n/a Yes n/a n/a n/a Complete 
paraplegia 
n/a n/a n/a 
Miyazawa 
2003* 
 
No- 
younger 
age 
No n/a n/a n/a No 
Babinski’s 
reflex 
n/a n/a No 
* Compilation of 50 case reports from Japan (1987-2001) 
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Transverse Myelitis and risk of Multiple Sclerosis 
The International Paediatric MS Study Group defined paediatric MS as requiring multiple 
episodes of CNS inflammatory demyelination separated in time and space as in adults.  
Dissemination in time can be met if new T2 or gadolinium enhancing lesions develop 3 
months following the initial clinical event. Dissemination in space can be met by one of the 
following: 
(i) The revised McDonald criteria for a “positive MRI” are applied; with 3 of: 1) >8 white 
matter lesions or one gadolinium enhancing lesion, 2) >2 periventricular lesions, 3) a 
juxtacortical lesion, 4) an infratentorial lesion 
(ii) The combination of an abnormal CSF (oligoclonal bands or elevated IgG index) and 2 
lesions on the MRI (at least one in brain). 
 
When compared with other CIS presentations, isolated TM carries the lowest risk of 
progression to MS (15, 51). Studies examining the relation of TM with polyfocal CIS and MS 
are sparse.  Case series in TM have also reported that a number of patients have 
asymptomatic brain lesions (Table 7). In a French cohort of children with a first attack of CNS 
inflammatory demyelination, 7% (2/29) with a monofocal TM at presentation were later 
diagnosed with MS (15). Another series reported only 2% (1/47) of TM cases progressing to 
MS (43).  However, 31% (13/42) of children with polysymptomatic clinical features including 
transverse myelitis at presentation were later diagnosed with MS (15). This highlights the 
importance of differentiating isolated TM from TM that is part of a polyfocal syndrome.  
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In adults with MS, spinal lesions are usually less than two segments and located in the 
posterolateral aspect of the spinal cord (46, 172, 173). A recent adult study (174)found that 
50% of patients converted to clinically definite MS when they had the combination of TM 
and brain lesions [Controlled High-Risk Subjects Avonex Multiple Sclerosis Prevention Study 
Criteria (175); >1 brain lesion >3mm in diameter with ≥1 periventricular or ovoid+. Children 
with MS have also been shown to tend to have spinal lesions less than 3 segments (see 
Figure 4), although longer segments (LETM) have been reported to progress to MS as well 
(65). Further prospective studies with longer term follow-up are needed to clarify this. 
 
Outcome in NMO 
Paediatric NMO appears to have a better prognosis than adult NMO in terms of disability. In 
one study median time from onset to EDSS 4 (20.7 vs 5.3 years; p <0.01) and EDSS 6 (26 vs 
8.5 years; p <0.01) was largely explained by the increased severity of the first myelitis in the 
adult NMO group (69). In contrast, the USA paediatric NMO-spectrum series showed 
residual disability in 43/48 patients (90%) with 54% having visual impairment (27% blind) 
and 44% motor deficits (median Expanded Disability Status Scale 4.0) at 12 months (71).  
Further prospective longitudinal studies are needed to clarify these findings. 
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Figure 6: Risk of childhood MS after a first attack of CNS Inflammatory Demyelination 
(RDEM: Recurrent ADEM; MDEM: Multiphasic ADEM) 
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1.10 Neurodisability 
A systematic review of the natural history of MS showed the most commonly reported 
physical and cognitive effects of the disease include: weakness, fatigue, ataxia, bladder 
complaints, bowel problems, sensory effects and visual impairment (34), illustrated in Figure 
7. The most reported and quoted tool for the grading of functional effects of MS in adults is 
the (Expanded) Disability Status Scale (EDSS). The scale ranges from 1 (least severe) to 10 
(death from MS). However, the scale is not ideal because there is a bias towards the physical 
effects of the disease (particularly ambulation) rather than the cognitive effects. Relapse 
rates in relapsing-remitting MS vary considerably over time for an individual and between 
individuals, but there is a general pattern of exacerbations of more frequent relapses, 
followed by long periods of lower rates. This makes assessment of the effects of treatments 
in an individual extremely problematic.  
 
Children, compared to adults, frequently have slower disability as progression measured by 
EDSS but reach disability levels at a younger age than individuals with adult onset MS (11, 
83, 176, 177). A large French study utilising data collected from 13 adult neurology 
departments via the European Database for Multiple Sclerosis (EDMUS) database identified 
a cohort of 394 patients who had multiple sclerosis with an onset at 16 years of age or 
younger and compared disability outcomes to 1775 cases who had adult onset multiple 
sclerosis. Time to secondary progression which heralds sustained build up of disability, 
independent of any relapse was one of the key outcomes measured. 
The median time from onset to secondary progression was 28 years (median at 41 years of 
age) for childhood onset MS compared to 19 years (median at 51 years of age) for adult 
onset MS . The median time from onset to disability score of 6 (ability to walk with unilateral 
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support no more than 100 m without rest) was 28.9 years (42.2 years of age). Age hence 
appears to be a major determinant of remyelination efficiency given that myelin destruction 
is an early observation in the disease course (178, 179). 
 
Cognitive deficits 
In comparison to adult-onset MS, the examination of cognitive functioning in paediatric ADS 
and MS, have been limited to a few small studies. Nevertheless, there is emerging evidence 
that children with MS, compared to adults, more frequently have cognitive deficits (180, 
181). Children may be particularly susceptible to cognitive impairment since the pathological 
processes affecting a developing central nervous system can also impinge on neural 
networks important for learning and language. In addition, neurodevelopmental co-
morbidities often occur in young people who develop an acquired neurological disease 
(182).  The prevalence estimates of intellectual impairment in childhood ADEM, CIS and MS 
range between 20 and 50% of patients (183, 184). As in adult onset MS, the most common 
impairments involve information processing speed, working memory, and executive 
functioning. Other aspects affecting children not highlighted in adult onset MS include a 
greater impact on overall IQ and also effects on language (185, 186)). As to be expected, 
intellectual functioning in children is most strongly correlated to the overall level of disability 
as measured by EDSS (183). Despite this, one study documented worsening cognitive 
functioning in over half of patients with MS, unrelated to worsening overall disability as 
measured on EDSS(187). 
Currently, conventional MRI cannot fully explain the neurocognitive impairment which is the 
earliest feature of neurodegeneration in children with MS. Advanced neuroimaging methods 
have been shown to be more sensitive to the evolution of MS damage in adults over time 
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and show that injury begins earlier than previously believed.  These techniques have started 
to be implemented in adult clinical trials (188), however standardising approaches for use in 
multicentre studies has been slow. In addition all paediatric studies have only been carried 
out on 1.5T scanners which result in longer scanning times and inferior quality (109-113). 
Additionally, these paediatric studies have only recruited relatively small numbers (20-46 
cases). Paediatric studies have reported an association between cognitive function and: 
reduced size of thalamus; global brain volume; and white matter integrity and 
microstructure as measured by fractional anisotropy (189, 190). Overall cognitive deficits 
associated with paediatric ADS affects school attendance, participation, and performance 
(191). 
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Figure 7: Outcome issues 
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1.11 Conclusions 
ADS and MS occur in children as well as adults. The presentation differs in children and 
adults, hence specific operational diagnostic criteria have been developed for children.  
Relatively little is known about the aetiology, incidence and prognosis of these conditions 
when presenting in childhood however.  There is no randomised control trial evidence to 
support the treatment of children, and as highlighted the differences between adult and 
paediatric MS do not support a straight forward extrapolation from results obtained in 
adults.  Evidence on incidence, natural history, imaging features prognosis and outcomes is 
required to inform trial design as well as to inform gaps in clinical and epidemiological 
evidence on ADS and MS in children. 
 
In the subsequent chapters I will describe a national ADS incidence study I set up which uses 
multiple sources and two well established active surveillance units. This prospective 
surveillance study has also integrated detailed review of MRI images and investigative 
features combined with the robust application of International Paediatric Multiple Sclerosis 
Study Group (IPMSSG) consensus definitions (using additional help of an expert panel for 
inclusion, exclusion and differential diagnoses). I will then report on the one year outcomes 
and describe demographic clinical, investigative and MRI risk factors for relapse. In the 
following chapter, I will discuss the set up of a prospective cohort and the methodological 
considerations needed for clinical trials and preventative trials in ADS. I will conclude with 
implications and directions for future clinical and research practice in the UK.  
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CHAPTER 2: INICIDENCE, CLINICAL AND MRI FEATURES OF ADS 
 
2.1 Study Aims  
In this chapter, I report a multinational multisource prospective active surveillance study in 
the British Isles (latitudes 50-59 degrees) with the primary objective of determining the 
incidence of fist presentation of childhood CNS inflammatory demyelinating disorders in the 
UK and Ireland. Secondary objectives were: 
- to report clinical features, and distribution by age, sex and ethnic group 
- to report the clinical, investigative and MRI features of childhood ADSs  using expert 
panel review  to apply IPMSSG consensus  definitions (including the incorporated 
McDonald MRI 2001 and Barkhof space diagnostic criteria).(12, 192)  
- to apply the newly revised 2010 McDonald space and time diagnostic criteria;(22) and 
the recent Verhey MRI prognostic MS criteria.(193) 
- to identify the frequency of proposed for MS in children. 
- to determine whether these children can be classified according to the new international 
classification and further characterise those that cannot. 
- to evaluate the prevalence of AQP4 and other CNS directed autoantibodies in childhood 
ADS.  
- to  describe current practices and treatments offered in the UK and Ireland and increase 
awareness amongst practicing clinicians. 
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2.2 Study Methods 
Study Design  
I carried out a prospective active surveillance study of first episode ADS in children aged 
between 1 and 15 years and 11 months of age, in the British Isles with multisource 
ascertainment using two well established surveillance units in order to establish incidence of 
new cases arising in the period September 2009 to September 2010. 
 
The British Paediatric Surveillance Unit (BPSU); primary source of data 
The British Paediatric Surveillance Unit (BPSU) is a unit within the Royal College of 
Paediatrics and Child Health which facilitates epidemiological surveillance for rare childhood 
diseases of public health importance in the UK and Republic of Ireland. It is funded by the UK 
Department of Health. The BPSU was launched in 1986 by the Royal College of Paediatrics 
and Child Health, the Health Protection Agency and the University College London-Institute 
of Child Health (London) and is operated in cooperation with the Health Protection Scotland 
(HPS) and the Faculty of Paediatrics of the Royal College of Physicians of Ireland. The BPSU is 
funded by the Department of Health.  
The BPSU has helped initiate over 80 studies with a card return rate consistently higher than 
93% (194). The BPSU system lessens the burden on practising clinicians of requests from 
numerous different sources. The BPSU also aims to increase clinicians and public awareness 
of rare disorders and improve prevention, treatment and service planning. Central to set up 
of a study is patient and public involvement.  
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The Process (see Figure 8): 
1. One month before commencing the study a protocol card and letter is sent to all 
clinicians informing them of the study. 
2. An Orange Card with a list of disorders is sent monthly to more than 3200 consultant 
paediatricians and other specialists. 
 Clinicians return the card to the BPSU notifying any cases or ‘nothing to report’ 
 A tear-off slip is provided for paediatricians to keep a record of patients reported. 
 Clinicians are contacted by study investigators with a short questionnaire, and 
requests for supplementary investigations. 
 Investigators inform BPSU if the case report fits the case definition. 
Approximately 3200 clinicians in the UK and Ireland are sent an orange card.  The aim is to 
involve every senior doctor who is likely to have clinical responsibility for children with rare 
conditions. The following receive the orange card: 
 All UK and Republic of Ireland Consultant Paediatricians 
 Associate Paediatric specialists (with their own case load) 
Two-phase BPSU application procedure: 
 A short initial Phase 1application submitted to the BPSU Executive committee. 
 Studies are required to fit the eligibility criteria: 
o the condition has low incidence (less than 300 cases a year) and requires national 
ascertainment of cases to generate sufficient numbers for study. 
o it addresses the epidemiology of a condition and/or variations in practice 
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o is of scientific or public health importance 
o use additional alternative data sources  
 A more detailed phase 2 application is submitted. 
 Requires the submission of the research questionnaire, details on costing and 
administrative support available. 
Consent & Confidentiality:  
 The BPSU requires study applicants to detail the security measures in place to protect 
patient confidentiality 
 BPSU studies are approved on the basis that there is no patient contact and consent 
is not sought.   
 BPSU studies are required to collect minimal identifier information in order to 
discount duplication.  To comply with Section 251 of the NHS Act 2006. BPSU studies 
therefore require approval from the National Information Governance Board's (NIGB) 
Ethics and Confidentiality Committee (ECC).  
 NIGB applications that have BPSU approval go through a fast track process so there is 
little delay. Approved applications are placed on the Section 251 Register. Approved 
applications are reviewed annually.  
Cost: 
There is an administrative charge of £10,000 for undertaking a study through the BPSU.  
There is an additional charge for the cost of the protocol card production (approx £500).    
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Figure 8: BPSU Methodology 
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The British Ophthalmological Surveillance Unit (BOSU); alternative source of data for optic 
neuritis cases 
The British Ophthalmological Surveillance Unit (BOSU) was set up by the Royal College of 
Ophthalmologists with support from the Fight for Sight charity. It enables ophthalmologists 
to participate in the nation-wide surveillance of uncommon ophthalmological conditions. 
The BOSU operates similarly to the BPSU and has a card return rate consistently higher than 
75%  (195). 
 
The unit relies upon a monthly response from consultant and associate specialist 
ophthalmologists in the United Kingdom about new cases of the conditions stated on the 
BOSU Reporting Card. When a respondent reports a new case of one of the conditions under 
study BOSU will pass this information on to the researcher for investigation. Details of 
conditions included in the reporting scheme are given in study protocols. 
 The principal aims of BOSU are to involve ophthalmologists in the surveillance of rare 
conditions of public health importance and research into uncommon ophthalmological 
disorders so that research can help in the improvement of prevention, treatment and service 
planning strategies of rare ophthalmological conditions. The provision of a unified system 
lessens the burden on reporting ophthalmologists of requests from numerous different 
sources for reporting cases of uncommon disorders. 
A gold report card containing a list of conditions being surveyed is sent every month to all 
respondents on the mailing list (The card used for this study is reproduced in Figure 8). The 
mailing also includes reporting instructions and, where appropriate, protocols for new 
studies. The reporting clinicians are asked to tick boxes against any of the reportable 
conditions they have seen in the preceding month, or tick the "Nothing To Report" box if 
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none have been seen, and return the card to BOSU. A detachable slip is attached to the card 
for the ophthalmologist to keep a convenient record of patients reported. 
"Positive" returns are identified by the Unit and then the appropriate investigator is notified. 
The investigator will then contact the reporting clinician directly to request completion of a 
brief questionnaire or permission to review case notes. Further research including enquiries 
to the patient is undertaken only with the permission of the ophthalmologist and, where 
appropriate the patient's GP. 
 
The mailing list of approximately 1000 Consultant Ophthalmologists, Associate Specialists 
and Senior Lecturers in Ophthalmology has been developed and is systematically updated. 
The aim is to involve every senior doctor who may have clinical responsibility for patients 
with rare ophthalmological conditions. 
 
Case ascertainment via active surveillance 
One month before commencing the study, a protocol card and letter was sent to all clinicians 
informing them of the study. Monthly notification cards (mean per month 4095) were sent by the 
BPSU (mean per month 2945) to all registered Consultant Paediatricians, Paediatric Neurologists, and 
BOSU (mean per month 1150) to all registered Ophthalmologists ( between September 2009 and 
September 2010 (13 months). In the UK, these clinicians are likely to see all cases of ADS. Clinicians 
returned the card to the surveillance units notifying any cases or confirming ‘nothing to report.’ 
Upon receipt of a positive notification the surveillance units provided the investigating team with a 
BPSU/BOSU case number, clinician name and contact details. The study team then contacted the 
clinician directly, sending a detailed data collection form and a blank CD for an anonymised MRI. As 
more than one clinician might notify the same patient seen in different settings, minimal identifiers 
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(National Health Service [NHS] number, district postcode, sex and date of birth) were used for record 
linkage and to exclude duplicates with a high level of certainty (www.rcpch.ac.uk/bpsu accessed 
12/02/2012).  
Rationale for study design 
Epidemiological surveillance methods for these rare conditions are essential to for full case 
ascertainment if the full extent is to be realised. Missed cases will introduce a bias in 
estimating incidence. To avoid this, approval to collect pseudo-anonymised data without 
individual patient consent was deemed essential.  
The UK & Ireland has robust surveillance systems and mechanisms for a national population 
based study.  
 
To avoid this, approval to collect pseudo-anonymised data without individual patient 
consent was deemed essential. Permission was sought from the National Information 
Governance Board (NIGB).  
  
ADS conditions and Multiple Sclerosis are rare disorders in the UK (and the overall number 
of cases reported through the surveillance units was expected to be small (e.g. 200-250/ 
year). If a large number of patients/parents/guardians do not consent to participate in the 
study, there will be uncertainty about the true incidence of these conditions. Furthermore, 
should consent to participate be lower within specific subgroups (e.g. children with different 
ethnicity, ages, socio-economic backgrounds),  then this will introduce important bias in case 
ascertainment and may obscure conclusions about the epidemiology of these disorders. To 
obtain consent for participation, it may be necessary for the responsible clinician to await 
the next patient visit to obtain formal, written consent. This creates an additional burden 
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step in case ascertainment. To attain a high level of case ascertainment, it is not practicable 
to rely on reporting of cases after formal written consent has been obtained. 
 
As with other epidemiological studies, complete case ascertainment may be difficult due to 
some cases not being reported or sub-clinical. This will be addressed by using clear 
internationally accepted and also multiple sources for case ascertainment. 
 
Confidentiality and Ethics: 
Data Protection Act and Caldecott guardian requirements were observed. Type A data 
(identifiers needed only for removing duplicates and corresponding with clinicians, i.e. NHS 
numbers) will be destroyed as soon as data collection has ended (including follow 
information). Type B data, the clinical data used for research which may also include patient 
identifiable data (e.g. date of birth, sex, that are also important for the data analysis) cannot 
be removed from the questionnaires and 
will be stored for 20 years in secure archives (MRC guidelines).  
Funding:  
Funding for a three years fellowship was secured from the UK MS Society and The Action  
Medical Research Charity. 
 
Public involvement: 
The study has been informed by consultation with various parties (including patients) at the 
first UK childhood MS conference hosted by the MS Society on 7th November 2007 in 
London. I have also recruited a lay representative from the MS Society in the study team to 
ensure that patient and family views are appropriately sought throughout the  study. The lay 
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representative has also helped in design of the patient information leaflet 
(www.rcpch.ac.uk/bpsu accessed 12/02/2012). 
 
 
 
Initial surveillance reports 
Using the IPMSSG consensus definitions for classification of paediatric ADSs,(12) clinicians 
were asked to report children experiencing clinical neurological events consistent with a first 
episode ADS and confirmed with white matter changes (except in optic neuritis) on MRI (see 
Table 17). 
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Table 17: Summarised inclusion definitions for CNS Inflammatory Demyelinating Disease  
 
  
Condition Definition 
Acute 
Disseminated 
Encephalo-
myelitis 
(ADEM)  
A polysymptomatic clinical event with acute/subacute onset that must 
include encephalopathy (behavioural change or altered consciousness). (2) 
MRI Brain shows multifocal lesions. 
 
If a new event occurs ≥3 months later and ≥1 month after completing 
steroid treatment, it is defined as: 
. Recurrent ADEM: recurrence of initial symptoms without involvement of 
new clinical areas. 
. Multiphasic ADEM: New event, but involving new anatomical areas of the 
CNS. 
 
Clinically 
Isolated 
Syndrome 
(CIS)  
A first acute-clinical episode of CNS symptoms which may either be 
monofocal or multifocal, but does not include encephalopathy (except in 
brainstem syndromes). The MRI will show white matter demyelination. 
These include: 
1. Transverse myelitis (TM): weakness and/or numbness of both legs +/- 
arms, usually with maximal deficits 1 week after symptom onset supported 
by demyelination on MRI spine. 
2. Optic Neuritis: Acute or subacute loss of vision and ≥1 of: relative afferent 
pupillary defect (unilateral cases), visual field deficit or scotoma, impaired 
colour vision, optic disc oedema, or abnormal visual evoked potentials. MRI 
is not necessary for diagnosis. 
3. Other CIS: Brainstem, cerebellar, and/or hemispheric dysfunction, 
supported by demyelination on MRI. 
 
Neuro-myelitis 
Optica (NMO)  
Must have: i. Optic neuritis and ii. Acute myelitis.  
Must have: Spinal MRI lesion extends over three or more segments or iv. 
Aquaporin-4 antibody testing is positive. 
The brain MRI may be abnormal but must not meet Multiple Sclerosis MRI 
diagnosis criteria. 
Exclusion 
criteria 
1. Leukodystrophies (e.g., metachromatic leukodystrophy, adrenoleukodystrophy) 
or mitochondrial disease. 
2. Proven CNS infection (e.g. viral encephalitis, bacterial meningitis, herpes simplex 
encephalitis, Lyme disease, HIV). 
3. Radiation/chemotherapy associated white matter damage. 
4. Condition fulfilling criteria for CNS connective tissue disease e.g. lupus, 
vasculitis. The sole presence of antibodies associated with CNS connective tissue or 
autoimmune diseases was not sufficient for exclusion. 
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Data Collection:  
A condition specific targeted neurological history (using a check box questionnaire) took 
place at the time of first demyelinating event (see appendix). The event would be classified 
as either ADEM, CIS, or NMO (see).  Data collected was broadly categorised to: 
1. Basic demographic data (ethnicity, place of birth, residential areas)  
2. Patient and family history of neuroinflammatory disorders (positive history of MS/ 
autoimmune disease)  
3. Any precedent neurodisability or learning difficulties. 
4. Demyelinating symptoms and signs (using tick box table, see attached questionnaire) 
5. Presence of behavioural disturbance or encephalopathy (to distinguish ADEM from CIS) 
6. Information which might predict the subsequent development of recurrent ADEM, 
multiphasic ADEM, or MS, like details of the anatomic distribution (optic nerve or spinal 
cord, monofocal or multifocal distribution), CSF findings, serological and neuroimaging 
results.  
7. Treatment (eg, steroids, immunoglobulins, intensive care) given and duration of hospital 
stay. 
8. Information as to whether the risk of future Multiple Sclerosis was given to the family. 
9. In order to answer clinical questions and for our expert panel (which meets at 3 monthly 
intervals) to determine how to categorise cases, I will also ask for anonymous copies of the 
MRI. 
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MRI imaging review 
MRI scans were reviewed blinded to clinical features jointly by MA and one of five 
neuroradiologists. A standardised proforma was completed utilising previously described 
nomenclature (see Table 18) (20, 77, 97). McDonald 2001 dissemination in space criteria (as 
recommended by the current IPMSSG criteria),(12, 192) McDonald 2010 dissemination in 
space and time (if a gadolinium enhancing scan was available) criteria and Verhey prognostic 
criteria were classified by MA according to the MRI variables and associated expert panel 
review.(22) Features of ADEM and CIS scans were compared. A single MRI protocol was not 
followed as this was a national population based study and collected data from established 
clinical practice in many centres. All MRI brain scans were performed on 1·5T scanners and 
had a minimum of a T1 weighted, and a T2 weighted or fluid-attenuated inversion recovery 
(FLAIR) sequence in two different planes. Additional sequences included gadolinium-
enhanced T1, diffusion weighted and spine images. MRI slice thickness varied from 3–5 mm. 
 
Autoantibody markers 
 
The frequency of known results for antibodies to: AQP4; N-methyl-D-aspartate receptor 
(NMDAR); voltage-gated potassium-channel (VGKC) complex and myelin oligodendrocyte 
glycoprotein (MOG) were ascertained from routinely tested samples in the Oxford 
neroimmunology centre (one point national referral centre). 
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Table 18:  MRI definitions used 
 
MRI Lesion definitions: 
- periventricular lesions: lesions in direct contact with the ventricular system (lateral or third);  
- juxtacortical lesions: lesions in direct contact with the cortical gray matter with no intervening white 
matter;  
- Infratentorial locations:  brainstem and cerebellar lesions; 
- cortical lesions: located within the cortical grey matter; 
- corpus callosum: lesions perpendicular to the corpus callosum long axis;  
- deep white matter: lesions in the supratentorial white matter which is not juxtacortical, corpus callosal 
or  periventricular; 
- large lesions: lesions in the white matter with a diameter larger than 2cm; 
- deep grey nuclei lesions: thalamic and basal ganglia lesions which are located predominantly within 
grey matter; 
- gadolinium enhancing lesion: hyperintense signal on T1-weighted contrast-enhanced imaging and 
corresponding to a T2 lesion;  
- well defined and discrete lesions: clear lesions borders with an abrupt decrease in intensity of T2-
weighted signal at the borderline between lesion and surrounding brain tissue; 
- black hole: hypointense lesion(at least to grey matter) on T1-weighted image and is concordant with a 
hyperintense lesion on a T2-weighted image;  
- spinal cord: lesion within the grey or white matter of the spinal cord; subclassified as whether  equal  or 
greater than 3 segments. 
 
International Paediatric MS Study Group (IPMSSG) recommended McDonald 2001 criteria for 
dissemination in space (DIS):  
Three out of four features are satisfied:  
(1) nine or more T2 white matter lesions or one gadolinium-enhanced lesion;  
(2) one juxtacortical lesion;  
(3) three periventricular lesions;  
(4) one infratentorial lesion.  
 
McDonald 2010 DIS criteria are fulfilled if: 
 One or moreT2 lesion is present in two out of four areas: 
(1) juxtacortical;  
(2) periventricular; 
(3) infratentorial;  
(4) spinal cord (if the patient has a brainstem or spinal cord syndrome, symptomatic lesions are excluded 
from the criteria and do not contribute to the count). 
 
 McDonald 2010 dissemination in time (DIT) criteria can be fulfilled if: 
 a new T2 and or gadolinium-enhanced lesion is present on follow-up MRI irrespective of the timing of a 
baseline MRI, or if there is simultaneous presence of gadolinium-enhanced and non-enhanced lesions at 
any time (including at time of first scan). 
 
Clinically Isolated Syndrome (CIS) Classifications: 
Type 1 CIS: clinically monofocal, at least one asymptomatic MRI lesion 
Type 2 CIS: clinically multifocal, at least one asymptomatic MRI lesion 
Type 3 CIS: clinically monofocal, MRI may appear normal; no asymptomatic MRI lesions 
Type 4 CIS: clinically multifocal, MRI may appear normal; no asymptomatic MRI lesions 
Type 5 CIS: no clinical presentation to suggest demyelinating disease, but MRI is suggestive.   
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Expert panel classification and agreement for inclusion:  
The co-investigators and members of the UK & Ireland Childhood CNS Inflammatory 
Demyelination Working Group met quarterly as an expert panel to review reported cases (at 
least four members present at each meeting). The expert panel consisted of eight paediatric 
neurologists with specialist expertise in ADS. Cases were presented by MA, and 
disagreements were resolved by consensus as per IPMSSG clinical criteria. Neuroradiologists 
were blinded to clinical features. MRI images (with neuroradiologist scoring) were used: to 
confirm presence of lesions consistent with inflammatory demyelination; to aid in exclusion 
of cases; classify according to MRI criteria; and to sub-classify CIS cases (see Table 18). (27)  
Statistical Analysis 
Descriptive statistics were used to summarise the key components of the dataset. Estimates of 
national incidence with confidence intervals (Byar's approximation of the exact Poisson) for the 13 
month study was annualised using mid 2010 UK and 2010 Republic of Ireland population 
estimates.(196, 197) Mid 2009 population estimates by ethnicity for England and Wales 
were used to evaluate rates of childhood ADSs by ethnicity (198). A sensitivity analysis was 
conducted on a worst-case scenario that all reported cases with missing clinical histories 
were actually cases of ADSs to assess the potential impact on estimated incidence of ADSs. A 
two source case capture-recapture analysis was used to estimate missed cases of optic 
neuritis on the assumption of independence,(199) but did not carry out capture-recapture 
analysis for other ADSs, as referral networks mean that the assumption of independence 
was violated.  The England 2010 index of multiple deprivation was used to derive the 
percentage of cases in England living in the 20% most deprived districts.(200) Parametric or 
non-parametric statistical tests (Kruskal Wallis tests) were used for continuous distributions 
as appropriate given normality and 2 or Fisher’s exact tests for nominal data. Agreement 
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between reporters and the expert panel was measured using the Kappa statistic. Statistical 
analysis was performed using PASW Statistics for Windows version 17·0 (© SPSS, Inc., 2009, 
Chicago, IL, www.spss.com) and the openepi software (version 2·3·1, 
www.openepi.com).(201) 
Ethical and regulatory approvals  
The study protocol was approved by both the BPSU and BOSU executive committees. To 
comply with collection of minimal identifier information regulations without patient consent 
as in Section 251 of the NHS Act 2006, the study has approval from the National Information 
Governance Board's Ethics & Confidentiality Committee (ECC/BPSU 4-03 [FT1] /2009) and 
the UK Multicentre Research Ethics Committee (09/H1202/92). The study received research 
and development approval from the Birmingham Children’s Hospital R&D department. 
Risks, burdens, benefits and Confidentiality:  
The Caldicott Principles and Data Protection act were be adhered to. Patient identifiable 
data was stored unlinked to the clinical data.  A lay representative was assigned via the MS 
Society to ensure that patient and family views were appropriately sought throughout the 
study. Data handling was restricted to only those with direct involvement in the project. 
Data was secured in a lockable cabinet which is in a locked room. Minimal identifier data was 
collected (Table 19). 
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Table 19: Identifiers used and their justification 
Identifier Justification 
NHS Number To allow matching and deduplication between records and sources, and 
identifying cases to reporting clinicians, e.g. at follow-up. 
Date of birth For clinical analyses, and allow for anonymised linkage 
Sex For clinical analyses 
District postcode For epidemiological analyses 
Ethnicity For clinical-epidemiological analyses 
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2.3 Incidence 
 
Card return rate, expert review and record linkage outcome 
Card return rate was 94% from the BPSU and 78% from the BOSU (total of 47910 from 53235 
[90%] cards returned including negative reports). A total of 222 positive notifications (197 
BPSU and 25 BOSU) were received. There was insufficient information for review of 22 
notifications (6 Scotland, 12 England & Wales, and 4 Ireland and Northern Ireland). In the 
remaining 200 (90%), 41 duplicate notifications were identified. Cases where the first event 
was outside the inclusion dates, September 2009 to September 2010 (n=16) were excluded. 
A further 18 cases were excluded by the expert panel (Figure 9).  A total of 124/125 cases 
remaining had MRI scans (one isolated optic neuritis had no MRI scan, four transverse 
myelitis cases had MRI spine only).  
 
Incidence of childhood CNS Inflammatory demyelination in the British Isles 
The minimum incidence of first onset CNS inflammatory demyelination in children aged 1-15 
years old in the British Isles is 9·83 per million children per year (95%CI 8·18-11·71). 
Incidence was highest in England and Wales (see Table 20). A sensitivity analysis on the 
assumption that all initial notifications where no further information was obtained were ADS 
showed no difference in incidence rates within countries in the British Isles. 
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Figure 9: Study flow chart showing expert review and record linkage outcome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
British Paediatric Surveillance Unit (BPSU); British Ophthalmological Surveillance Unit (BOSU); N-
Methyl-D-aspartate (NMDA); Chronic inflammatory demyelinating polyneuropathy (CIDP); Post 
transplant lymphoproliferative disorder (PTLD). 
 
 
  
 
 
Av rage monthly 4095 cards (2945 BPSU, 1150 BOSU) to clinicians every month for 13 
months 
(94% card return rate for BPSU- primary source & 78% for BOSU- secondary source 
Overall 90%) 
 
200/222 (90%) information available for classification 
 
41 duplicates 
(4 of excluded cases and 37 of included cases) 
 
159/200 remaining 
                                                               
                                                                        143/159 remaining                                  First 
event outside  
                                                                                                                             inclusion date 
(n=16) 
                                                                                                                 
125 cases included                                                                        Excluded conditions (n=18) 
 
 
 
 
 
 
 
 
 
  
Cerebellitis (n=1); 
H1N1 associated encephalitis (n=1); 
Mumps associated encephalitis (n=1);  
NMDAR antibody encephalitis (n=1);  
Encephalitis (n=2);  
Guillian Barre syndrome (n=2); 
Chronic inflammatory demyelinating  polyneuropathy (n=2); 
Opsoclonus myoclonus syndrome (n=1);  
Pneumococcal meningitisvasculitis (n=1);  
Hypereosinophilic syndrome (n=1);   
Cerebral vasculitis (n=1); 
Metabolic syndrome (n=1); 
Hodgkin’s disease associated ON (n=1);  
Post radiotherapy (n=1);  
Post transplant lymphoproliferative disorder (n=1). 
Reported by: 
Paediatrician- 22.4% 
Paediatric Neurologist-  45.6 
Ophthalmologist-  6.4% 
Paediatrician & Paediatric Neurologist-  
20.0% 
Paediatrician or Paediatric Neurologist & 
Ophthalmologist-  5.6% 
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Table 20: Incidence of childhood Acquired demyelinating syndromes by country, sensitivity 
analysis and ethnic group in England and Wales 
CONFIRMED CASES 
Region Number  Percent  Pop. 2010 
 1-15 years (per 
thousands) or % 
Incidence 
per annum 
per million  
95% CI 
lower  
95% CI 
upper  
England, Wales 
& Channel 
Islands  
117  93.6  9636  11.2  9.27  13.4  
Scotland 3  2.4  853  3.25  0.65  9.49  
Ireland & 
Northern 
Ireland 
5  4.0  1254  3.68  1.19  8.59  
Total  125  100.0  11743  9.83  8.18  11.71  
 
SENSITIVITY ANALYSIS ASSUMING ALL REPORTS WITH MISSING INFORMATION ARE CASES 
England, Wales 
& Channel 
Islands 
129 87.8 9636 12.36 10.32 12.68 
Scotland 9 6.1 853 9.74 4.44 18.5 
Ireland & 
Northern 
Ireland 
9 6.1 1254 6.63 3.0 12.6 
Total 147 100.0 11743 11.6 9.76 13.6 
 
INCIDENCE BY ETHNICITY IN ENGLAND & WALES 
White     93 80.17% 83.93%    10.62 8.57 13.00 
South Asian     11  9.48% 7.30%    14.43 7.20 25.83 
Black     7 6.03% 3.31%    20.25 8.12 41.73 
Chinese, mixed 
and other     
5 4.31% 5.46%    8.78 8.28 20.27 
Total 116 116 100%    
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Capture-recapture analysis 
Capture-recapture analysis (Table 21) for optic neuritis cases (n=31) assuming that BPSU and 
BOSU were independent sources of cases estimated the total population to be 47 (95% CI 
30-55). 
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Table 21: Two source case capture-recapture(199): 
 
 
Cases ascertained 
via BPSU 
            Cases ascertained via BOSU 
 Yes No Total 
Yes 7 (c) 16 23 (a) 
No 8 (d) b – c + d 
  15 (b) a- c +d N=estimated total 
 
Assumption: probability of ascertainment from both sources equal where: 
a= cases ascertained by primary source 
b= cases ascertained by secondary source 
c= cases ascertained by both sources 
d= cases not ascertained by either source (N- a -b + c) 
N= [(a+1) x (b+1)/ (c+1)] -1= 47 (95% CI 30-55) 
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2.4 Demographic & Clinical Features of the ADS 
 
Demographic characteristics 
Median age was 10·0 years (range=1·3-15·9) and 51·2% (64) of cases were female (see Table 
22).  The median age for males was 8·9 years (IQR 5·0-13·5) and for females was 11·4 years 
(IQR 6·8-14·4) (p=0·046 Kruskal Wallis test). The female to male ratio in children younger 
than ten years (n=62) was 0·72:1 and in children older than 10 years old (n=63) was 1·52:1. 
White children comprised 81% of the total cohort.  Higher incidence rates of ADS in children 
of South Asian and black ethnicity in England and Wales compared to white children were 
not statistically significant (see Table 20). A total of 34% of the cases in England lived in the 
most 20% deprived districts.  
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Table 22: Clinical, demographic, and phenotypic classification of the childhood Acquired demyelinating syndromes 
 Expert classification 
 CIS (n=83)  
ADEM (n=40) ON (n=31) TM (n=26) Other CIS (n=26) NMO (n=2) 
Age At Presentation: median (IQR) 5.3 (3.6-7.0) 11.8 (9.0-13.9) 12.6 (9.3-14.0) 14.0 (9.5-14.5) n/a 
6.4, 14.8 years 
Sex 
(n=125) 
Male: Female (% female) 
61: 64 (51%) 
24:16 (40%) 15:16 (52%) 11:15 (58%) 11:15 (58%) 0:2 (100%) 
37:46 (55%) 
Ethnicity 
(n=124/125) 
White (n=101) 36 (90%) 21 (68%) 22 (85%) 21 (81%) 1 (50%) 
Asian  (n=11) 3 4 2 1 1 
Black (n=7) 1 3 1 2 0 
Chinese, mixed, other 
(n=5) 
0 3 1 1 0 
Clinical: MRI:   
Monofocal ≥ 1 asymptomatic lesion                                 
 
                                                                                         
 
7 (23%) 9 (35%) 4 (15%)  
no asymptomatic 24 17 3 (12%) 
Multifocal ≥ 1 asymptomatic 0 0 16 (62%) 
no asymptomatic 0 0 2 (8%) 
Radiologically isolated n/a n/a 1 
Spinal lesion(s) present: n (% ≥3 lesions) 8/12 (100%) 1/8 (0) 26/26 (62%) 4/9 (75%) 2/2 (100%) 
Death  1/40 (2.5%) 0 0 0 0 
Seizures 8/40 (20%) 0 0 0 0 
Optic neuritis: Unilateral: bilateral (% bilateral) 0:3 (100%) 22:9 (29%) 0:0 0:1 1:1 (50%) 
Cerebellar signs: n (%) 18 (45%) 0 0 11 (42%) 0 
Brain stem signs: n (%) 11 (28%) 0 1 13 (50%) 0 
Pyramidal signs: n (%) 24 (60%) 0 0 10 (38%) 0 
Intensive Care Unit admissions; n=12 (10%) 8 (20%) 0/31 (0%) 3/26 (12%) 1/26 (4%) 0/2 
Plasma exchange; n=4 (3%) 2 (5%) 0/31 2/26 (8%) 0/26 0/2 
Intravenous Corticosteroids 37/40 (93%) 23/31 (74%) 25/26 (96%) 18/26 (69%) 2/2 (100%) 
Oral steroids 27/40 (68%) 21/31 (67%) 16/26 (62%) 11/26 (42%) 2/2 (100%) 
Intravenous Immunoglobulin 6/40 (15%) 0 7/26 (27%) 1/26 (4%)  0 
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Results of expert panel review and clinical classification 
Childhood ADS disorders were classified as CIS in 66·4%, ADEM in 32·0% and neuromyelitis 
optic (NMO) in 1·6%. Of the CIS cases, optic neuritis (ON) represented 37·4%, transverse 
myelitis (TM) 31·3% and other clinically isolated syndromes 31·3% (see Table 22). The 
majority (70%) of the other CIS cases were polysymptomatic. Children with ADEM were 
more likely to be younger than cases presenting with CIS (p<0·001) (see Figure 10). The risk 
ratio for CIS in females compared to males was 1·46 (95% CI 1·17, 1·83). The expert panel 
reclassified (blinded to initial diagnosis) a total of 15 out of the 125 cases (12%): ADEM to CIS 
(n=11); Other CIS to TM (n=3); TM to other CIS (n=1). The overall level of agreement 
between reporters and the expert panel was good (Kappa 0·838 [95 % CI 0·761-0·914]). 
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Figure 10: Childhood CNS inflammatory diseases phenotype by age (younger and greater 
than 10 years old) and sex 
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Deaths 
Clinicians reported three deaths in the initial hospital admission, one in a child with ADEM 
and two in cases which proved not to have ADS (post transplant lymphoproliferative 
disorder and hypereosinophilic syndrome). 
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2.5 MRI features 
 
More CIS cases fulfilled MRI McDonald 2010 dissemination in space criteria (42%) compared 
to the 2001 criteria (28%; see Table 23). Of the CIS cases which had contrast enhanced scans 
(n=38), 10 cases (26%) fulfilled McDonald 2010 space and time criteria for MS diagnosis. 
Verhey MRI prognostic criteria for identifying childhood ADS cases at high risk of MS 
(presence of one T1 hypointense and one periventricular lesion) were fulfilled in 11/78 (14%) 
CIS cases compared to 1/40 (2·5%) ADEM cases. A total of 19/78 (24%) CIS cases fulfilled 
either Verhey prognostic criteria or McDonald 2010 MS space and time criteria for MS (8/10 
cases which fulfilling McDonald 2010 space and time criteria did not fulfil Verhey criteria, 
whilst 3/5 fulfilling Verhey criteria did not fulfil McDonald criteria).  
ADEM cases compared to CIS cases with abnormal MRI (see Table 24) were more likely to 
have more: deep grey nuclei (p<0·001); large white matter (p<0·001); and cortical grey 
matter (p=0·001) high T2 signal lesions. CIS scans were more likely to have more: 
periventricular (p<0·001); deep white matter (p=0·003); corpus callosum (p=0·001); well 
defined and discrete high T2 signal lesions (p<0·001) and black holes (p=0·008). The number 
of total high T2 signal, enhancing, infratentorial, juxtacortical and spinal lesions did not 
differentiate between CIS and ADEM patients (see Table 24). Of the ON and TM cases 
(monofocal CIS) 23% and 35% had one or more high T2 signal brain lesion respectively.   
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Table 23:  MRI criteria fulfilled 
 Expert classification 
 CIS (n=83) 
 ON (n=31) TM (n=26) Other CIS (n=26) 
McDonald 2001 space criteria 4/30 5/22 13/26 
22/78 (28%) 
McDonald 2010 space criteria 5/30 8/22 20/26 
33/78 (42%) 
McDonald 2010 time criteria 
(Gadolinium given scans) 
0/12 3/11 7/15 
10/38 (26%) 
Meets McDonald MRI criteria for MS 
on initial presentation 
(dissemination in space and time) 
10/38 (26%) 
Verhey or McDonald 2010 MS 
criteria present 
19/78 (24%) 
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Table 24: Comparison of MRI features in Clinically Isolated Syndrome (CIS) cases with 
abnormal MRI scans (n=41) and Acute Disseminated Encephalomyelitis (ADEM) cases (n=40) 
 Lesions (n) CIS ADEM 
T2 total lesions 
 
P=0.084 
1-4 lesions 12 17 (43%) 
5-10 lesions 8 7 
>10 lesions 21 (51%) 16  
Gadolinium enhancing lesions 
p=0.385 
 
0 lesions 12 (52%) 13 (72%) 
1-2  lesions 7 2 
>2  lesions 4 3 
Periventricular lesions 
 
p<0.001 
0 lesions 13 31 (78%) 
1-4 lesions 11 5 
>4 lesions 17 (41%) 4 
Juxtacortical lesions 
 
P=0.42 
0 lesions 14 16 (40%) 
1-4 lesions 9 10 
>4 lesions 18 (44%) 14 
Deep white matter lesions 
 
p=0.003 
0 lesions 11 20 (40%) 
1-4 lesions 7 11 
>4 lesions 23 (56%) 9 
Cerebellar lesions 
 
p=0.053 
0 lesions 27 (66%) 23 (58%) 
1-2  lesions 10 15 
>2  lesions 4 2 
Brainstem lesions 
 
p=0.931 
0 lesions 20 (49%) 18 (45%) 
1-2  lesions 16 19 
>2  lesions 5 3 
Corpus Callosum lesions 
 
p=0.001 
0 lesions 24 (59%) 37 (93%) 
1-2  lesions 12 1 
>2  lesions 5 2 
Thalamic/ basal ganglia 
p<0.001 
 
0 lesions 39 16 
1-2  lesions 1 18 
>2  lesions 1 6 
Black Holes p=0.008  11/41(27%) 2/40 (5%) 
Well Demarcated  (p<0.001)  30/41(73%) 11/40 (28%) 
Large lesions present (p<0.001)  26/41(63%) 8/40 (20%) 
Cortical grey lesions 
p=0.001 
0 lesions 39 (95%) 26 
≥1 lesion 2 14 (35%) 
Spinal lesions (p=0.851)  13/20 (65%) 8/12 (67%) 
Spinal >3segments (p=0.13)  9/13 (69%) 8/8 (100%) 
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2.6 Investigative & Immunological Features 
 
Investigative features 
Children with ADEM more commonly had CSF lymphocytosis (p=0·005) and less commonly 
CSF positive oligoclonal bands (p=0·011) compared to those with CIS (see Table 26: 
Investigative features). One ADEM case was reported as having the common missense 
mutation (c.1880CT, p.Thr585Met) of the Ran Binding Protein 2 (RANBP2) gene previously 
reported in recurrent or familial acute necrotising encephalopathy.(134) Of those tested for 
the aquaporin-4 antibody (n=52), none of the ADEM, TM, and other CIS cases tested positive 
while one child with optic neuritis and both NMO patients tested positive.  
 
Autoantibody markers 
The following were positive (total 8/63, 13%) for antibodies against: 3/52 AQP4 (6%), 2/17 
NMDAR (12%), 1/12 VGKC-complex (8%) and 2/8 MOG (25%) (Table 25). Of the AQP4 
positive: one had unilateral optic neuritis (ON) and longitudinal extensive transverse myelitis 
(LETM) with normal brain MRI; one had bilateral ON and LETM with an acute disseminated 
encephalomyelitis (ADEM) like MRI; and one had isolated ON with poor visual recovery 
(normal brain and spine MRI). Of the NMDAR positive: both had severe ADEM presentations 
and bilateral external capsule involvement and either deep grey nuclei or cortical 
involvement. The VGKC positive case had ADEM like presentation with bilateral basal ganglia 
involvement. Both MOG positive cases had ADEM presentation with MRI showing 
asymmetric and diffuse cortical grey, white matter, deep grey nuclei, and infratentorial 
lesions.  
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Table 25: Autoantibodies in ADS 
 
 
Expert classification 
 
ADEM 
(n=40) 
CIS (n=83)  
ON (n=31) TM (n=26) Other CIS 
(n=26) 
NMO (n=2) 
AQP4 antibody 0/5 1/18 0/20 0/7 2/2 
MOG antibody 2/2 0/2 0/2 0/2 0/0 
NMDAR 
antibody 
2/9 0/3 0/3 0/2 0/0 
VGKC antibody 1/7 0/1 0/2 0/2 0/0 
Cerebrospinal Fluid (CSF); Aquaporin-4 antibody (AQP4); N-methyl-D-aspartate receptor 
(NMDAR); voltage-gated potassium-channel (VGKC) complex; myelin oligodendrocyte 
glycoprotein (MOG); Ran Binding Protein 2 gene (RANBP2). 
  
110 
 
Table 26: Investigative features 
Cerebrospinal fluid (CSF) 
Result 
Expert classification 
 
ADEM (n=40) 
CIS (n=83)  
ON (n=31) TM (n=26) Other CIS (n=26) NMO (n=2) 
CSF Oligoclonal bands 2/20 (10%) 6/17 (35%) 6/19 (32%) 10/15 (67%) 0/1 (0%) 
CSF WBC ≥5x 106/L 21/36 (58%) 3/17 (18%) 8/20 (40%) 8/21 (38%) 0/2 (0%) 
CSF protein median (IQR) 0.38 (0.25-0.58) 
n=28 
0.26 (0.23-0.35) 
n=17 
0.36 (0.26-0.52) 
n=19 
0.29 (0.21-0.36) 
n=17 
0.29 
n=2 
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2.7 Differential Diagnosis 
 
Excluded cases 
On review 19 cases were considered not to have 1st episode demyelination. Table 27 details 
the excluded cases by final expert panel diagnosis against how they were reported to the 
study. The final column also details comments on why the diagnosis was changed.   
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Table 27:  Details of excluded cases 
Case 
number
/ ID 
 
Expert panel  
diagnosis 
Reported by     Country Reported 
as  
Age/sex Comments i.e. why 
change of diagnosis 
1.  
1001/10 
Cerebellitis Paediatrician  England CIS 7yr,  
male 
Cerebellar symptoms 
limited to cortical 
grey matter on MRI 
 
2. 
 
0911/06 
H1N1 associated 
encephalitis  
Paediatrician & 
Paediatric 
Neurologist 
Scotland ADEM 1yr, 
female 
Normal MRI brain 
scan 
H1N1 positive 
 
3. 
1004/17 
Mumps 
associated 
encephalitis  
Paediatrician England ADEM 15yr,  
male 
Mumps positive 
Cortical brain MRI 
changes 
 
4. 
 
1007/05 
NMDAR antibody 
encephalitis  
Paediatrician England ADEM 15yr, 
female 
Mycoplasma positive/ 
NMDAR positive 
MRI brain normal 
 
5. 
 
1003/30 
Encephalitis  Paediatrician England ADEM 5 yr, 
female 
MRI brain normal 
6. 
 
1008/10 
Encephalitis Paediatric 
Neurologist 
England ADEM 15yr,  
Female 
MRI brain normal 
7. 
 
0910/05 
Guillain-Barre 
syndrome  
Paediatrician England TM 9yr, 
male 
MRI spine normal 
Clinical and 
electrophysiological 
findings of peripheral 
demyelination 
 
8. 
 
1001/03 
Guillain-Barre 
syndrome 
Paediatrician England TM 11 yr, 
male 
MRI spine normal 
Clinical and 
electrophysiological 
findings of peripheral 
demyelination 
 
9. 
0909/14 
Chronic 
inflammatory 
demyelinating  
polyneuropathy  
 
Paediatrician England TM 14yr, 
female 
Abnormal nerve 
conduction studies. 
Also has known 
Systemic Lupus 
Erythematosus 
10 
1007/07 
Chronic 
inflammatory 
demyelinating  
polyneuropathy 
 
Paediatrician England TM 4yr,  
female 
Abnormal nerve 
conduction studies 
Normal MRI spine 
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Table 27:  Details of excluded cases continued.. 
Case 
number
/ ID 
 
Expert panel  
diagnosis 
Reported by     Country Reported 
as  
Age/sex Comments i.e. why 
change of diagnosis 
11 
1009/03 
Opsoclonus 
myoclonus 
syndrome  
Paediatrician England ADEM 1yr, 
male 
Normal MRI brain 
Clinical features of 
Opsoclonus 
Myoclonus Syndrome 
 
12 
0911/11 
Pneumococcal 
meningitis/ 
vasculitis  
Paediatric 
Neurologist 
England ADEM 2yr,  
Male 
Vasculitic lesions on 
MRI brain. CSF 
positive for 
pneumococcus 
 
13 
1002/02 
Hypereosinophilic 
syndrome   
Paediatrician England CIS 14ys, 
female 
Eosinophilia, and 
clinical features of 
hypereosinophilic 
syndrome .  
MRI brain: numerous 
small deep white 
matter lesions. 
 
14 
1009/02 
Cerebral vasculitis  Paediatrician England ADEM 12yr,  
male 
Localised cortical 
inflammation. 
Ophthalmic zoster. 
 
15 
1008/12 
Metabolic 
syndrome  
Paediatrician 
 
England ADEM 2yr, 
male 
Referred to tertiary 
metabolic centre. 
Demyelination ruled 
out. 
16 
ON 
0910/03 
Hodgkin’s disease 
associated ON  
 
Ophthalmologist 
 
England ON 12yr, 
female 
Hodgkin’s disease 
related relapse 
17 
0909/02 
Post radiotherapy  Paediatrician Scotland ADEM 5yr,  
female 
Post radiotherapy 
disease for 
medulloblastoma. 
MRI: cortical diffuse 
cerebellar lesion. 
 
18 
0911/01 
Post transplant 
lympho-
proliferative 
disorder  
Paediatric 
Neurologist 
England ADEM 2yr,  
male 
Immunosuppression 
 Post bowel 
transplant.  
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2.8 Treatment 
The majority (89%) received either intravenous corticosteroids (84%) and/or oral 
prednisolone in the first instance (see Table 28). Children with ADEM were more likely to 
require intensive care unit (ICU) admission, and four children (2 ADEM and 2 TM) received 
plasma exchange. Intravenous immunoglobulin was administered to 11% of the cohort. 
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Table 28: Treatment of ADS 
 
 Expert classification 
 CIS (n=83)  
ADEM (n=40) ON (n=31) TM (n=26) Other CIS (n=26) NMO (n=2) 
Intensive Care Unit admissions; n=12 (10%) 8 (20%) 0/31 (0%) 3/26 (12%) 1/26 (4%) 0/2 
Plasma exchange; n=4 (3%) 2 (5%) 0/31 2/26 (8%) 0/26 0/2 
Intravenous Corticosteroids 37/40 (93%) 23/31 (74%) 25/26 (96%) 18/26 (69%) 2/2 (100%) 
Oral steroids 27/40 (68%) 21/31 (67%) 16/26 (62%) 11/26 (42%) 2/2 (100%) 
Intravenous Immunoglobulin 6/40 (15%) 0 7/26 (27%) 1/26 (4%)  0 
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2.9 Discussion 
 
 
Incidence of childhood ADS 
The minimum incidence of first onset childhood ADS in the British Isles is 9·83 per million 
(95% CI 8·18-11·71) children per year aged 1-15 years. This is the highest reported incidence 
of childhood ADSs from a prospective childhood surveillance study. Published studies 
reporting on the incidence of childhood ADSs (summarised in Table 5) included one 
retrospective analysis of a patient database, a multicentre retrospective study, a single 
centre prospective study, and two prospective population based surveillance studies.  This 
study is a novel large multinational interdisciplinary epidemiological study which uses 
multiple sources and two well established active surveillance units. Unique to this 
surveillance study is integrated detailed review of MRI images and investigative features and 
combines this with the robust application of criteria by an expert panel (for inclusion, 
exclusion and differential diagnoses).  
 
To date, there have been two surveillance studies studying ADSs.  A Canadian surveillance 
study (2004-2007) estimated the incidence of childhood ADSs to be 9·0 per million,(32) with 
22% classified as ADEM and 78% as CIS. This study however used a single surveillance system 
with a card return rate of 80%; did not have MRI available or have expert panel review; 
included adolescents up to the age of 18; did not include neuromyelitis optica; and 
commenced before IPMSSG definitions were published.  An earlier surveillance study from 
Germany (1997-1999) estimated the incidence of MS in children <16 years as 3·0 per million 
children, and that of ADEM as only 0·7 per year per million children.(31) This study also used 
only one source with ascertainment from paediatric departments; did not have MRI 
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available or expert review; and did not include other ADSs.  Diagnosis of MS depends on 
clinical definitions and MRI criteria used. Hence, reliable ascertainment requires expert 
review as in the study reported here. 
Limitations 
This study is not without limitations. As with other epidemiological studies, some cases may 
not have been reported or have had sub-clinical presentations, and it is plausible that 
children in our study who met criteria for MS at first clinical presentation may have had 
previous symptoms not identified as ADS.  This was addressed as far as was possible by using 
clear consensus case definitions and multiple sources of case ascertainment. A capture-
recapture analysis estimated that a possible 16 optic neuritis cases were missed out of a 
potential 47, although this relies on strong assumptions of complete independence that may 
not hold in practice.   It suggests however that actual incidence may be higher than 
reported.  
 
Demographics and clinical-radiological phenotype 
Previous MS studies have shown that adolescent females are over-represented compared to 
males with ratios of up to 3:1 (5-7). A recent retrospective study from the USA showed the 
incidence of childhood ADSs and MS to be higher in black children compared with white and 
Hispanic children(33). While non-white ethnic groups were over represented in our study, 
this did not reach statistical significance but this still contrasts with the adult MS population 
where white ethnic groups are over-represented. Adult MS studies have also shown a 
consistent increase in female MS incidence, compared to males, as well as a higher risk ratio 
of females developing CIS,(8) the first presentation of MS. Our study is the first to show that 
in childhood ADSs, sex ratios also varied with age, with more males in younger age groups 
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and more females in the older age groups (F:M ratio of 1·52:1 in children over 10 years). 
Children older than 10 years more often had CIS compared to those less than 10 years of age 
who presented more often with ADEM. A Japanese retrospective multicenter study showed 
the male to female ratio of ADEM to be 2·3:1, and that ADEM was three times more 
common than MS.(36) These observations regarding the demographics of childhood ADSs 
support the hypothesis that gene-environment interactions (which might include vitamin D) 
may indeed be acting as early as in childhood. 
 
Our study shows that CIS occurs more often than ADEM (ratio 2·1:1) in children and also 
confirms a previous report that ADEM can be a severe disease with one death and one in 
five requiring intensive care admission.(202)  I found that 43% of CIS patients had one or 
more asymptomatic brain lesion. Previous studies have shown that children with CIS with 
abnormal brain scans are at a higher risk of relapse than those with ADEM (21, 23).  
 
MRI features 
This is the first study which has applied the newly revised MS 2010 McDonald diagnostic 
criteria in a population based series.  A total of 26% of CIS cases who had gadolinium given 
scans (n=38) fulfilled McDonald 2010 MRI criteria for MS at onset (space and time), hence a 
minimum 12% of CIS patients met McDonald 2010 MS diagnostic criteria at diagnosis. In 
addition 24% of CIS cases fulfilled either McDonald 2010 or Verhey criteria which are 
thought to indicate higher risk of MS, although both the McDonald criteria and the Verhey 
model require further validation in prospective multinational cohorts. This is particularly the 
case as in this study 8/10 of cases fulfilling McDonald 2010 MS criteria did not meet the 
criteria from Verhey’s predictive model. Also it is of interest that a number of MRI measures 
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significant helped differentiate ADEM from CIS cases. For example ADEM cases compared to 
CIS had more: deep grey nuclei; and cortical grey matter; high T2 signal lesions. CIS had 
more: periventricular; deep white matter; corpus callosum; and black holes.  I have 
previously shown that 61% of children eventually diagnosed with MS and who had contrast 
enhanced scans at ADS onset fulfilled McDonald 2010 MS criteria at first scan.(7)  Not all 
children in this study had spinal imaging and contrast administered, and MRI sequence 
variation could have affected the sensitivity of MRI. 
Investigative features 
CSF lymphocytosis and negative CSF oligoclonal bands were significantly associated with an 
ADEM diagnosis, in contrast to a previous study (26). 
Autoantibody markers 
CNS inflammatory demyelination (ADS) results from activation of antigen-specific T cells 
together with a humoral response. Potentially pathogenic CNS directed antibodies like 
myelin oligodendrocyte glycoprotein (MOG) are increasingly being reported in the context of 
adult (203) and childhood Acquired demyelinating syndromes,(204-206) implicating a role 
for B cell and antibody mediated mechanisms in ADS. In neuromyelitis optica (NMO), 
antibody to aquaporin 4 (AQP4) is a specific disease biomarker (207). 
In addition to AQP4, other circulating CNS directed autoantibodies, are associated with 
childhood ADS. In this study 14% of cases (other than NMO) tested were positive for these 
antibodies. As the presence of these self directed autoantibodies may simply reflect the 
secondary upregulation of the immune system, future systematic biomarker studies are 
required to evaluate the pathogenic role of these auto-antigens, or if they may be potential 
biomarkers for a subtype specific ADS.  
120 
 
Genetic insights 
It is of interest that one case was reported as positive for the common mutation in the 
RANBP2 gene, which has been recently described in familial or recurrent acute necrotizing 
encephalopathy (ANE) (134). With the increasing recognition of the overlap between the 
MRI and clinical features of ADEM and ANE, and further reports of other genetically 
predetermined encephalopathies,(208) this potential novel group of genetic determinant(s) 
of  encephalopathy in demyelination requires further exploration. 
Differential Diagnosis 
The differential diagnoses for ADEM and MS are recognised as challenging dilemmas when 
presenting to clinicians and need to be carefully considered (27, 28). The differential in the 
study included: other CNS inflammatory causes (cerebellitis); infections (H1N1 encephalitis, 
mumps encephalitis, other viral encephalitis, pneumococcal meningitis); auto-antibody 
mediated diseases (Anti-N-methyl-D-aspartate receptor encephalitis); other CNS 
autoimmune disorders (Opsoclonus myoclonus syndrome); peripheral demyelinating 
diseases (Guillian Barre syndrome, and chronic inflammatory demyelinating 
polyneuropathy); cerebral vasculitis; peripheral demyelinating diseases (Guillian Barre 
syndrome, and chronic inflammatory demyelinating polyneuropathy); tumour related events 
(Hodgkin’s disease associated optic neuritis, post radiotherapy, post transplant lympho-
proliferative disorder); metabolic syndromes; haematological (hypereosinophilic syndrome).   
Out of the 18 cases incorrectly reported; 11 (61%) were reported as ADEM; 4 (22%) were 
reported as TM; and 3 were other CIS cases. This indicates that more severe presentations 
including those with encephalopathy are most likely to be misdiagnosed which has 
implications for NHS clinical practice and indeed internationally. Of note is that 14 of the 18 
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cases initially presented to general paediatricians (who reported the cases) who are likely to 
have relatively little experience of recognising managing these rare neurological diseases— 
this raises the issue of continuous education and increasing awareness in rare neurological 
presentations amongst practicing generalists. Importantly two patients not classified as 
having ADS died, raising the possibility that early recognition may have changed 
management and outcome. In children who have received immunosuppression, 
chemotherapy or radiotherapy and present with polyfocal neurological symptoms and 
multiple white matter lesions; tumour related events should be considered.   
 
The study has highlighted a number of other key management issues Cerebellitis should be 
considered when a patient presents with cerebellar symptoms limited to cortical grey matter 
on MRI. It is important to recognise cerebellitis as hydrocephalus is a well recognised and 
treatable complication (209). Normal MRI brain scans or those showing just cortical grey 
matter changes in the context of children presenting with encephalopathy and polyfocal 
neurological symptoms/signs, should raise the suspicion of infective or immune mediated 
CNS disease. In children presenting with bilateral lower limb weakness, and a normal MRI 
spine- abnormal nerve conduction studies will help confirm clinical findings of peripheral 
demyelinating disease.  Children presenting with encephalopathy, polyfocal neurological 
symptoms, and MRI brain showing multiple widespread grey and white matter punctuate 
ischaemic/ vasculitic lesions should point towards infectious meningitis (with CSF 
examination providing further support).  
 
The management of paediatric acquired demyelinating syndromes indeed are also relatively 
under-recognised amongst practising paediatric neurologists, hence the set up of the UK 
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childhood inflammatory demyelinating disease working group (I am one of founding 
members) and the international paediatric multiple sclerosis study group (12, 210). The 
surveillance study has highlighted a number of differential diagnostic features which may be 
incorporated into national clinical guidelines or education programmes for paediatricians 
and neurologists. 
 
Treatment 
There are no controlled trials for the treatment of ADS in childhood. Most recommendations 
are mainly extrapolated from case series or data from clinical trials for the treatment of 
exacerbations of adult MS (41, 50, 158). Children are usually treated with high dose 
intravenous steroids for 3-5 days to attenuate inflammation .In this study, the majority 
(84%) received intravenous corticosteroids for the acute treatment of ADS. Subsequent oral 
steroid taper with a duration of 2–6 weeks is usually recommended for ADEM (5, 15, 211). 
Despite this, in this study only 68% of ADEM cases received an oral steroid taper. In children 
who do not respond to steroids, intravenous immunoglobulin is often used, although the 
data to support this is limited to small case series and single case reports (5). Intravenous 
immunoglobulin was administered to 11% of the cohort, with 13 of the 14 being given to 
children with ADEM or TM, representing the more severe ADS presentations. In cases of 
severe or life-threatening  acute  demyelination,  plasma exchange should be considered. 
Plasmapharesis is increasingly used as rescue therapy based on its efficacy in a small 
randomised controlled trial in adults with acute CNS demyelination  (160). Only four children 
(2 ADEM and 2 TM) received plasma exchange in this study, despite 12 having a severe 
disease as evidenced by needing an intensive care unit admission. The variable treatments 
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given at first ADS presentation, highlights the need for future clinical trials for acute ADS 
therapies and establishing guidelines for clinical practice. 
 
 
Conclusions 
In this study I report the highest surveillance incidence rates of childhood ADS to date and 
show that children of non-white ethnicity are not underrepresented as expected from adult 
MS studies. This study is the first to show that in childhood ADS, sex ratios varied with age, 
with more females in older age groups. The observations regarding the demographics of 
childhood ADS (changing sex ratios with age, and increased over representation of non-
white ethnicity) support the hypothesis that changing environmental risk factors for MS may 
indeed be operating in childhood, hence having implications for future preventative studies 
(such as use of Vitamin D supplementation). 
  
This is also the first study which has applied the newly revised MS 2010 Macdonald 
diagnostic criteria in a prospective population based series.  I also showed that a minimum 
24% of first onset met criteria for being at high risk of MS diagnosis at first presentation and 
hence were potentially eligible for early disease modifying treatment. The variable 
treatments given at first ADS presentation also highlights the need for future clinical trials 
for acute ADS therapies. 
 
 
The potential to diagnose MS at disease onset has implications for MRI protocols for children 
with suspected ADS, and individual patient treatment decisions. This may be particularly 
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important as new MS drugs are emerging with reported better efficacy in adults than current 
injectables, and the simultaneous requirement for new drugs to undergo testing in children 
with the aim of ensuring robust evidence to support authorisation by regulatory agencies. To 
date, eight new MS drugs have been recommended for a Paediatric Investigation Plan,(212) 
hence earlier diagnosis may increase the eligible clinical trial population.  Prognostic and 
outcome data are needed to inform these decisions. In the next chapter I will discuss a 
prospective one year follow up of this patient cohort is under way and a further multicentre 
cohort study which will yield prognostic information for early diagnosis of MS in children. 
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CHAPTER 3 OUTCOMES IN ADS  
There is limited data limited data on the natural history and prognostic features of acquired 
demyelinating syndromes (ADS). In this chapter I describe a series of longitudinal 
retrospective case series to address the prognosis following a first episode of ADS, and also 
describe the one year outcomes from the national prospective surveillance study. In the 
chapter I aim to present a number of childhood ADS conditions and prognostic features, 
these are:  
- Chapter 3.1: a multicentre longitudinal retrospective case series including 44 children 
with childhood optic neuritis; 
- Chapter 3.2:  a multicentre longitudinal retrospective case series including 44 children a 
population based study involving intensive care units (n=27); 
- Chapter 3.3: a retrospective analysis of 38 childhood onset MS cases from three UK 
demyelination clinics was conducted; 
- Chapter 3.4: a historical neuromyelitis optica (NMO) longitudinal cohort (n=22) with 
known aquaporin-4 antibody (AQP4-ab) status and compare it to a contemporary 
incident national cohort sample; 
- Chapter 3.5: early outcomes and prognostic factors in a one year follow up of the 
national surveillance study, 
  
126 
 
3.1  Childhood optic neuritis clinical features and outcome 
 
INTRODUCTION 
Childhood optic neuritis (ON) due to demyelination is a potentially treatable condition that 
may lead to visual impairment. A recent Canadian surveillance study showed an incidence of 
0.2 per 100,000 children (32). However, incidence rates are likely to be geographically 
different and more studies are needed. Isolated ON may also be the first manifestation of 
Multiple Sclerosis (MS) or Neuromyelitis Optica (NMO). The natural history of childhood 
optic neuritis (ON) remains relatively unreported. Case series reported in the literature have 
tended to be single centre studies, not included NMO as an outcome and some have 
included cases of polysymptomatic clinically isolated syndromes (CIS) at presentation (54-
59). I reviewed isolated first episode childhood ON cases in three tertiary UK centres to 
evaluate clinical features and outcome. A secondary aim was to inform the design of a 
prospective national epidemiological surveillance study. 
 
METHODS 
Computerised databases were searched for consecutive cases to indentify ON cases 
between 1st  January 2002 and 31st  March 2008. The age at presentation was limited from 1 
month to less than 16 years of age. A text-based departmental database of patients seen in 
the paediatric neurology and ophthalmology departments was searched using the terms 
“optic neuritis.” Searches were conducted in three UK Children’s Hospitals. Patients’ notes 
were retrospectively analysed. I included cases with acute or subacute visual loss and one or 
more of the following: relative afferent pupillary defect (RAPD) in the affected eye in 
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unilateral cases, visual field deficit or scotoma, impaired colour vision, optic disc oedema, or 
abnormal visual evoked potentials (VEPs). 
I excluded cases with; other neurological findings; concurrent acute disseminated 
encephalomyelitis (ADEM); other causative aetiology; or previous CNS inflammatory 
demyelinating episodes.  Conditions excluded were anterior ischemic optic neuropathy; 
neuroretinitis; compressive or infiltrative optic neuropathies; Leber's hereditary optic 
neuropathy. 
Any pre-existing ophthalmic conditions that had affected visual acuity were noted. At least 
two researchers in each centre carried out the search and decided on inclusion, and in case 
of disagreement the first author was consulted. The primary outcome was visual acuity at 
recovery, and the secondary outcome was MS or NMO diagnosis on follow up.  A ‘positive 
MRI’ was defined as showing one or more brain T2 hyperintense lesions. International 
Paediatric MS Study group consensus definitions(12) were used for defining MS and other 
CNS demyelinating conditions. 
An excel spreadsheet was designed to collect and record anonymised data in the three 
centres. Descriptive data are presented. Statistical analysis utilised life-table analysis by the 
Kaplan-Meier method performed using SPSS (version 17.0) software. 
 
RESULTS 
Presenting features 
Searches indentified a total of 44 consecutive cases that were eligible for inclusion.  Ages 
ranged from 2.0 years to 15.8 years with a median of 10.9 years (interquartile range 9.0-13 
years). The female: male ratio was 1.8 (p= 0.07). ON was unilateral in 43% and bilateral in 
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57%. Maximal visual deficit at presentation was severe (a snellen equivalent of <6/60 
[LogMAR 1.00]) in 77% of cases. 
 
 
Outcome 
Cases were followed up for 2 months to up to 6 years (mean 1 yr, 10months, median 1 yr). 
Visual recovery (to pre-existing visual acuity if known, or a snellen equivalent of 6/9 or 
better[LogMAR 0.18]) occurred in 70% (41/59 eyes). Data on visual recovery was not 
available for 10 eyes. On follow up, 32% were diagnosed with MS (11/44) or NMO (3/44). 
Cumulative probability of cases developing MS or NMO (see Figure 11) by 2 years after ON 
onset was 0.45 (95% CI 0.25-0.65). Gender, age (younger or older than ten years of age), 
unilateral/bilateral ON, and visual acuity severity did not predict MS development. Relapsing 
ON (see Figure 12) was a strong predictor for the development of MS or NMO (logrank 
p<0.001).  
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Figure 11: Kaplan-Meier Curve showing cumulative probability of MS or NMO diagnosis after 
ON onset 
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Figure 12: Kaplan-Meier Curves showing cumulative probability of MS or NMO diagnosis 
after ON onset with relapsing ON 
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Investigation Findings 
At presentation out of the 44 isolated ON cases, 38 (86%) had MRI brain imaging, of which 
34% had white matter lesions other than in the optic nerve. A positive MRI for MS (see 
Figure 13) was a strong predictor for development of MS (logrank p<0.001). One patient with 
an initial normal MRI developed MS.  
A total of 17 patients had CSF oligoclonal (OGB) band testing (Table 29). CSF OGB had poor 
sensitivity (50%) but good specificity (89%) and did not reliably predict progression to MS 
(Fisher exact test p=0.1, negative LR=0.56). Two patients who later developed NMO had 
negative CSF OGB. All three patients later diagnosed with NMO had NMO antibody testing 
after they had relapsed with transverse myelitis (after 0.3, 0.4, and 2 years) and diagnostic 
criteria were met . 
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Figure 13: Kaplan-Meier Curves showing cumulative probability of MS diagnosis after ON 
onset with positive or negative initial MRI 
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Table 29: CSF oligoclonal band testing results and outcome 
 MS diagnosis on follow up  Monophasic ON/NMO  
Positive CSF OGB  4 1 
Negative CSF OGB  4 8 
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Treatment 
Out of the 44 cases, 32 (73%) were documented to have received treatment with steroids. 
Administration and dosage varied widely, and the favoured regime was three days of 
intravenous methylprdenisolone (30mg/kg, maximum 1 gram) with various lengths (0 to 6 
weeks) and doses of a prednisolone weaning regime. Children who had clinical CNS 
demyelinating relapses, and later diagnosed with Multiple Sclerosis by a Paediatric 
Neurologist were treated with disease modifying treatment (Rebif, BetaInterferon, or 
Copaxone). 
  
DISCUSSION 
Case series reported in the literature have tended to be single centre or smaller studies, not 
included NMO as an outcome, and some have included cases of polysymptomatic clinically 
isolated syndromes (CIS) at presentation(54-59). Our multi-centre study design utilised two 
sources for maximal case ascertainment, although capture-recapture analysis was not 
suitable due to problems with dependence and heterogeneity. Clear case definitions for 
inclusion and strict exclusion criteria were used at the outset. The retrospective nature as 
well as ascertainment being from tertiary centres raises the possibility of bias of case 
severity. The variable length of time to events, and follow of the study up was adjusted for 
by applying life table statistical analysis methods. 
Acute optic neuritis in children differs from the typical adult form(56, 58, 213). Bilateral 
disease is thought to be more common in children, as is severe loss of visual acuity (6/60 or 
worse in 84% of eyes in one series, with recovery of visual acuity to 6/12 or better in 76% of 
patients )(56). In another recent case series involving 36 children, ON was unilateral in 58% 
and bilateral in 42%. Maximal visual deficit was severe in 69%, but full recovery occurred in 
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39 of 47 affected eyes (83%) (59).  In our series ON was associated with severe visual deficit 
(<6/60 in 77%) with generally good visual recovery (70% in 41/59 eyes). Bilateral ON (57%) 
wasn’t significantly more frequent than unilateral cases. 
Age at presentation in our cohort (median 10.9 years) and a female predominance (ratio 
1:1.8) was comparable to other studies(54-59). Neither variables (age greater than 10 years, 
and female predominance) reached significance levels. 
As in adults, the condition is predictive of the subsequent risk of multiple sclerosis, although 
estimates of risk vary among studies. ON may also represent the first attack of Devic Neuro 
Myelitis Optica (NMO), an inflammatory, demyelinating condition in which clinical disease is 
referable to the optic nerves and spinal cord, without involvement of the remaining CNS 
white matter(214, 215). Devic NMO is associated with a high mortality (30%) in adults(214), 
but it is possible that the same process may have milder manifestations in children(216). 
Recently, a serum antibody that targets the aquaporin 4 molecule has been identified in 
Devic’s NMO (60). In one longitudinal study, multiple sclerosis was diagnosed in 13% of 
children within 10 years after the first episode of optic neuritis, and in 19% within 20 
years(58). In a Canadian cohort, 36% were diagnosed with MS at 2 years. In our study, I used 
lifetable analysis due to varying follow up lengths, and differing time points to relapse and 
MS or NMO diagnosis. The risk of MS or NMO development after isolated ON was high, with 
a cumulative probability of 0.45 at 2 years. 
In our series a positive MRI at ON onset was a strong predictor for development of MS. Only 
one patient with a normal MRI developed MS. This data is comparable with that of the other 
cohort studies. In terms of other predictors, relapsing ON was also a strong predictor for MS 
or NMO development. Two case series have implicated bilateral (58, 59)as opposed to 
unilateral ON (57)as a predictor for development of MS, whilst one smaller series indicated 
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that female sex and an older age(57) indicated a higher MS risk after ON onset. Our study 
showed that gender, age (younger or older than ten years of age), unilateral/bilateral ON, 
and visual acuity severity did not appear to predict MS or NMO development. 
Effects of corticosteroid treatment and other therapies on the recovery of visual function 
and on the risk of multiple sclerosis in children have not been established by randomized 
trials, but on the basis of data in adults, treatment with intravenous methylprednisolone is 
generally recommended if visual loss is unilateral and severe or is bilateral(213). Interferon 
therapy is considered in children with abnormal MRI scans of the brain, but data regarding 
the efficacy of therapy to prevent multiple sclerosis are lacking in this population. In our 
cohort 77% of cases received corticosteroid treatment with the favoured regime being three 
days of intravenous methylprednisolone with various lengths of a prednisolone weaning 
doses. 
Our data suggests that childhood ON is associated with severe visual deficit with good 
recovery. The risk of development of MS or NMO was high. An initial abnormal MRI brain 
scan or relapsing ON should alert the clinician to MS or NMO diagnosis. A UK and Ireland 
population based prospective epidemiological surveillance study with multi-source case 
ascertainment is now underway to evaluate incidence rates and short term outcomes (at 
two years). Evaluating potential risk factors for early CNS demyelinating relapse and MS or 
NMO diagnosis may guide treatment guidelines and inform future longitudinal therapeutic 
trials.  
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3.2  Severe acute disseminated encephalomyelitis: a paediatric intensive care 
population-based study 
Introduction 
Acute   disseminated   encephalomyelitis   (ADEM)   is defined as an episode of inflammatory 
central nervous system (CNS) demyelination with polyfocal neurological  deficits  
accompanied  by  encephalopathy  (behavioural  change  or  altered  consciousness)(12). 
ADEM is more common in children than adults, although there are no adult epidemiological 
studies. Available population based incidence data of ADEM in childhood have reported an 
incidence of 0.7–4 per million children/year(31, 32, 38). There is often a wide variation in the 
severity of the illness. Occasionally, ADEM can present as a subtle disease, with nonspecific 
irritability, headache and somnolence.  However, ADEM can present with a rapid progression 
of symptoms and signs to coma and decerebrate rigidity requiring admission to the 
Paediatric Intensive Care Unit (PICU), and may result in death(18). There is a paucity of 
literature describing the more severe life-threatening spectrum and its management.  I 
describe a population-based study to determine the epidemiology, clinical characteristics, 
management and outcome of children with severe ADEM. 
Methods 
Severe ADEM was defined as requiring PICU admission or resulting in death. All 25 PICUs in 
England and Wales contributed towards data collected by PICANet between 2004 and 2008. 
PICANet is a UK national dataset which continuously records details of admission, discharge, 
diagnoses (coded using Clinical Terms 3 (The Read codes)), medical history, physiology,  
interventions  and  outcome.  The  Read  codes (X001c ADEM – Acute disseminated 
encephalomyelitis; X001P Acute haemorrhagic leucoencephalitis; and X005  Subacute  
haemorrhagic  leucoencephalitis)  were used to search the database. The Paediatric Index of 
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Mortality (PIM) scoring system was used to evaluate severity of illness(217). The PIM score is 
a simple model that consists of eight variables (type of admission; condition; response of 
pupils to light; base excess in blood; partial  pressure  of  oxygen  in  arterial  blood; fraction 
of  inspired  oxygen;  systolic  blood  pressure; mechanical ventilation during first hour) 
measured at the time of admission to a PICU to predict expected probability of patient 
mortality (0–100%). The original version of PIM with recalibrated coefficients (218) was 
used. The Office for National Statistics (ONS) mortality database(219) (deaths registered in 
England and Wales (Series  DR)  2009)  which  only  provides  ICD  codes for cause of death 
and age ranges, was also searched as  an  additional  method  of  case  ascertainment  of 
severe   ADEM   causing   death.   Equivalent   ICD-10 codes (G4.0 –  Acute  Disseminated  
encephalitis;  and G36.1 – Acute and subacute haemorrhagic leucoencephalitis) were used. 
Incident and mortality rates were calculated using a denominator  from  the  mid-2006  
England  and  Wales population  estimates  (10.2 million  children  younger than 16 years of 
age). Descriptive statistics were used to report on demographic and clinical features. Non-
parametric tests (Kruskall–Wallis) were used to test the effect of age, PIM score, use of 
inotropes, and clinical features  on  length  of  ventilation  days.  Anonymised data   were   
analysed   using   SPSS   Statistics   v17.0. Ethical approval for the collection of PICANet data, 
has previously been sought and obtained from a multi-centre   research   ethics   committee   
(Trent   Medical Research Ethics Committee ref.  05/MRE04/17)  and collection  of  person-
identifiable  data  has  previously been  approved  by  the  Patient  Information  Advisory 
Group. 
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Results 
In  total,  27  PICANet  ADEM  cases  (13  females, 14 males) were ascertained, giving a PICU 
population incidence for ADEM of 0.53 per million children/year (95%  CI  0.36–0.76).  There  
were  three  deaths  (three female,  aged  1–9  years)  all  ascertained  via  the  ONS 
database, giving a mortality rate of 0.06 per million children/year  (95%CI  0.02–0.2).  The  27  
PICANet cases which were available for further analysis had a median age of 4.8 years (range 
1.0–13.8 years). Clinical features   reported   included:   seizures   (n ¼ 5),   upper airway 
respiratory obstruction/stridor (n ¼ 2), polyfocal neurological deficits (n ¼ 6) and unspecified 
encephalopathy/encephalitis/encephalomyelitis   (n ¼ 27).   The number of children 
requiring invasive ventilation was 21/27 (78%), with   median number   of ventilation days =3   
(interquartile   range   1–5).   Inotropes   were used in four (15%) cases.  One patient had 
invasive intracranial pressure monitoring. No patients received plasmapheresis. There were 
no children with acute or subacute haemorrhagic leucoencephalitis. The median PIM score 
was 4.00% (interquartile range 2.4–6.2%). PIM scores were <1% in 11% and 1–5% in 48%.  All 
children were alive on discharge from PICU. Using the Kruskal–Wallis non-parametric test, 
only use of inotropes had a significant (p < 0.05) effect on length of invasive ventilation 
(Table 30). There was  no  observed  effect  on  admission  to  PICU  with regards to 
seasonality as measured by month of admission (October–March: 52%).  
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Table 30: Kruskal-Wallis tests to explore effect of proposed predictor variables on length of 
ventilation days 
Predictor Number Significance 
Use of Inotropes (median length of ventilation days) Yes= 4 (7.5 days) 
No= 23 (2.0 days) 
0.027* 
Seizures 
Respiratory obstruction 
Encephalopathy/polyfocal neurological 
5 
2 
20 
0.97 
PIM score>5%; variables measured: 
1. Type of admission to PICU  
2. Specified condition 
3. Response of pupils to light  
4. Base excess in arterial or capillary blood, mmol/l  
5. PaO2, mmHg  
6. FIO2 at time of PaO2  
7. Systolic blood pressure, mmHg  
8. Mechanical ventilation at any time during first hour in ICU 
 
11 0.92 
Age > 7 years of age 7 0.29 
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Discussion 
The incidence of childhood severe ADEM admitted to the PICU or resulting in death in 
England and Wales is approximately 0.5 per million children/year (32).  This represents  
approximately  a  quarter  of  all  children admitted  with  ADEM,  with  the  denominator  
being 2009 Canadian ADEM incidence data of 2 per million children/year. The  mortality  rate  
described  in  this study indicates that ADEM results in death in approximately 3% of children 
affected. ADEM occurs more commonly  in  young  children  less  than  10  years  of age(18), 
and  this  is  supported  by  our  study.  The  sex ratios  have  previously  been  reported  to  
be  approximately  equal (31, 38), and  this  is  supported  by  our  data. A  seasonal  
distribution  in  the  winter  and  spring months that has been found in studies conducted in 
the  United States (38) was not observed  in  our  severely affected cohort. The PIM scores 
for ADEM patients in this study were  similar  to  those of national  data  of all  patient 
admissions  in  2005(220), (PICANet  national  report 2005), where  15.3%  of  PICU  
admissions  had  a  PIM  of <1% and 51.8% had a PIM of 1–5%. Respiratory failure  secondary  
to  brainstem  involvement  or  severely impaired consciousness has previously been 
reported(18). In this study a large proportion of children required invasive ventilation for 
several days. Other indicators of severity are represented by the observation that inotropes 
were used in four (15%) cases, and one patient required invasive intracranial pressure 
monitoring. The clinical  presenting  features  to  PICU  did  not  predict severity   as   
measured   by   length   of   ventilation. However, cases that required the use of inotropes 
had a longer period of invasive ventilation. There are no controlled trials for the treatment 
of ADEM in childhood or adulthood. Most recommendations are based on observational 
studies. There is a consensus  that  intravenous  corticosteroids  should  be administered in 
order to shorten the acute inflammatory process and hasten recovery(18).   In cases of 
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severe or life-threatening acute demyelination, plasmapheresis is usually considered in 
adults(160).  Interestingly, none of the patients in our study received plasmapheresis. The 
database does not afford us enough information for us to comment if children responded to 
corticosteroids, or whether they received intravenous immuno-globulin.  I  speculate  that  
the  median  number  of ventilated   days   (n ¼ 3)   would   suggest   a   window where  
plasmapheresis  could  be  considered  prior  to improvement.  Thus  it  may  be  likely  that  
a  lack  of clinical trials in children, practical procedural difficulties, and a lack of consensus 
amongst treating clinicians  in  the  UK  are  reasons  for  the  lack  of  use  of plasmapheresis. 
Limitations of the study, that include the possibility of under-ascertainment, or 
misclassification as the case notes  and  magnetic  resonance  imaging  (MRI)  data were not 
available for review, preclude us from establishing long-term morbidity, outcome and best 
treatment. There are likely to be regional differences in the incidence  of  ADEM,  and  this  
has  to  be  taken  into account when interpreting estimates. In the PICANet dataset only six 
children were recorded as having polyfocal neurological deficits and unspecified 
encephalopathy, a widely accepted diagnostic criterion for ADEM. The diagnosis of ADEM is 
likely to have been made by a paediatric neurologist in conjunction with the evolution of 
clinical picture (not captured in dataset), and neuroimaging.  However,  it  is  important  to  
acknowledge that the diagnosis of these children may indeed be  of  some  variant  of  acute  
severe  demyelination rather  than  ADEM.  Our  group  has  embarked  on  a surveillance 
study where all paediatric cases of CNS inflammatory  demyelination  in  the  UK  and  Ireland 
are  being prospectively  ascertained  by active  surveillance (paediatricians, paediatric 
neurologists, ophthalmologists) over 13 months (September 2009–September 2010), with 
detailed clinical and MRI data collected at the  outset.  This  cohort  will  also  be  followed  
up  for more detailed outcome data, and will enable validation of the new international 
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definitions. Nevertheless, this intensive care cohort provides important insights into the 
epidemiology and management of severe ADEM. 
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3.3  Paediatric multiple sclerosis: examining utility of the McDonald 2010 criteria 
 
Introduction 
Paediatric  multiple  sclerosis  (MS)  is  becoming  increasingly  recognized, (221)  with  up  to  
10%  of  adults  having  their first symptoms in childhood. (222, 223)Magnetic resonance 
imaging (MRI)  is  increasingly  utilized  in  aiding  the  prompt diagnosis  of  MS  in  children. 
(224) Currently  the  International Paediatric  MS  Study  Group  (IPMSSG)  recommends  that 
paediatric MS diagnosis is based on McDonald 2001 MRI criteria (225, 226) whilst 
eliminating any lower age limit. In addition, the IPMSSG state that an episode of acute 
disseminated encephalomyelitis (ADEM) cannot be considered as the first event of MS, 
unless a second non-ADEM demyelinating  event  is  accompanied  by  further  evidence  of  
dissemination in time (DIT) (either with new MRI T2 lesions ≥3 months from the second 
event, or a new *third+ clinical event  developing  ≥  3 months  subsequent  to  the  second 
event). Recently the new McDonald 2010 diagnostic criteria, for the first time, have been 
recommended for use in children with acute demyelination presenting with a clinically  
isolated  syndrome  (CIS)(227). Common and  important  to both the McDonald 2001 and 
McDonald 2010 MRI criteria  is  the  requirement  of  lesion  dissemination  in  space (DIS)  
and  time  (DIT). The McDonald 2001 criteria state DIS  can  be  fulfilled  if  three  out  of  four  
features  are satisfied: (1) nine or more T2 white matter lesions or one gadolinium-enhanced  
lesion;  (2)  one  juxtacortical  lesion; (3)  three  periventricular  lesions;  (4)  one  
infratentorial lesion. The McDonald 2001 DIT criteria are fulfilled if new T2 lesions  or  
gadolinium-enhanced  lesions  develop  after 3 months  following  the  initial  attack (225). 
McDonald 2010 criteria state that DIS criteria are fulfilled if one or more T2 lesion is present 
in two out of four areas: (1) juxtacortical;  (2)  periventricular;  (3)  infratentorial;  (4)  spinal  
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cord (if  the  patient  has  a  brainstem  or  spinal  cord  syndrome, symptomatic lesions are 
excluded from the criteria and do not contribute to the count). McDonald 2010 DIT criteria 
can be fulfilled if a new T2 and or gadolinium-enhanced lesion is present on follow-up MRI 
irrespective of the timing of a baseline MRI, or if there is simultaneous presence of 
gadolinium-enhanced and non-enhanced lesions at any time (including at time of first scan). 
Previous retrospective MRI paediatric MS studies have shown McDonald 2001 criteria lack 
sensitivity for diagnosis of paediatric MS (224, 228). The same study groups have also shown 
that McDonald 2001 MRI criteria have high specificity and differentiated children with MS 
from those with relapsing non-demyelinating disorders with central nervous system  (CNS)  
involvement,  such  as  migraine  and  small vessel vasculitis (228).I hence aimed to assess 
the utility of the  new  McDonald  2010  criteria  in  comparison  with  the 2007 IPMSSG 
criteria for the early diagnosis of paediatric MS, and also compare these criteria in a cohort 
of children with  relapsing  non-demyelinating  neurological  disorders. To our knowledge 
this is the first study examining  the McDonald 2010 criteria in a paediatric cohort. 
 
Methods 
 
Cases with clinically definite relapsing–remitting MS (229)  from three tertiary UK paediatric 
demyelination clinics were retrospectively identified using hospital databases for MS. The 
demyelination  clinics  are  led  by  paediatric  neurologists with a specialist interest in MS 
and allow comprehensive and longitudinal evaluation of children with CNS inflammatory   
demyelination.   Consecutive   cases   of   children younger than 16 years old with a first 
demyelinating episode (post publication of McDonald 2001 criteria; 2001–2009) and with 
both initial (within 3 months of clinical onset) and first follow-up scan (routine or relapse 
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associated) available for review were included. All MRI scans were performed on 1.5T 
scanners. DICOM viewing software (IMPAX version; © 2007 Agfa HealthCare, Mortsel, 
Belgium) was used to view scans. Sequences used included, T1, T2, T2 FLAIR ± gadolinium-
enhanced.  A  standardized  MRI  protocol  was not used as this was a retrospective study 
based on collecting data from established clinical practice. MRI slice thickness varied from 3–
5 mm. MRI scans were examined for the presence of DIS and DIT criteria which allowed 
diagnosis via the McDonald 2001 criteria and McDonald 2010 criteria, respectively. Two 
assessors reviewed scans and reports, with consensus agreement with regards lesion 
number and location, and then inputted anonymised data into a standardized Excel 
spreadsheet. Migraine patients (International Headache Society Criteria  (230) with MRI 
brain T2 white matter  signal  changes  with  or  without  other  CNS  manifestations were 
used as controls (age and sex matched to patients with MS). Statistical analysis was 
performed using PASW Statistics for Windows version 18.0 (© SPSS, Inc., 2009, Chicago,   IL,   
www.spss.com).   Descriptive   and   non-parametric  statistics  were  used  (binomial,  
Fishers  exact, Kruskal–Wallis,  and  McNemar  tests)  to  summarize  key aspects  of  the  
dataset.  Ethical  approval  was  deemed  not necessary  for  this  retrospective  evaluation  
of  criteria  for routine clinical practice (National Research Ethics Service and National Patient 
Safety Queries Line 17/06/2011) and confidentiality of patients was maintained (data 
anonymised and cases cannot be identified). 
 
Results 
 
The initial search identified 49 patients, 11 of whom were excluded due to: lack of 
availability of initial or first follow-up  scan  for  review  (two  patients);  MS  diagnosis  not 
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clinically  confirmed  (two  patients);  monophasic  ADEM (three patients); multiphasic ADEM 
(two patients); or neuromyelitis optica (two patients). In total, 38 children with MS (Table 1) 
were included, 28 female and 10 male (p = 0.005). The median age of onset was 12.9 years 
(25–75th centile  =  10.5–14.3 years)  and  duration  of  follow-up  was median 3.5 years (25–
75th centile = 2.3–4.6 years). Clinical features  at  first  presentation  of  the  MS  cohort  
included: optic neuritis (16 patients); cerebellar (12 patients); pyramidal (11 patients); 
brainstem (10 patients); headache (seven patients);  hemisensory  (five  patients)  and  
myelitis  (four patients).  One  patient  presented  with  encephalopathy  on initial attack but 
had two subsequent CIS relapses consistent  with  MS.  Time  to first  relapse  was  median  
0.6 years (25–75th centile = 0.3–0.8 years) and median relapse rate was  0.8 relapses/year  
(25–75th  centile  =  0.4–1.5 relapses/year). Cerebrospinal fluid oligoclonal bands were 
positive in 23/31 (74%) and aquaporin-4 antibody was negative in 6/6  patients  tested. 
Twenty-nine  children  were  given  disease modifying treatment (DMT) in the form of 
interferon 1a (seven patients), interferon 1b (17 patients) or glatiramer acetate  (five  
patients)  at  a  median  age  of  13.7 years  (25–75th centile = 12.4–15.9 years). All patients 
had  T2  white  matter  brain  lesions  at  first MRI (Table 2). The McDonald 2001 DIS criteria 
were fulfilled in 26/38 (68%) at first scan, whilst McDonald 2010 DIS criteria were fulfilled in 
32/38 (84% p = 0.03). Only 18 patients had gadolinium contrast administered at first scan, of 
which 11 showed lesion enhancement (61%) hence fulfilling McDonald 2010 DIT criteria. The 
11 children who had gadolinium contrast upon their initial scan also fulfilled McDonald 2010 
DIS criteria, and hence fulfilled a diagnosis of MS  at  first  presentation.  On follow-up  MRI,  
3/38 (8%) children failed to meet the McDonald 2001 DIS and DIT  criteria,  whilst  all  
children  fulfilled  McDonald  2010 DIS and DIT criteria. Eighteen control cases were matched 
for age and sex to MS cases. The median age was 10.9 years for both groups (MS  cases  25–
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75th  centile  =  8.1–14.1;  control  25–75th centile = 7.7–14.2, p = not significant). Six control 
cases had  follow-up  imaging  at  a  median  of  0.7 years  (range: 0.3–2.1 years). There was 
no significant difference between the number of total T2 white matter lesions found in MS 
and controls (Table 3). Of those control cases given contrast (n = 2) at first scan, none 
showed enhancement. Only 1/18  control  case  fulfilled  both  the  McDonald  2001  and 
McDonald 2010 DIS criteria at first scan. This case did not fulfil  the  McDonald  2001  or  
McDonald  DIT  criteria  on follow-up scan (was never given contrast). Of the five other 
control cases that had a follow-up scan performed, all failed to meet DIS and DIT according 
to both the McDonald 2001 criteria and McDonald 2010 criteria. 
 
Discussion 
 
To my knowledge this is the first study examining the utility of the new McDonald 2010 
criteria in a paediatric MS cohort. The 2010 McDonald criteria allow MS diagnosis on the first 
scan and may allow diagnosis at first presentation of CIS in at least a half of paediatric cases. 
In addition, our study confirms that on follow-up imaging, the McDonald 2001 MS criteria 
(currently recommended by the IPMSSG) were met by fewer patients in contrast to 
McDonald 2010 criteria.  This  study  also  supports  the  hypothesis  that children presenting 
with typical clinical features of a CIS consistent with CNS inflammatory demyelination (227) 
should be  given  gadolinium  to  allow  for  earlier  diagnosis.  The abolition of specific time 
limits, as those of the older criteria, (226)  may make it easier for paediatric neurologists 
with an interest in MS to decide on early treatment of their patients and allow for prompt 
entry in to future paediatric clinical trials.  From the control group, only one control case 
fulfilled the McDonald 2001 and McDonald 2010 DIS criteria but did not fulfil DIT criteria on 
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follow-up. This is potentially reassuring, given that the new simpler criteria did not perform 
differently when compared with the more stringent established criteria. Limitations  of  this  
study  include:  its  retrospective nature; the fact that it contains cases with confirmed 
clinically definite MS as opposed to being a prospective follow up cohort study at first CIS 
presentation; that not all children had spinal imaging and contrast administered; the 
relatively small numbers precludes testing subgroups; and that MRI sequence  variation  
could  affect  the  sensitivity  of  results. Nevertheless the study provides useful data towards 
assessing the utility of the new McDonald 2010 criteria in children. Future longitudinal 
prospective studies are required to further evaluate these criteria in children presenting with 
a first episode CIS.  
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3.4  Prognostic factors for paediatric NMO and NMO spectrum disorders 
INTRODUCTION 
Neuromyelitis Optica (NMO) is a severe and rare inflammatory condition characterised by 
the presence of both optic neuritis and transverse myelitis occurring simultaneously or 
separated in time and distinct from multiple sclerosis. Auto-antibodies to the astrocytic 
water channel protein Aquaporin-4 (AQP4-Ab) AQP4 (60) are found in the majority of cases 
and are believed to be the cause of the observed astrocytic and myelin damage. The 
discovery of AQP4 antibodies has broadened the disease spectrum. AQP4-Ab appears to be a 
specific test as it is invariably negative in MS patients of all ages (61, 62). NMO usually 
presents  as an isolated optic neuritis (63)   (64) or as TM before further relapses reveal the 
underlying diagnosis (63). It is usually a relapsing remitting disorder unless treated with 
immunosuppression. NMO comprises 3-8% of the childhood Acquired demyelinating 
syndromes (61) and needs to be distinguished at onset from the commoner disorders 
namely multiple sclerosis, acute disseminated encephalomyelitis and idiopathic monophasic 
transverse myelitis. The revised diagnostic by Wingerchuck et al.(66), which are also 
accepted by the paediatric international MS study group (IPMSSG)(12); require two absolute 
criteria: (i) optic neuritis; (ii) myelitis; and at least two of three supportive criteria: (i) Spinal 
cord MRI lesion extending >2 vertebral segments; (ii) MRI criteria not satisfying the revised 
McDonald diagnostic criteria (67) for MS; (iii) AQP4-Ab in serum. 
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Table 31 summarises the clinical features in the three recent case series of paediatric NMO 
using diagnostic criteria (61, 68, 69). Importantly, out of the 38 NMO cases described in the 
three studies, only 16 (42%) tested negative for AQP4-Ab. In children as in adults (168), 
AQP4-Ab negativity is associated with recurrence and higher risk syndromes. In addition 
although brain involvement is increasingly recognised in NMO, yet the MRI features are still 
not well delineated. It is important to recognise NMO early as permanent disability is more 
attack-related in NMO than in MS. In paediatric practice, clinicians are often uncertain as to 
when to test for AQP4-Ab in children presenting with their first onset acquired 
demyelinating syndrome. I have previously reported in a national incident cohort (n-125), 
that of those  for  the AQP4-Ab (n=52), one child with optic neuritis and both Wingerchuck 
criteria positive NMO patients tested positive for AQP4-Ab; whilst  none of the ADEM, TM, 
and other CIS cases tested  positive(231). Very early onset NMO onset as occurs in children 
may inform different aspects of the disease such as MRI lesions, disability progress and other 
associated features. 
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Table 31:  Summary of recently described paediatric NMO case series (61, 68, 69)  
Ref Setting, Design & 
Criteria Used 
Demo-graphics AQP4-Ab & CSF OGB First attack & 
course/  
Time to first 
relapse/ 
Annualised relapse 
rate (ARR) 
 
MRI Brain  
features 
Disease Modifying 
Treatment 
Outcome/ 
disability 
Collongues 
2010 
Multicentre (mainly 
adult); retrospective;  
France; 
Follow up mean 19.3 
yrs; 
Wingerchuk  2006 
criteria 
12 cases 
 
Age: 14.5 yrs 
median (4.1-17.9) 
3F:1M 
8/12 AQP4-Ab 
positive 
First attack: 
6ON/5SC/1OS 
All relapsing-
remitting; 
 
first attack interval 
17 months (7–154) 
6/12 MRI brain 
abnormal (1-10 
lesions) 
 
3 MS radiological 
criteria positive 
(2MS/1ADEM) 0 
Barkhof 
All treatments used: 
Azathioprine; 
cyclophosphamide; 
glatiramer acetate; IVIG; 
interferon; mitoxantrone; 
MMF; rituximab 
Median time to EDSS 
4= 20.7 yrs 
 
Vision: residual visual 
loss  +1  logMAR or 
20/200 Snellen=1.3 
yrs. 
Lotze 
2008 
Retrospective single 
centre; USA;  
Follow up 4 yrs 
median (0.6-9); 
Wingerchuk  2006 
criteria 
9 cases 
 
Age: 14yrs 
median (1.9-16);  
All female  
6/9 AQP4-Ab  positive 
(1 had recurrent TM 
only) 
First attack: 5 
OS/1TM/2ON 
 
All relapsing 
 
ARR=2.6 
 
9/9 MRI brain 
abnormal (5 
symptomatic) 
All treatments used: 
6 steroids + MMF  
5 rituximab  
1 monthly IVIG  
1had  azathioprine, 
glatiramer, and monthly 
PLEX.  
Median EDSS=3 
(range 0-8) 
Banwell 
2008 
Selected prospective 
cohort; Canada & 
Argentina; 
Follow up 36 months 
median (1.2-126 
months); 
Wingerchuk  1999 
17 cases 
 
Age: 10.4 yrs 
median (4.4–
15.2) 
3.2F:1M 
 8/17 AQP4-Ab 
positive  
 
13 CSG OGB negative 
 
(1 recurrent ON, and 
1 recurrent TM AQP4-
Ab positive; 68 other 
CNS inflammatory 
demyelination were 
negative) 
9 relapsing (AQP4-
Ab pos)  
 
8 monophasic 
(AQP4-Ab pos)  
 
 
9/17 MRI brain 
abnormal 
At time of serum: 
7 prednisone,  
1 glatiramer acetate, 
1 interferon-1a, 
2 monthly IV 
cyclophosphamide 
 
1 non-ambulant, 1 
gait limited aid not 
required; 
 
Vision: 12/18 
decreased visual 
acuity or severe visual 
impairment (4/18) 
ADEM= Acute Disseminated Encephalomyelitis; ARR= annualised relapse rate; EDSS= Expanded Disability Status Scale; IVIG= intravenous immunoglobulin; MMF= mycophenolate mofetil; MRI= 
Magnetic Resonance Imaging; MS= Multiple Sclerosis; AQP4-Ab= Neuromyelitis Optica antibodies; ON= Optic Neuritis; OS= Optico-spinal; PLEX= plasmapharesis; SC= Spinal Cord; yrs= Years 
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I aimed to collect details of paediatric NMO and spectrum disorder cases to describe the 
clinical; MRI features; outcome; and prognostic features in relation to the AQP4-Ab status.  
  
METHODS 
 I conducted retrospective case ascertainment and case note review of paediatric (<17 years) 
cases from four UK paediatric demyelination centres and / or patients known to the UK 
national NMO service (Table 2).  MRI scans previously reported by a neuroradiologist were 
also reviewed at multidisciplinary NMO meetings Inclusion criteria used were the 
Wingerchuk 2006 criteria or AQP4-Ab positivity. 
Descriptive statistics, univariate associations, and Kaplan-Meir lifetable analysis were used to 
explore differences between AQP4-Ab positive/negative cases and predictors for relapse.  
In addition the MRI characteristics of the NMO cohort were compared to those of a national 
cohort selected sample of known AQP4-AB negative cases and not satisfying Wingerchuck 
criteria but with abnormal MRI brain scans(231).   
 
RESULTS 
Demographics 
A total of 22 cases were ascertained (Table 32) of which 19 were females (86%) and 14 were 
AQP4-Ab positive (64%). The median age of onset was 9.4 years (range 2.9-16.8 years) and 
median follow-up time was 5.9 years (range 1.5-17 years). 
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Table 32:  (A) NMO Cohort description (B) Phenotype of first relapse relative to the first 
attack 
A. NMO Cohort description AQP4 status Significance  TOTAL 
NMO 
cohort  
n=22  
 Demyelination 
cohort  
(n=29) 
AQP4 neg 
(n-8) 
AQP4 pos  
(n=14) 
Sex  Male: Female  0:8  3:11  p=0.17  3:19  13:16 
Age at onset 
(years) 
Median  
Range  
10.9  
(5.4-16.8)  
9.3  
(2.9-15.0)  
p=0.50   13.6  
(1.3-15.8) 
Follow up 
duration (years)  
Median  
Range  
5.4  
(1.5-12.0)  
6.1  
(1.8-17.8)  
p=0.92   1.0 
Wingerchuck 2006 
criteria positive 
 8/8  12/14   20/22  0/29 
First presentation/ 
cohort phenotype 
unilateral ON  
bilateral ON  
TM  
TM and ON  
ADEM  
2  
2  
2  
2  
0  
7  
2  
2  
1  
2  
p=0.38 (for 
unilat ON)  
9  
4  
4  
3  
2  
ADEM=3 
ON=2 
TM=11 
MS= 13 
MRI brain changes present  5/8  10/14  p=0.67  15/22 
(65%)  
29 
CSF OGB- positive  0/7  2/11  p=0.25  2/18  10/19 
Relapsing  6/8  13/14  P=0.25  19/22  n=11 
Phenotype of first 
relapse  
unilateral ON  
bilateral ON  
TM  
TM & ON  
CIS/ADEM  
3  
0  
2  
0  
1  
5  
0  
5  
1  
2  
n/s  8  
0  
7  
1  
3  
 
 
n/a 
 B. Phenotype of first relapse relative 
to the first attack 
 
Phenotype of first relapse  
unilateral 
ON  
TM  TM and 
ON  
CIS/ADEM  
First presentation  unilateral ON  5  1  1  1  
bilateral ON  2  2  0  0  
TM  1  2  0  0  
TM and ON  0  1  0  1  
ADEM  0  1  0  1  
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At presentation: 9 had unilateral ON; 4 had bilateral ON; 4 had TM; 3 had simultaneous TM 
& ON; 2 acute disseminated encephalomyelitis.  A half (11/22) of cases had a brain 
syndrome episode during the disease course and 20/22 (91%) had LETM. Table 2 also 
represents the phenotype of the relapse relative to the first attack. Differentials diagnoses 
recorded included: osmotic myelinolysis; mitochondrial; metabolic; ADEM; multiple 
sclerosis; isolated ON or TM; tumour.  
 
MRI  
Six of twenty-two cases (27%) had an abnormal brain MRI at disease onset, and 14/22 (64%) 
had an abnormal MRI brain on follow up (Figure 14). Eleven out of 14 (79%) had an abnormal 
within first year). Table 33 describes MRI brain lesion location and characteristics in the 
NMO cohort, as compared to the acquired demyelinating national sample.  
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Table 33:  MRI lesion location and characteristics in NMO patients as compared to an 
incident national cohort with abnormal MRI scans  
  n=14 NMO cases with 
abnormal MRI brain (out of 
22) 
N=29 Acquired demyelinated 
syndromes from a national 
cohort (non-NMO and AQP4-
Ab negative) 
Location Centrum semiovale / 
Deep White Matter  
7  (50%) 16 (55%) 
Periventricular  7 (50%) 14 (48%) 
Brainstem  6 (43%) 12 (41%) 
Thalamic/ basal ganglia  5 (36%) 5 (17%) 
Juxtacortical  5 (36%) 14 (48%) 
Periaqueductal grey 5 (36%) n/a 
Cerebellar  4 (29%) 7 (24%) 
Corpus Callosum 4 (29%) 10 (34%) 
Hypothalamic  3 (21%) n/a 
Cortical  2 (14%) 4 (14%) 
 
Nature 
of lesion 
Large 10 (71%) * 9 (31%) 
Acute lesions mostly 
resolving on repeat 
8 (57%) * 4/22 (18%) 
T1 hypointense 6 (43%) * 3 (10%) 
Gadolinium enhancing 5 (33%) 6/17 (35%) 
Barkhof 3 (21%) 11 (38%) 
LETM 20/22 (91%) * 11/29 (38%) 
*Fisher’s exact test p<0.05 
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Figure 14:  NMO MRI Brain Scans 
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Relapse 
 
 Using life table analysis (Figure 15), mean time to relapse was 2.4 years in AQP4-Ab negative 
cases (95% CI 1.1-3.6 years) vs 0.76 years (95% CI 0.43- 1.1 years) for AQP4-Ab positive cases 
(p=0.03 log rank test -mantel-cox). Six out of eight AQP4-Ab negative cases were relapsing vs 
13/14 AQP4-Ab positives. The annualised relapse rate for AQP4-Ab positive cases was 0.70/ 
year vs 0.38/ year for AQP4-Ab negative cases (z score=2.316; p=0.21).  
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Figure 15: Kaplan-Meier curves showing cumulative probability of relapse after first attack 
for children with AQP4-Ab positive NMO vs AQP4-Ab negative NMO 
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In order to conduct a clinical trial to reduce ARR from 0.70 to 0.35: a sample size requires 
based on a negative binomial model with a dispersion index k of 0.43; power =80%; 
alpha=0.05; would require a sample size of n=84 per arm. 
 
Outcome 
AQP4-Ab positive cases 11/14 had visual acuity of <6/60 snellen in at least one eye (0/8 in 
AQP4-Ab negatives). Three cases were wheelchair dependent on follow up (AQP4-Ab 
negative).  
 
 
DISCUSSION 
 
I describe a historical NMO longitudinal cohort with known AQP4-ab status and compare it 
to a contemporary incident national cohort sample.  As in other adult and paediatric series, 
NMO predominantly affects females. Interestingly all 8 AQP4-Ab NMO cases were females.  
 
At presentation a large proportion of children had optic neuritis (73%) compared to 
transverse myelitis (32%). Importantly two of the 22 cases presented with an acute 
disseminated encephalomyelitis, hence potentially delaying AQP4-Ab testing.  A half of cases 
had a brain syndrome episode during the disease course and the majority (91%) had LETM. 
As in other case series NMO is a relapsing disease with AQP4-AB positivity associated with 
higher relapse rates compared to AQP4-Ab negativity. 
The National MS Society task force on differential diagnosis of MS, (27) described MRI brain 
abnormalities  which were more likely indicative of NMO in adults as opposed to MS: 1. Non-
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specific brain T2-signal abnormalities not satisfying the Barkhof criteria for dissemination in 
space used in the revised McDonald criteria; 2. lesions in the dorsal medulla; 3. 
hypothalamic and/or brainstem lesions; 4.  linear periventricular/corpus callosum signal 
abnormality, but not ovoid, not extending into the parenchyma of the cerebral hemispheres 
in Dawson finger configuration. Brain lesions in paediatric NMO appear to occur more 
commonly (>50%) when compared with adult NMO (25%) (63). In one series (61) 9/17 (53%) 
children with NMO (Wingerchuk et al., 2006) had brain lesions. Our cohort confirms that 
brain involvement is common in paediatric NMO with nearly two thirds having an abnormal 
MRI brain scan. In a recent case series (69) showed that the first brain MRI in paediatric 
NMO (as defined in Wingerchuk et al., 2006) can show a diffuse inflammatory process, such 
as MS-like (2 patients) or acute disseminated encephalomyelitis-like lesions (1 patient). Brain 
lesions in another series (68) also confirm this observation and demonstrated that MRI brain 
changes in paediatric NMO frequently involve the diencephalon. In our cohort over one 
quarter of children had an abnormal MRI brain scan. In childhood NMO, lesions located in 
the hypothalamus, brainstem, or cerebral white matter, have been described.  In our cohort 
Lesion location did not appear to differentiate both samples but NMO lesion nature 
appeared different. NMO brain scan lesions compared to the acquired demyelinating cohort: 
tended to be large (>2 cm); acute lesions largely resolved on repeat scan; and often had T1 
hypointense lesions. It is important to recognise the spectrum of brain abnormalities in NMO 
as the occurrence of such lesions and sometimes the presence of encephalopathy and 
polyfocal neurological deficits may resemble ADEM, with misleading implications as to 
prognosis and therapy. 
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It is important to recognise NMO early in the course of the disease as permanent disability is 
more attack-related in NMO than in MS (168). Hence, early and aggressive intensive 
treatment with disease modifying treatment may be beneficial in reducing the disability and 
ameliorating the course of disease in children (27, 61, 68, 69, 168).  There have been no 
large randomised trials in children or adults and current practice is based on case series and 
expert opinion. Recent adult European consensus guidelines have been published (168). A 
wide variety of disease modifying drugs have recently been used but recent reports show 
that drugs used to treat multiple sclerosis (interferons, glatiramer) may exacerbate NMO 
(169). Although rare, early AQP4 testing may allow diagnosis and prompt 
immunosuppressive treatment. Clinical trials with designs for rare diseases are needed early 
in the disease course but with long term follow up in order to determine best treatment 
strategies in children with NMO. 
Paediatric NMO has been reported to have a better prognosis than adult NMO in terms of 
disability. In one study median time from onset to Expanded Disability Status Scale (EDSS) 4 
([significant disability but self-sufficient and able to walk without aid for approximately 
500m] 20.7 vs 5.3 years; p <0.01) and EDSS 6 ([requires a walking aid to walk about 100m]26 
vs 8.5 years; p <0.01) was largely explained by the increased severity of the first myelitis in 
the adult NMO group (69). In contrast, a USA paediatric NMO-spectrum series showed 
residual disability in 43/48 patients (90%) with 54% having visual impairment (27% blind) 
and 44% motor deficits (median Expanded Disability Status Scale 4.0) at 12 months (71).  In 
this cohort, childhood NMO is associated with clinical relapses and disability. AQP4-Ab 
positivity is associated with early recurrence and visual disability. 
NMO may be difficult to identify at first presentation due to similarity of clinical and MRI 
phenotype with other acquired demyelinating syndromes. MRI brain lesion characteristics 
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and early MRI repeat scans may be useful to raise suspicion.  In order to be alert to early 
visual failure in this rare disease, widespread AQP4-Ab testing may be needed as a standard 
investigation at first demyelination presentation. 
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3.5 Early outcomes and predictors after a first episode of an acquired demyelinating 
syndrome 
Aims 
In this section, I report on the outcomes from the British Isles (UK, Ireland, & Channel 
Islands) multisource prospective active surveillance study (See chapter 2.1 for a description 
of case ascertainment, methods, and incidence).  The primary objective of the follow up of 
cases in this chapter is to determine the following outcomes following a first episode of CNS 
Inflammatory Demyelination: occurrence of a relapse; multiple sclerosis diagnosis as per the 
International Paediatric MS Study Group (IPMSSG) criteria;   evidence of disability as per the 
EDSS functional scores. 
Secondary objectives were: 
- to report distribution of MS diagnosis by age, sex and ethnic group 
- to report MRI features of childhood MS  
- to classify diagnostic categories by using the IPMSSG consensus  definitions for MS 
diagnosis (including the incorporated McDonald MRI 2001 and Barkhof space diagnostic 
as recommended by IPMSSG criteria).[1, 2]  
- to investigate the sensitivity and specificity of MRI criteria and prognostic models 
proposed for children, including the newly revised 2010 McDonald space and time 
diagnostic criteria;(22) and the recent Verhey MRI prognostic model MS criteria using the 
IPMSSG MS criteria as the reference standard (193). 
- Consideration of risk factors with exploratory analyses for  phenotypic characteristics in 
predicting MS 
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- to describe the frequency with which  proposed clinical, investigative and MRI features 
for MS occur in children. 
Methods 
Study Design  
I carried out a one year follow up study, by following up positive cases reported from the 
prospective active surveillance study of first episode ADS in children aged between 1 and 15 
years.  
 
Case follow up  
After the one year follow up date, I contacted the original reporting clinicians throughout 
the UK & Ireland directly, by sending a data collection form to capture outcome data. 
Minimal identifiers (National Health Service [NHS] number, district postcode, sex and date of 
birth) were used to help the clinicians identify cases they have reported. A reminder email 
and letter was sent at 2 months if nothing was returned. MRI copies and/or reports were 
collected where possible. 
 
Definitions 
A relapse is a new occurrence of neurological symptoms that lasted > 24 hours and stabilized 
or resolved either partially or completely.  Table 34 describes the paediatric ADS forms of 
relapsing disease.  
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Table 34:  IPMMSG Definitions of relapsing disease 
 
  
Condition Definition 
Recurrent and 
Multiphasic 
Acute 
Disseminated 
Encephalo-
myelitis 
(R-ADEM & 
ADEM)  
If a new event occurs ≥3 months after the first ADEM attack and ≥1 month after 
completing steroid treatment, it is defined as: 
. Recurrent ADEM: recurrence of initial symptoms without involvement of new 
clinical areas. 
. Multiphasic ADEM: New event, but involving new anatomical areas of the CNS. 
 
Multiple 
Sclerosis  
- Two or more episodes of CNS demyelination separated in time and space: 
- Dissemination in space requirement can be met if: MRI shows three of: 1) nine or 
more white matter lesions or one gadolinium enhancing lesion, 2) three or more 
periventricular lesions, 3) one juxtacortical lesion, 4) an infratentorial lesion. OR 
combination of an abnormal CSF (oligoclonal bands or elevated IgG index) and two 
lesions on the MRI (one in the brain). 
- Dissemination in time requirement can be met if: MRI shows new T2 or 
gadolinium enhancing lesions developing 3 months following the initial event. 
 
Neuro-myelitis 
Optica (NMO)  
Must have: i. Optic neuritis and ii. Acute myelitis.  
Must have: Spinal MRI lesion extends over three or more segments or iv. 
Aquaporin-4 antibody testing is positive. 
The brain MRI may be abnormal but must not meet Multiple Sclerosis MRI 
diagnosis criteria. 
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Data Collection:  
A targeted neurological and outcome history (using a check box questionnaire) was 
requested, and data collected was broadly categorised to document: (See Appendix 
Surveillance Outcome Questionnaire) 
- Occurrence of a relapse  
- Demyelinating symptoms and signs  
- Information which might confirm the development of recurrent ADEM, multiphasic 
ADEM, or MS, for example the anatomic distribution (optic nerve or spinal cord, 
monofocal or multifocal distribution), CSF findings, serological and neuroimaging results. 
- Treatment of relapse (eg, steroids, immunoglobulins, intensive care) given and duration 
of hospital stay. 
- Disability outcomes including: motor- using the EDSS scale; attainment at School; vision 
loss; fatigue; new onset of seizures. 
 
MRI imaging review 
All cases already had had their initial MRI scan reviewed as described in Chapter 2.1. Data 
from any follow up MRI scan results was collected, and when available, scans were reviewed 
blinded to clinical features jointly by MA and one of five neuroradiologists. A standardised 
proforma was completed utilising previously described nomenclature (see x) [5-7]. 
McDonald 2001 dissemination in space criteria (as recommended by the current IPMSSG 
criteria),[1, 2] McDonald 2010 dissemination in space and time criteria (if a gadolinium 
enhancing scan was available) and Verhey prognostic model were applied by MA according 
to the MRI variables.(22) All MRI brain scans were performed on 1·5T scanners and had a 
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minimum of a T1 weighted, and a T2 weighted or fluid-attenuated inversion recovery (FLAIR) 
sequence in two different planes. Additional sequences included gadolinium-enhanced T1, 
diffusion weighted and spine images. MRI slice thickness varied from 3–5 mm. 
 
Disability outcomes 
At one year, clinicians were asked to complete outcome questionnaires (see Appendix). 
Questions were designed to closely map onto the Kurtzke functional systems (pyramidal, 
cerebellar, brainstem, sensory, sphincter, mental, and visual functions) and the expanded 
disability status scales (EDSS) (232). The Kurtzke and EDSS scales have long been the 
accepted scales for disability in adulthood multiple sclerosis, although there are many 
limitations (233), which include: its emphasis on motor  function; insensitivity to change; 
insensitive to patient reported outcomes and of quality of life; and only moderate  inter- and 
intra-rater reliability (234, 235). They can also be somewhat complex to score to the 
unfamiliar busy clinician. By using questions familiar to paediatricians, and by using one 
scorer, I aimed to ensure with scoring measures. In addition, other questions were also 
asked of the reporting clinician, such as presence of fatigue and symptoms of depression to 
try and obtain as complete a picture as possible, whilst acknowledging clinician time 
constraints. The following question were hence asked (also see appendix xx for 
questionnaires) of clinicians, and data additionally also mapped on to the EDSS (see Table 35 
below):   
 
1. Mobility/ motor skills 
- whether the patient had a motor impairment or limitations on mobility?  
- whether participation was limited due to gait 
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- the frequency of walking aids and wheelchair use 
- whether weakness was present due weakness in arm (s) and/or legs(s) 
- ataxia of the limbs present 
- difficulties with fine motor skills 
- loss of sensation 
- rehabilitative therapy required  
 
2. Vision:   
- whether the case had poor visual recovery (ie. worse than a snellen of 6/9 or to previous 
level of visual acuity if pre-existing impairment)  
- level of visual acuity in each eye     
 
3. Mental functioning, Attainment at School: 
- whether there were any difficulties at School (according to the national special education 
needs code of practice framework; www.education.gov.uk )  
 
 4. Sphincter function 
- frequency of abnormal non age-related bedwetting/soiling 
 
5. Specific daily and other neurological functioning and symptoms: 
- fatigue affecting activities of daily living 
- presence of symptoms of depression requiring further psychological support 
- presence of seizures 
- other neurological:  brainstem; sensory problems. 
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The Expanded Disability Status Scale (EDSS) was also established(232). This is a tool method 
of quantifying disability in MS It is widely used in clinical trials and in the assessment of 
people with MS. The EDSS scale ranges from 0 to 10 in 0.5 unit increments that represent 
higher levels of disability. EDSS steps 1.0 to 4.5 refer to people who are able to walk without 
any aid and is based on measures of impairment in neurological functional systems as above. 
Each functional system is scored on a scale of 0 (no disability) to 5 or 6 (more severe 
disability). EDSS steps 5.0 to 9.5 are defined by the impairment to walking.  
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Table 35: Expanded Disability Status Scale (EDSS) 
Score Description 
1.0 No disability, minimal signs in one Functional System  
1.5 No disability, minimal signs in more than one Functional System 
2.0 Minimal disability in one Functional System 
2.5 Mild disability in one FUNCTIONAL SYSTEM or minimal disability in two Functional Systems 
3.0 Moderate disability in one Functional System, or mild disability in three or four Functional 
Systems. No impairment to walking 
3.5 Moderate disability in one Functional System and more than minimal disability in several 
others. No impairment to walking 
4.0 Significant disability but self-sufficient and up and about some 12 hours a day. Able to walk 
without aid or rest for 500m 
4.5 Significant disability but up and about much of the day, able to work a full day, may 
otherwise have some limitation of full activity or require minimal assistance. Able to walk 
without aid or rest for 300m 
5.0 Disability severe enough to impair full daily activities and ability to work a full day without 
special provisions. Able to walk without aid or rest for 200m 
5.5 Disability severe enough to preclude full daily activities. Able to walk without aid or rest for 
100m 
6.0 Requires a walking aid - cane, crutch, etc - to walk about 100m with or without resting 
6.5 Requires two walking aids - pair of canes, crutches, etc - to walk about 20m without resting 
7.0 Unable to walk beyond approximately 5m even with aid. Essentially restricted to wheelchair; 
though wheels self in standard wheelchair and transfers alone. Up and about in wheelchair 
some 12 hours a day 
7.5 Unable to take more than a few steps. Restricted to wheelchair and may need aid in 
transferring. Can wheel self but cannot carry on in standard wheelchair for a full day and may 
require a motorised wheelchair 
8.0 Essentially restricted to bed or chair or pushed in wheelchair. May be out of bed itself much 
of the day. Retains many self-care functions. Generally has effective use of arms 
8.5 Essentially restricted to bed much of day. Has some effective use of arms retains some self 
care functions 
9.0 Confined to bed. Can still communicate and eat 
9.5 Confined to bed and totally dependent. Unable to communicate effectively or eat/swallow 
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Statistical Analysis 
Descriptive statistics were used to summarise the key components of the dataset. Univariate 
associations between potential prognostics factors and potential confounders and second 
demyelinating episode within 12 months of a CIS (diagnosis of MS within 12 months of the 
first episode) will be described.  Parametric or non-parametric statistical tests (Kruskal Wallis 
tests) were used for continuous distributions as appropriate given normality and 2 or 
Fisher’s exact tests for nominal data. These associations were further explored in a logistic 
regression model (see below for detail) that allowed for control of confounding factors.   
Statistical analysis was performed using PASW Statistics for Windows version 17·0 (© SPSS, 
Inc., 2009, Chicago, IL, www.spss.com) and the openepi software (version 2·3·1, 
www.openepi.com).(201) 
The following statistics are also presented for the various proposed diagnostic tests (236-
240): 
- Sensitivity- probability that the index test result will be positive in a diseased case. 
- Specificity- probability that the index test result will be negative in a non‐diseased case. 
- Positive predictive value- probability that a case with a positive index test result is 
diseased. 
- Negative predictive value-probability that a case with a negative index test result is 
non‐diseased. 
- Positive likelihood ratio- describes how many times more likely positive index test results 
were in the diseased group compared to the non‐diseased group.  
- Negative likelihood ratio describes how many times less likely negative index test results 
were in the diseased group compared to the non‐diseased group. 
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Results 
 
Case Report form return 
Table 36 below shows that a total of 90 out of 125 case report forms (72%) were returned 
(as of 28/05/2012). There were no differences between percentage number of  ADEM, ON, 
TM, and CIS-other cases as compared to the original incident cohort described in chapter 2.4 
(Chi squared= 4.409 with 3 degrees of freedom; two-tailed p value= 0.22). There may be a 
selection bias, towards cases returned being those with  a clinical relapse, however, the 
occurrence of a clinical relapse did not influence the return of a case report form (as may 
have been expected).  ADEM and TM cases had the highest case report return rates but the 
lowest clinical relapse rates. 
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Table 36: Outcome data follow up obtained 
Expert classification Follow up Obtained Clinical Relapse in those with 
outcome obtained- 
n (% of cases with follow up) 
Yes No % data 
obtained 
ADEM (n=40) 32 8 80% 2 (6%) 
ON (n=31) 17 14 55% 4 (24%) 
TM (n=25) 20 5 80% 5 (20%) 
CIS-other (n=27) 19 8 70% 11 (58%) 
NMO (n=2) 2 0 100% 2 (100%) 
Outcome (n=125) 90 35 72% 24 (27%) 
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Outcome- relapse and MS diagnosis  
 
Table 37 below details the final one year outcomes for all cases. Out of the 90 cases with a 
reported outcome, one case died, 24(27%) had a clinical relapse; hence a minimum of 19.2% 
(24/125) had a clinical relapse. A total of 23 cases fulfilled IPMSSG multiple sclerosis 
diagnostic criteria (18 having two CIS relapses, and 5 having an initial CIS attack and then 
fulfilling the stringent McDonald 2001 MS MRI criteria for space and time).  One ADEM case 
died in Hospital (see chapter 2.4). Two thirds of cases remained monophasic at one year 
follow up. Three cases had a non-MS clinical relapse and thee had a neuromyelitis optica 
relapse. 
 
I am reporting both the minimum percentage based on the total cohort (n=125) as well as 
the percentage of responders (n=90). The fourth column represents the minimum 
percentage (and associated confidence intervals) of the described outcome. It is likely that 
the true value lies in between both values (%responders and minimum %). 
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Table 37: Outcome at one year following a first episode ADS.  
Outcome Count  % of 
responders 
[out of 
n=90](and 
95% CI)* 
Minimum % (and 
95% CI)* based 
on n=125 cases 
Multiple Sclerosis as per IPMSSG: 
CIS Clinical Relapse (n=18) OR 
new lesions on follow up MRI scan & 
fulfilling IPMSSG  Multiple Sclerosis 
criteria-stringent McDonald 2001 MS 
MRI criteria for space and time (n=5)  
 
23 
 
25.6% 
(16.9-35.8%) 
 
18.4 % 
 (12.0-26.3%) 
Relapse non-Multiple Sclerosis 3  3.3% 
(0.70-9.4%) 
2.4 % 
 (0.5-6.9%) 
Neuromyelitis Optica Relapse 3 3.3% 
(0.70-9.4%) 
2.4%  
(0.5-6.9%) 
Death  1  1.1% 
(0.03%-6.0%) 
0.8 %  
(0.02%-4.4%) 
Monophasic illness (i.e. no relapse 60 66.67% 
(56.0-76.3%) 
48.0%  
(39.0-57.1%) 
No follow up 35 N/A 28.0% 
(20.3-36.7%) 
Total  125   
Confidence intervals based on Exact method for proportions  
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Clinical Phenotype, relapses and MS Diagnosis 
 
All cases fulfilling IPMSSSG criteria for MS diagnosed had a CIS as an initial presentation 
(Table 38 below). Of those with clinical relapses that did not receive an MS diagnosis (6/24) 
at one year follow up: 
- 2 cases initially presented as NMO and had further relapses: transverse myelitis and optic 
neuritis. 
- 1 case initially presented with TM, and the diagnosis changed from TM to NMO as the case 
had relapsed with optic neuritis and had longitudinally extensive transverse myelitis. 
- 1 case initially presented with TM and had another transverse myelitis relapse (aquaporin-4 
antibody negative) with a normal MRI brain (i.e. no asymptomatic T2 lesions). 
- 2 cases initially presented with ADEM and had 2 further ADEM relapses. 
11/43 (33%) monofocal cases developed MS, whilst 12/13 (92%) multifocal cases developed 
MS (Fisher’s exact p<0.001). If multifocal CIS presentation is considered a predictive marker 
at one year follow up for MS diagnosis: Sensitivity= 52.2% (33.0, 70.8%); Specificity= 97.0% 
(84.7, 99.5%); Positive Predictive Value= 92.3% (66.7, 98.6%); Negative Predictive Value= 
74.4% (59.8, 85.1%). 
 
Cases presenting with monofocal with no asymptomatic MRI lesions were statistically less 
likely to develop MS at one year compared to:   vs monofocal ≥ 1 asymptomatic lesion; & 
also compared to multifocal ≥ 1 asymptomatic lesion. There were no multifocal changes with 
no asymptomatic lesions (there were n=2 in the original incidence cohort).  
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Table 38: (A) Presenting phenotype as classified by the expert panel at onset of 
demyelination and corresponding MS outcome (B) All CI|S by detailed clinical (monofocal vs 
multifocal) and MRI phenotype (presence or absence of asymptomatic lesion) 
  Multiple Sclerosis 
outcome 
 Significanc
e 
For MS 
diagnosis 
at one year  
Non MS 
relapse 
(n=6) 
No (n=61); 
monophasi
c  
Yes 
(n=23);  
MS 
% 
contribution 
to MS 
diagnosis 
(column %) 
 
A. Expert 
panel 
classification 
(n=90) 
ADEM (n=32) 
[row%] 
2¶ 
[6.3%] 
30 [93.7%] 0 0%  
 
 
All CIS 
(n=56) 
ON (n=17) 
[row%] 
0 13 [76.5%] 4 [23.5%]  17.4% p<0.001  
(chi2 15.9; 
df=2) * 
 
TM (n=20) 
[row%] 
2** 
[10.0] 
14 [80.0%] 4 [20.0%] 17.4% 
CIS- other 
(n=19) 
[row%] 
0 4 [21.1%] 15 
[78.9%] 
65.2% 
NMO (n=2) 
[row%] 
2 [100%] 0  0  0%  
 
 
 
 
     
 monofocal no 
asymptomatic (n=28) 
- 26 [92.9%] 2 [7.1%] 8.7%   
 
p< 
0.001 
§ 
B. All CIS 
clinical 
(monofocal vs 
multifocal) and 
MRI 
classification 
(≥1 
asymptomatic 
lesions) 
 (n=56) 
monofocal  ≥ 1 
asymptomatic lesion 
(n=15) 
- 6 [30.0%] 9 [60.0%] 39.1%  
p= 
0.0
9 ¥ multifocal  ≥1 
asymptomatic  (n=12) 
- 1 [8.3%] 11 
[91.7%] 
47.8% 
radiologically isolated 
with ≥ 1 asymptomatic 
lesion (n=1) 
- 0  1 [100%]  4.3%  
*ON vs TM vs CIS 
¥ Fisher’s exact; monofocal ≥ 1 asymptomatic lesion vs multifocal ≥ 1 asymptomatic lesion 
 ¶ 2 MDEM (multiphasic acute disseminated encephalomyelitis) relapses 
§ Fisher’s exact; i.  monofocal  no asymptomatic vs monofocal ≥ 1 asymptomatic lesion & 
  ii. monofocal  no asymptomatic  vs multifocal ≥ 1 asymptomatic lesion 
**One child’s diagnosis changed from TM to NMO as the case had relapsed with optic neuritis and 
had longitudinally extensive transverse myelitis. Another child had another transverse myelitis 
relapse (aquaporin-4 antibody negative). 
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Details of CIS presenting phenotype, CIS type and Multiple Sclerosis diagnosis at one year are 
described in Table 39. 
 Of children, with CIS: 
All 4 ON cases who developed MS had ≥1 asymptomatic brain lesion 
Of TM cases developing MS, 3/4 had had ≥1 asymptomatic brain lesion 
Of monofocal other CIS cases developing MS, 2/3 had ≥1 asymptomatic brain lesion 
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Table 39: CIS presenting phenotype, CIS type and Multiple Sclerosis diagnosis at one year 
CNS site clinical 
presentation 
CIS phenotype MRI brain Multiple 
Sclerosis 
No Yes 
MONO-FOCAL  
(n=43) 
ON (n=17) ≥ 1 asymptomatic lesion 1 4 
no asymptomatic 12 0 
TM (n=20) ≥ 1 asymptomatic lesion 4 3 
no asymptomatic 12 1 
Other CIS (n=6) monofocal  ≥1 asymptomatic lesion 1 2 
monofocal no asymptomatic 2 1 
Total  32 11 
MULTI-FOCAL 
(n=13) 
Other CIS  (n=13) multifocal  ≥1 asymptomatic 1 11 
multifocal no asymptomatic 0 0 
Total  1 11 
radiologically isolated  0 1 
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On univariate analysis, Children who at first presentation of their CIS were older, and non-
white (Table 40) were more at risk of developing MS compared to younger children or those 
of white ethnicity. Although females were more likely to receive a diagnosis of MS, this trend 
did not reach statistical significance. The duration of symptoms before presentation, and 
deprivation indices also did not influence MS diagnosis. 
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Table 40: Demographics and MS diagnosis 
 Multiple Sclerosis  Significance (T-test/ 
Chi2/ Fisher’s exact) 
No (n=67)  
 
Yes (n=23)   
Median Age at Presentation in years  (range)  8.0  (1.3-15.9)  14.0 (9.5-15.0)  p<0.001 
Sex (Male n=43: Female n=47) and % 35:32 
 (52%: 48%) 
8:15  
(35%: 65%) 
p=0.15 
White(n=67): non-white(n=22) 56:11 
(84%:16%) 
14:8  
(64%: 36%) 
p=0.048 
risk ratio= 2.1 
(95%CI:1.0-4.1)  
Time from presentation to admission on 
initial presentation > 1 week 
6/67  
(9%:91%) 
4/23  
(15%: 85%) 
p=0.27 
Living in the most 20% deprived districts 19/58 (33%) 8/21 (38%) p=0.66 
Kruskal Wallis 
  
183 
 
CSF oligoclonal bands 
Table 41, Table 42 and Table 43 demonstrate: CSF oligoclonal bands results at disease onset; 
CSF oligoclonal bands positivity and MS outcome; and value of CSF oligoclonal bands at 
disease onset for prediction of MS outcome. 
 
In children with an outcome available who had a lumbar puncture done at initial 
presentation (55/90; 61%), 20 had positive CSF oligoclonal bands (20/55- 36%). Of those 
16/17 (94%) with an eventual diagnosis of MS had positive CSF oligoclonal bands, whilst 4/38 
(11%) with a monophasic illness had positive oligoclonal bands. There was a trend towards 
more children with CIS compared to ADEM cases having more CSF oligoclonal bands tested, 
probably as a result of the need to inform prognostication for future MS diagnosis. 
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Table 41: CSF oligoclonal bands results at disease onset  
 
Expert panel classification CSF oligoclonal bands 
Done  Not done  
Positive Negative 
ADEM (n=40) 2/20 (10%) 18/20 (90%) 20/40 (50%) 
ON (n=31) 6/19 (32%) 13/19 (68%) 12/31 (39%) 
TM (n=25) 5/18 (28%) 13/18 (72%) 7/25 (28%) 
CIS (n=27) 11/16 (69%) 5/16 (31%) 11/27 (41%) 
NMO (n=2) 0/1 1/1 (100%) 1/2 (50%) 
Total 24/74 (32%) 50/74 (68%) 51/125 (41%) 
Multiple Sclerosis as an 
outcome (n=24)where follow is 
obtained (out of n=90) 
16/20 (80%) 1/35 (3%) 7/24 (29%) 
 
 
Table 42: CSF oligoclonal bands positivity and MS outcome 
 Multiple Sclerosis outcome Significance* 
For MS diagnosis at 1 year  
No (n=61); 
monophasic  
Yes (n=23);  
MS 
CSF oligoclonal bands positive  4/38 (11%)  16/17 
(94%)  
p<0.001  
 
 
Table 43: Value of CSF oligoclonal bands at disease onset for prediction of MS outcome 
Parameter Estimate Lower - Upper 95% CIs 
Sensitivity 94.1% (73.0, 99.0) 
Specificity 89.5% (75.9, 95.8) 
Positive Predictive Value 80.0% (58.4, 91.9) 
Negative Predictive Value 97.1% (85.5, 99.5) 
Diagnostic Accuracy 90.9% (80.4, 96.1) 
Likelihood ratio of a Positive Test 8.9 (5.4 - 14.7) 
Likelihood ratio of a Negative Test 0.066 (0.0092 - 0.47) 
Cohen's kappa (Unweighted) 0.80 (0.54 - 1.06) 
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MRI predictors and Sensitivity and Specificity of MRI parameters for Multiple Sclerosis 
Diagnosis 
 
Table 45 reports on the prognostic performance of the: 
-  McDonald 2001 and 20010 (Table 44) pace criteria at first CIS presentation for MS 
diagnosis at one year (using IPMSSG diagnostic criteria as the reference standard).  
- McDonald 2010 MS criteria for space and time at first CIS presentation. 
- Verhey model for all CIS and ADEM presentations. 
The Verhey model (for first presentation of ADEM and CIS) and the McDonald 2010 space 
and time criteria (for cases presenting with CIS and had gadolinium contrast) had the highest 
specificity. Only the McDonald 2010 space criteria for children presenting with CIS had 
sensitivity and specificity values above 80%. 
I also the present the likelihood ratios for the MRI criteria/ predictor models.  
Likelihood ratios are  alternative  statistics  for  summarising  diagnostic accuracy, which 
have several particularly powerful properties that make them more useful clinically than 
other statistics, such as sensitivity and specificity. Positive and negative likelihood ratios are 
useful to understand the role of a test result in changing a clinician’s estimate of the 
probability of disease in a patient (236-240). 
LR it is the ratio of the probability of the specific test result in people who do have the 
disease to the probability in people who do no:  
The further likelihood ratios are from 1 the stronger the evidence for the presence or 
absence of disease. 
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Likelihood ratios can be used to help adapt the results of a study to patients. To do this they 
make use  of  a  mathematical  relationship  known  as  Bayes theorem  that  describes  how  
a  diagnostic  finding changes our knowledge of the probability of abnormality.  
Post-test odds for having disease= pretest odds x by the likelihood ratio.  
A normogram can be used to help conversions between odds and probabilities. 
In general, post-test probability, as estimated from the likelihood ratio and pre-test 
probability, is generally more accurate than if estimated from the positive predictive value of 
the test, if the tested individual has a different pre-test probability than what is the 
prevalence of that condition in the population. 
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Table 44: McDonald criteria definitions 
 McDonald 2001 (87) as used in IPMSSG McDonald 2010 (22) 
DIS 3 or more of (a-d): 
a. ≥9 T2 lesions or 1 Gadolinium enhancing 
b. ≥3 periventricular lesion(s)   
c. ≥1 juxtacortical lesion(s) 
d. ≥ 1 infrantentorial brain lesion(s)* 
2 or more of: 
≥1 periventricular 
≥1 juxtacortical 
≥1 infratentorial§ 
≥ 1 spinal cord§ 
OR the presence of 2 or more T2 lesions plus CSF 
oligoclonal bands 
DIT 1 Gadolinium  enhancing lesion at least 3 months 
after CIS onset  
 
 
OR A new T2 lesion with reference to a prior scan 
obtained: >3 months after CIS onset 
 
>1 new lesion when compared to a 
previous scan (irrespective of timing).  
 
OR presence of asymptomatic 
enhancing lesion and a non-enhancing 
T2 bright lesion on any one scan  
DIS= dissemination in space; DIT=dissemination in time. 
*In McDonald 2001 1 cord lesion can replace 1 brain lesion.  
§ All lesions in symptomatic regions excluded in Brainstem and spinal cord syndromes. 
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Table 45: Specificity; Sensitivity; negative & positive predictive values; and likelihood ratios 
of various MRI parameters for multiple sclerosis diagnosis using the reference standard of 
IPMSSG diagnostic criteria. 
MRI feature Multiple Sclerosis  NPV (100%-
NPV= -ve post-
test) 
/ 
PPV (= +ve 
post-test 
probability & 
95%CI)  
Positive LR 
[95%CI] / 
 
 Negative LR 
No (n=67)  
[specificity; 
95% 
confidence 
intervals] 
Yes (n=23) 
[sensitivity; 
95% 
confidence 
intervals]]  
[95% CI] 
McDonald Space 
criteria 2001 fulfilled 
for CIS patients 
3/33 
Specificity= 
91%; [76-97%]  
15/23 
Sensitivity= 
65%; [45-
81%]  
79%/ 
83% [62-94]  
7.2 [2.3-22] 
 0.38 [0.22-
0.68] 
Mc Donald Space 
criteria 2010 fulfilled 
for CIS patients 
5/33 
Specificity= 
85%; [69-93%]  
19/23  
Sensitivity= 
83%; [63-
93%]  
88%/ 
79% [62-89] 
5.5 [2.4-12] 
0.20 [0.08-
0.51] 
Mc Donald Time 2010 
space and time fulfilled 
for CIS 
(at first scan, and with 
gadolinium contrast)  
1/26 
Specificity= 
96%; [81-99%]  
7/12  
Sensitivity= 
58%; [32-
81%]  
83%/ 
88% [49-98] 
15.2 [2.1-110] 
0.43 [0.22-
0.85] 
Verhey model for CIS & 
ADEM (1 black hole 
and 1 periventricular 
lesion)  
2/66 
Specificity= 
97%; [90-99%]  
9/23 
Sensitivity= 
39%; [22-
59%] 
82%/ 
82% [51-95] 
12.9 [3.0-55] 
0.63 [0.45-
0.87] 
McDonald 2010 space 
criteria fulfilled for 
ADEM & CIS 
20/67  
Specificity= 
70%; [58-%] 
19/23  
Sensitivity= 
83%; [63-
93%] 
92%/ 
49% [39-59] 
2.8 [1.8-4.2] 
0.25 [0.10-
0.51] 
LR: likelihood ratio 
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Multiple Sclerosis risk & Univariate analysis of MRI features 
 
In Table 46, I explore univariate associations between MRI parameter and multiple sclerosis 
diagnosis within 12 months of a first demyelinating episode. Many MRI features could be 
associated with MS as an outcome. The following parameters reached significance (p<0.05) 
values: 
 
- MRI abnormal 
- McDonald 2010 space criteria fulfilled (including for ADEM & CIS cases) 
- Verhey Prognostic Model criteria fulfilled (including  ADEM & CIS cases) 
- Presence of Gadolinium  enhancing lesions 
 
- Presence of Black Holes 
- Presence of MRI infratentorial lesion 
- Presence of Corpus Callosum lesion 
- Presence of Periventricular lesions 
- Presence of Juxtacortical lesions 
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Table 46: Univariate associations between MRI parameter and multiple sclerosis diagnosis 
within 12 months for all presentations of demyelination 
 
 Multiple Sclerosis   
No Yes 
Count Count Significance
*  
Risk Ratio (95% 
CI) 
MRI abnormal 42/66 (64%) 22/23 (96%) p=0.003 8.6 (1.2-60.6) 
McDonald 2010 space criteria fulfilled 
for ADEM & CIS 
20/67 (30%) 19/23 (83%) p<0.001 6.2 (2.3-16.8) 
Verhey Prognostic Model for ADEM & 
CIS 
2/66 9/23 p<0.001 4.6 (2.6-7.9) 
Gadolinium  lesions 5/30 (17%) 7/12 (58%) p=0.01 4.2 (1.5-11.8) 
Black Holes 3/65 (5%) 9/23 (39%) p<0.001 4.1 (2.3-7.2) 
MRI infratentorial lesion 24/65 (37%) 14/23 (61%) p=0.046 2.0 (1.0-4.2) 
Poorly demarcated lesions 27/67 (40%) 6/23 (26%) p=0.32 0.61 (0.27-1.4) 
Cortical Grey 12/66 (185) 0/23 (0%) p=0.1 n/a 
Corpus Callosum 5/66 (8%) 12/23 (52%) p<0.001 4.6 (2.5-8.6) 
Deep grey nuclei  19/66 (29%) 2/23 (9%) p=0.084 0.3 (0.8-1.2) 
Periventricular lesions 0 lesions 54 (82%) 4 (17%) p<0.001 § 8.9 (3.3-23.8) 
1-4 lesions 6 6  
=> 5lesions 6 13  
Juxtacortical lesions 0 lesions 40 (61%) 7 (30%) p=0.05 § 2.4 (1.1-5.4) 
1-4 lesions 9 4  
5-9 lesions 10 5  
>10 lesions 7 7  
Spinal lesions present 24/36 (67%) 9/10 (90%) p=0.07 3.5 (0.5-25.2) 
Spinal lesions ≥3segments 20/36 (56%) 3/10 (30%) p=0.15 0.4 (0.1-1.5) 
* Fisher’s exact; except where §:  Kruskal- Wallis 
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Logistic Regression 
Table 47 describes the binary logistic regression model and model summary. 
Variables used as predictors 
Proposed candidate predictors which have previously been reported as prognostic (and were 
significant [p<0.05] on univariate analysis) were used. Oligoclonal bands were not used as 
not all cases had CSF testing (55/90 of those with an outcome-61%). The following 8 
variables were derived from the dataset and investigated as predictors in the dataset where 
the outcome was known (n=90): 
 
- Age, and ethnicity  
- MRI brain abnormal 
- MRI features:  
o Black Hole(s) present 
o MRI infratentorial lesion present 
o Corpus Callosum lesion present 
o Periventricular lesion present 
o Juxtacortical lesion present 
 
Outcomes measured 
For the purposes of this study, multiple sclerosis diagnosis as per the 2007 IPMSSG 
definitions were used. 
Statistical methods 
Statistical analysis was carried out with SPSS version 17.0. For the binary logistic regression 
(for multiple sclerosis diagnosis), a backward elimination approach was used for the logistic 
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regression, with entry at p value of <0.01 and removal at p<0.05. Performance of the model 
was assessed with a classification plot and table, Hosmer and Lemeshow test, ROC analysis, 
Cox & Snell R square and, Nagelkerke R Square. The dataset was not randomly split to 
conduct an internal validation due to the relatively small numbers (for example by assessing 
the predictive accuracy of the model on a second portion of the dataset) and therefore 
remains exploratory. 
 
 
Figure 16: ROC curve analysis illustrates the ROC curve analysis; while Table 48 describes the 
area under ROC curve, test results: predicted probability and selected consecutive 
coordinates of the ROC Curve 
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Table 47: Binary logistic regression model and model summary 
 
Variables 
B Wald 
Chi2 
Significance OR 95% C.I.for EXP(B) 
Lower Upper 
Age At Presentation 0.537 11.2 p=0.001 1.71 1.25 2.34 
Periventricular lesion 
present 
4.008 17.8 p<0.001 55.1 8.54 354.9 
Constant -9.4 16.269 p<0.001 <0.001   
 
Performance Test value 
-2 Log likelihood 38.622 
Cox & Snell  0.498 
Nagelkerke R Square 0.731 
Hosmer and Lemeshow 
Test (chi2, significance) 
Df=7 
4.595; p=0.709 
 
The predicted risk or probability of MS diagnosis at one year can be calculated as 1/(1+e-risk score) 
where the risk score = -9.4 + (0.537x age) + (4.008 x presence of periventricular lesion [1=yes]). 
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Figure 16: ROC curve analysis 
 
 
 
Table 48: Area under ROC curve, test results: predicted probability and selected consecutive 
coordinates of the ROC Curve 
Area Std. 
Errora 
Asymptotic 
Sig.b 
Asymptotic 95% 
Confidence Interval 
Lower 
Bound 
Upper 
Bound 
0.956 .020 <0.001 0.916 0.995 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
 
Test Result Variable(s):Predicted probability 
Positive if Greater Than or Equal 
To 
Sensitivity 1 - Specificity 
0.1633706 0.870 0.152 
0.1936447 0.870 0.136 
0.2356800 0.870 0.106 
0.2746848 0.870 0.076 
0.2855053 0.826 0.076 
0.2947609 0.826 0.061 
0.3599139 0.826 0.045 
0.4278547 0.783 0.045 
0.4811851 0.739 0.045 
A predicted probability ≥0.27 yields a sensitivity=87.0% and specificity =92.4%.  
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Classification and regression tree analysis (CART) 
 
The CART algorithm is based on classification and regression trees devised by Breiman et al 
(241). A CART tree is a binary decision tree that is constructed by splitting a node into two 
child nodes repeatedly, beginning with the root node that contains the whole learning 
sample. It is likely to provide a useful model for clinicians to aid in decision making. A tree is 
grown starting from the root node by repeatedly using the following steps on each node. For 
each continuous and ordinal predictor, its values are sorted from the smallest to the largest. 
The best split point is the one that maximize the splitting criterion the most when the node 
is split according to it. The definition of splitting criterion is in a later section. Figure 17 
illustrates the Decision Tree for multiple sclerosis outcome at 1 year (N=90); whilst Table 49 
shows the classification table based on decision tree and CHAID method of tree growing. 
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Figure 17: Decision Tree for multiple sclerosis outcome at 1 year (N=90) 
 
 
Table footnote: 
Node = 1; prediction = not MS probability = 0.932203 
Node = 2; prediction = MS probability = 0.612903 
 
Node = 3; not MS probability = 1.000000 (less than 12.3 years old & no periventricular lesion) 
Node = 4; not MS probability = 0.777778 (more than 12.3 years old & no periventricular lesion) 
Node = 5; not MS probability = 1.000000 (less than 8 years old & ≥1 periventricular lesion) 
Node = 6; MS probability = 0.826087 (more than 8 years old & ≥1 periventricular lesion) 
 
 
 
Table 49: Classification table based on decision tree and CHAID method of tree growing 
Classification 
Observed Predicted 
not MS MS Percent 
Correct 
not MS 63 4 94.0% 
MS 4 19 82.6% 
Overall Percentage 74.4% 25.6% 91.1% 
Risk estimate= 0.089 (standard error=0.30) 
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Disability outcomes 
 
A total of 39% of children had an EDSS of 2.0 or worse (minimum 32/125 or 23.2% of entire 
study cohort), that is a least minimal disability in one functional system or more (Table 50). 
The majority of ADEM and ON cases had an EDSS of less than 2.0 (75% and 85% respectively) 
at one year outcome.  Also, at one year, 10% of the outcome group had an EDSS of 6.0 or 
worse, requiring a walking aid of for the majority of the time (minimum 8/125 or 6.4% of 
entire study cohort). The majority of these children with severe disability presented with a 
transverse myelitis phenotype (6/8).  
Fatigue was reported to clinicians as affecting 19% of children with a first demyelinating at 
the one year outcome. Multiple sclerosis patients were most commonly reported fatigue 
with 9/17 being affected (53%). Poor visual recovery was reported in 10%, and all 3 patients 
with NMO (of which 2/3 were aquaporin-4 antibody positive) affected. Sphincter 
disturbance at one year was reported in 11% with the majority being TM sufferers. School 
attainment was affected in 10%, with 5/8 affected patients presenting with ADEM. 
Depressive symptoms were also spread across the different phenotypes with 13% being 
affected. 
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Table 50: Summary of disability outcomes by presenting phenotype, where all disability 
outcomes reported (83/90) 
 MS  
(n=19) 
ADEM 
(n=28) 
ON 
(n=13) 
TM 
(n=14) 
CIS- 
other 
(n=3) 
Relapse- 
non MS 
(n=3) 
NMO 
(n=3) 
Total 
(n=83) 
Poor visual recovery 
in at least 1 eye 
1 1 2 0 0 1 3 8 (10%) 
Sphincter 
disturbance 
0 2 0 6 0 0 1 9 (11%) 
School attainment 1 5 0 0 1 1 0 8 (10%) 
Fatigue 7 4 0 4 0 0 1 16 (19%) 
Focal symptomatic 
seizures 
0 2 0 0 0 0 1 3 (4%) 
Depression 
symptoms 
3 3 0 2 2 0 1 11 (13%) 
EDSS 
disability 
0/1.0 11 
(58%) 
21 
(75%) 
11 
(85%) 
5 
(35%) 
2 
(67%) 
1  
(33%) 
0 
(0%) 
51 
 (61%) 
2 3 3 0 2 1 0 1 10 (12%) 
2.5 1 0 0 0 0 0 0 1 (1%) 
3 3 2 2 1 0 0 0 8 (10%) 
4 1 2 0 0 0 0 2 5 (6%) 
6 0 0 0 3 0 2 0 5 (6%) 
6.5 0 0 0 1 0 0 0 1 (1%) 
7 0 0 0 2 0 0 0 2 (2%) 
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Discussion and Conclusions    
 
Follow-up case return after initial ascertainment  
 
Outcome data return was available for the majority of cases (72%), however, case report 
return was lowest for optic neuritis (55%) cases compared to the other acquired 
demyelinating syndromes. This may be due to a lower rate of clinical follow up for these 
cases. This however if anything, should not bias the analysis towards higher MS percentage 
outcomes, given that syndromes typically associated with lowest MS rates had the highest 
case return rate (ADEM; 80% and TM 80%). In addition, cases with the highest case return, 
also had the lowest clinical relapse rate after one year (ADEM 6%; TM 20%) hence reducing 
the likelihood that case return was due to cases more likely to have a relapse. 
 
It is important to acknowledge that some of the children currently classified as being 
monophasic demyelination may eventually be reclassified as having multiple sclerosis at a 2 
year or longer follow up, however, published data  to date consistently reports a short 
interval between the first attack and a relapse (typically <12 months) in paediatric multiple 
sclerosis [13-16]. This fact reduces the likelihood of a misclassification of demyelination 
outcome in this study. In addition, MRI brain scans are now widely and routinely utilised, 
hence increasing the chance of diagnosis by MRI criteria for multiple sclerosis before a 
clinical attack occurs. Also, throughout this chapter, I report the minimum percentage of the 
outcome (relapse, disability outcomes) based on the entire cohort (where appropriate) of 
the described outcome.   
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The methodological advantages of this surveillance study, is that it prospectively reports 
detailed outcomes (with MRI review) from children with first onset demyelination 
ascertained from all clinicians seeing cases with paediatric demyelination in the British Isles. 
Asking all secondary care paediatricians and ophthalmologists (as well as tertiary care 
specialists) to report cases potentially has the advantage of seeing ‘milder’ cases which may 
not have been clinically referred to tertiary centres. However, children who have a relapse 
are frequently referred to a paediatric neurologist (typically tertiary care for another 
opinion). It is worth considering also that the 100% recruitment rate of reported cases was 
only made possible after stringent ethical reviews by an NHS multicentre ethics board, and 
the NIGB ethics boards to collect data without patient consent. Annual reports and progress 
were provided to both bodies (as well as to the BPSU, BOSU, and the MS Society) to ensure 
good progress, adherence to ethical and to system level security policies. Patient 
confidentiality remained a top-priority as described in chapter 2.1.  
 
Outcomes: relapse and MS diagnosis 
Just over one quarter of this British Isles cohort where outcome was available (minimum 
18.4% of entire cohort [n=24/125]) satisfied IPMSSG criteria for MS. This is comparable to a 
large prospective multicentre cohort Canadian study, with a reported rate of 21% within one 
year (23, 96). In addition, six other children had a clinical relapse within one year after first 
presentation: three with a neuromyelitis optica relapse; 2 with MDEM; and one TM There 
was also one death (chapter 2.4) after a presentation with ADEM. Cumulatively, this means 
that a minimum of 24% (30/90; 33% of those with a reported outcome) had an adverse 
outcome (MS diagnosis, relapse, death). These outcome data confirm that approximately 
one third of cases of demyelination have an adverse outcome, and that a one year follow up 
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is sufficient to consider the efficacy of possible future interventions at the onset of the 
acquired demyelinating syndrome. 
 
 
Clinical Phenotype, relapses and MS Diagnosis 
All cases diagnosed with MS had CIS as the initial presentation, confirming results from 
recent reports in the literature [16]. The presence of encephalopathy, hence appears to be a 
useful negative predictor for MS diagnosis, and useful in diagnosis ADEM in children with 
multifocal presentation. However, this term has often caused controversy in the literature 
(20) as it is a loosely defined clinical term and is somewhat subjective. Also the fact that a 
significant number of patients were reclassified by the expert panel from ADEM to CIS in the 
surveillance incidence study (chapter 2.4) confirms the difficulty of classifying ADEM from 
polyfocal CIS based only on clinical parameters. Hence, additional supportive features, such 
as conventional MRI measures, would be particularly helpful. 
 
The majority of cases meeting IPMSSG MS criteria presented with other-CIS syndromes 
(15/23 [65%]) at initial onset, whilst 4 initially presented with ON and 4 with TM. Of all CIS 
types, the majority had asymptomatic MRI brain lesions (20/23 – 87%).  This confirms adult 
and paediatric observations that the presence of symptomatic brain lesions are an important 
predictor of MS development (40). Another way to describe these cases is as ‘CIS suggestive 
of MS’ as in the recent emerging adult literature (88, 242-244).  A total of 11/23 (47%) cases 
diagnosed with MS presented with a monofocal syndrome, 11/23 presented with a 
multifocal syndrome, and 1 presented with a radiologically isolated syndrome. This ratio of 
an equal number monophasic and multiphasic cases is different than a retrospective Dutch 
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study (n=117) where 43% of monophasic CIS cases vs 21% polyfocal CIS cases developed MS 
(20). It may be that, in this study, the consistent classification of multifocal CIS cases with 
encephalopathy to ADEM has resulted in the observed ratios. Three recent studies applying 
the 2007 IPMSSG definitions of ADEM (2 single centre cohort studies; and one large 
Canadian multicentre prospective cohort study) have shown an MS conversion rate of less 
than 10% (13, 14, 96). It hence appears that encephalopathy at presentation is a negative 
predictor of MS, however, long term follow up (as in the PUDDLS study I set up, see chapter 
4.1, (210)) is still needed to clarify, which cases are actually MDEM, MS or other recurrent 
forms of demyelination. Until reliable biomarkers of subgroups of demyelination are 
established in the future, clinical epidemiology will continue to provide valuable information 
about subgroups in the likely heterogeneous acquired demyelinating syndromes and their 
relapsing forms. Once biomarkers are proposed, as in the case of neuromyelitis optica 
(aquaporin 4 antibody), clinical-MRI phenotyping will play an important part in validating 
these potential biomarkers(245).  
 
   
Only two children with CIS presentations and no other asymptomatic brain lesions 
developed MS (one with optic neuritis and one with a brain stem syndrome). All other CIS 
presentations who later were confirmed as having MS had asymptomatic MRI brain lesions. 
Multifocal CIS presentations had a higher MS conversion rate for MS at one year compared 
to children presenting with monofocal presentations (sensitivity 52% and specificity 97%). 
Overall, children with clinical presentations consistent with a clinically isolated syndrome, 
and have MRI brain silent lesions are at high risk of developing MS. It is important to bear in 
mind that, these cases were referred by the clinician following inclusion criteria as to what 
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constitutes a paediatric acquired demyelinating syndrome (see chapter 2.1) and after expert 
panel exclusion of cases (n=19) which were other conditions. These results regarding the 
prognostic risk factors at demyelination onset confirm recent trends reported in the 
literature (23, 96, 246, 247). 
 
Demographics and MS diagnosis 
The ratio of females to males diagnosed with MS reached 1.9:1. Although this did not reach 
statistical significant numbers, this ratio is consistent with recent paediatric as well as adult 
reported literature (3, 4, 23). This observed sex ratio, adds weight that it is likely that events 
(e.g. environmental exposures) occurring at or even before puberty onset that. Also 
consistent with recently reported studies, children with MS were significantly older at 
presentation compared to those with monophasic ADS (24). In addition, non-white children 
with a first episode of demyelination were more at risk of an MS diagnosis at one year (risk 
ratio 2.1). 
 
CSF oligoclonal bands 
As this is a clinical pragmatic study, and lumbar punctures were not done routinely as part of 
research, a relatively limited number of CSF information was available. Although there was a 
trend towards more children with ADEM having a lumbar puncture as compared to CIS (50% 
vs 63% p=0.35), this did not explain these findings. 
 
MRI predictors parameters for Multiple Sclerosis Diagnosis 
The McDonald Space criteria 2001, as used by the IPMSSG, fulfilled for CIS patients had a 
high specificity (91%) but a low sensitivity (65%). The Verhey model (for first presentation of 
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ADEM and CIS) and the McDonald 2010 space and time criteria (for cases presenting with CIS 
and had gadolinium contrast) had the highest specificity. Only the McDonald 2010 space 
criteria for children presenting with CIS had sensitivity and specificity values above 80%. My 
results are consistent with a recent retrospective MRI Austrian and German study of 52 
children with CIS; the 2010 McDonald dissemination in space criteria were also more 
sensitive (85% versus 74%) but less specific (80% versus 100%) compared to the Barkhof 
criteria for space. The 2010 McDonald criteria for dissemination in space and time also had a 
high specificity (93%) (248). 
 
With regards to MRI parameters for all children presenting with an acquired demyelinating 
syndrome, the following had a significant association with MS diagnosis (listed from highest 
to lowest risk ratio): 
Periventricular 
MRI abnormal 
McDonald 2010 space criteria fulfilled for ADEM & CIS 
Corpus Callosum 
Gadolinium  lesions 
Black Holes 
Verhey or MacDonald 2010 Space + Time fulfilled for ADEM & CIS 
Juxtacortical 
MRI infratentorial lesion 
Interestingly, also similar to the recent Austrian/ German study, the Inclusion of the spinal 
cord did not increase the accuracy of the McDonald criteria. (248). 
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Disability and Functional outcomes 
There is a paucity of data on the neurodisability and functional outcomes following 
paediatric acquired demyelinating syndromes. In this study more than one in three children 
has at least minimal disability in one functional system or more. The majority of ADEM and 
ON cases had a good functional recovery. One in ten children however suffered a severe 
disability at one year with an EDSS of 6.0 or worse, requiring a walking aid of for the majority 
of the time. The majority of children with severe disability presented with a transverse 
myelitis phenotype (6/8).  
As in adult MS where fatigue is a prominent feature, 1 in 5 children reported symptoms of 
fatigue at the one year outcome. Multiple sclerosis patients were most commonly reported 
fatigue. Importantly, poor visual recovery was reported in 1 in 10, and in all 3 patients with 
NMO. School attainment was affected in 1 in 10 children, hence highlighting the importance 
of participation and considering  every day activities of daily living (191). 
Conclusion & Clinical Implications 
In children presenting with an acquired demyelinating syndrome, children with a CIS are 
more likely to have a clinical relapse than those with ADEM over the course of one year. This 
has important implications with regards monitoring and the requirement of repeating an 
MRI scan after an interval. Currently with the wide availability of MRI, an increasing number 
of children are having follow up scans. Internationally proposed criteria which help the 
clinician in predicting and diagnosing multiple sclerosis in childhood have been proposed 
which require validation. Table 51 summarises findings from the surveillance 1 year outcome 
findings relative to similar international contemporary cohorts. 
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Table 51: Characteristics of UK ADS cohort compared to similar international contemporary cohorts 
 Thesis  Dutch cohort (249) 
 
French cohort  (15, 77) Canadian Cohort (32, 98, 
250) 
 
USA cohort (33) 
 
 
 
 
Study Design; 
 
Year 
 
Active surveillance 
population  
2012 
Population/ prospective 
 
2011 
Population/ prospective 
 
2003 
Population/ prospective 
 
2008 
Retrospective; Southern 
California population 
2010 
Sample size N=125     
Duration of follow up      
Age range      
Age of onset of first event 
(any) 
     
Age of onset of ADEM      
Age of onset of MS      
      
% ADEM with relapse      
% of CIS with MS diagnosis      
% patients <10 years at 
onset of MS 
     
% patients < 6 years at 
onset MS 
     
Time to first relapse      
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The results in this chapter compare the IPMSSG (use McDonald 2001), the Verhey prognostic 
model, and also the latest version of the McDonald 2010 MRI criteria. AN important 
overarching assumption in this study is that these cases are indeed presenting with an initial 
inflammatory demyelinating event, as opposed to a ‘mimicker.’ I have already highlighted 
the wide differential diagnoses in chapter 2.7 and that in fact 19 cases were excluded as they 
did not represent an acquired demyelinating syndrome. This is an important factor to 
consider when drawing up guidelines for childhood multiple sclerosis, and relapsing 
inflammatory demyelinating diseases. The McDonald 2010 criteria have only been 
recommended for use in children presenting with CIS, and not ADEM. Children with ADEM 
have several features on initial presentation (as highlighted in chapter 2.4) that appear to 
distinguish them from polyfocal CIS. The presence of encephalopathy is by a definition a 
clinical requirement to distinguish between ADEM (presence of) and polyfocal CIS (absence 
of). The new McDonald 2010 criteria appear to have good overall specificity and sensitivity 
(over 80%) for children presenting with CIS. However, on univariate analysis there were 
other factors (besides MRI) that were important to take into account when predicting 
outcome such as age; and CSF oligoclonal bands. Previous international studies (this is the 
first study of its kind in the UK) have tended to focus on clinical features, MRI features and 
CSF oligoclonal bands in isolation. By combining these factors  in a clinical algorithm, more 
accurate predictors could be devised. Interestingly, and consistent with other studies, MRI 
spine does not seem to be an important factor in predicting early MS progress, and hence 
this could save on follow up scan time, an important factor when scanning children who may 
require sedation.  
This may be because it is unusual for MRI spine in children to show asymptomatic lesions, 
and in fact children presenting with myelitis usually have sign and hence have a spinal MRI. 
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The logistic regression and decision tree analysis both highlighted that age, and the presence 
of periventricular lesions on the MRI in all children presenting with acquired demyelinating 
syndromes are important predictors of childhood MS.  
 
Prognostic indicators as highlighted will have to be externally validated in other populations, 
and there is an opportunity for this as the IPMSSG are already setting up a database to allow 
multinational collaborations and externally validating models. Importantly, CSF oligoclonal 
bands were not inserted in to models or decision tress as not all children had a lumbar 
puncture. On univariate analyses, CSF oligoclonal bands were very useful as a predictor test 
for MS development. In children presenting with possible demyelination, it may be that 
national guidelines are needed to mandate a protocol MRI and a lumbar puncture to be 
done at outset, or close to onset. However, this indeed may be difficult to apply, for example 
in a child who present with mild symptoms and who is already recovering.  
 
Strengths of this work include that it is a large national interdisciplinary epidemiological 
study which uses multiple sources and two well established active surveillance units. Unique 
to this prospective population surveillance study is integrated detailed review of MRI images 
and investigative features combined with the robust application of International Paediatric 
Multiple Sclerosis Study Group (IPMSSG) consensus definitions by an expert panel (for 
inclusion, exclusion and differential diagnoses). This is study has applied the newly revised 
MS 2010 Macdonald diagnostic criteria for MRI in a population based series. This has 
implications for diagnostic work-up of these patients, potentially for therapeutics including 
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proposed clinical trials given that, to date, the European Medical Agency has approved nine 
new MS drugs for study in the paediatric population.  
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CHAPTER 4: TOWARDS FUTURE LONGITUDINAL COHORT & BIOMARKER 
STUDIES, AND CLINICAL TRIALS  
 
I will describe the set up of the Paediatric UK Demyelinating Disease Longitudinal Study 
(PUDDLS), a prospective multicentre longitudinal observational study, which will help to 
determine the natural history, predictors and clinical and patient centred outcomes of 
childhood acquired demyelinating syndromes.  
 
To date, eight new MS drugs have been recommended for a Paediatric Investigation Plan, 
with earlier diagnosis increasing the eligible clinical trial population.  There are no clinical 
trials in childhood ADS or in MS. I will hence discuss consideration in the design of trials in 
paediatric ADS and multiple sclerosis. Specifically I will illustrate this by: 
(i) exploring how by using large phase adult 3 clinical trials can  inform paediatric clinical trial 
design; (ii) calculating sample sizes for clinical trials by using published paediatric multiple 
sclerosis annualised relapse rates to calculate samples sizes for a clinical trial;  
(3) exploring the potential design of a future transverse myelitis treatment clinical trial. 
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4.1  Multicentre cohort study setup and methodology for patient centred and 
clinical outcome measurement 
INTRODUCTION 
Although I have set up a national surveillance study with one year follow up (2.1 and 3.5), 
there is limited knowledge on detailed patient functional outcomes following childhood 
onset acquired demyelinating syndromes, I therefore established a prospective longitudinal 
cohort study. You will find the protocol detailing study aims, hypothesis, design and methods 
in Appendix 4. The Paediatric UK Demyelinating Disease Longitudinal Study (PUDDLS) is a 
prospective longitudinal observational study which aims to determine the natural history, 
predictors and outcomes of childhood acquired demyelinating syndromes. Here I will 
describe some of the consideration that needed to be addressed and reviewed for the 
protocol design and also in order to provide useful outcome measures, and to establish a 
biomarker resource for further hypothesis research. 
ISSUES TO ADDRESS 
The available literature on paediatric MS, is primarily limited to smaller case series and larger 
retrospective reviews of established adult MS populations (11, 26, 31, 39, 77, 83, 176, 221, 
251-256).  Evidence for differences in natural history of childhood onset MS(5) are also 
primarily derived from retrospective cohorts, as are studies linking environmental factors 
(EBV infections or Vitamin D deficiency) with possible MS development(257). In the following 
section I will address the following four issues: 
1) Recruitment & Follow up  
2) Patient involvement 
3) Biological biomarkers and genetic analysis 
4) Patient reported outcome measurement.  
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1) Recruitment & Follow up 
In order to establish a large cohort in a rare disease and also longitudinally follow children 
up, treating neurologists will need to recruit affected children and from  many tertiary 
centres from as many centres in England at first onset of the acquired demyelinating 
syndrome (Figure 18: PUDDLS Flowchart with link to epidemiological study). In contrast to 
the surveillance study described in Chapter 2.1, parents will need to provide consent (and 
children assented). Given the rarity of the disease, the recruitment period will need to 
extend beyond 3 years. In addition, in order to allow for the movement of patients and to 
avert the loss of follow up, patients will need to be requested to consent to be contacted in 
the future, directly or via the NHS Information Centre [Medical Research Information Service 
(MRIS)] and the NHS Central Register. In addition, patients will be consented to also be 
contacted by telephone interview as the clinician may have decided that clinic follow up was 
not necessary unless the patient has another event or relapse.. Finally, future international 
collaboration in this rare group of disorders is likely to be important and hence, establishing 
a dataset with key core information as per agreed published guidance ((12)) and definitions 
will be important. 
The need for longitudinal follow up is important as the proposed international consensus 
definitions (12) for ADS are operational and require evaluation in prospectively followed up 
cohorts. Furthermore, MRI criteria used in adults to diagnose MS e.g. MRI McDonald criteria 
may not be valid in children (24, 91, 224). The utilisation of revised McDonald criteria (22) 
and others including the Verhey prognostic model (96) need to be validated in new cohorts. 
Although most children relapse within the first 2 years of after ADS onset, there may be a 
group of children who have  more benign disease course or suffer a relapse many years after 
initial onset, and hence the need for longitudinal follow up.  
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Figure 18: PUDDLS Flowchart with link to epidemiological study 
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2) Patient involvement 
I have also recruited a lay representative from the MS Society in the study team to ensure 
that patient and family views are appropriately sought throughout the study. The lay 
representative has helped towards input into appropriate questionnaires to administer to 
children and their parents/guardians and also in design of the patient information leaflets. 
 
 
3) Biological biomarkers and genetic analysis 
In line with adult based studies (258), there is no currently available biomarker that fulfils 
the criteria of a surrogate endpoint in MS in children. Current routine tests including CSF 
oligoclonal bands, lack sensitivity and specificity in individuals presenting with a first CNS 
inflammatory demyelinating event. Genetic epidemiology to date supports the dual role of 
“nature and nurture” in MS pathobiology(2). As such paediatric cohorts can also offer 
further valuable insights into the genetic and environmental interactions in the pathogenesis 
of MS. The corner stone of cohorts that are likely to be able to address complex disorders 
such as MS, depend on the availability of biological sample with comprehensive databases 
with clinical information (Figure 19) as well as genetic-environmental questionnaires.  
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Figure 19:  The 5 major study themes are represented in flow the Figure below.  
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4) Patient reported outcome measurement 
The determination of the patient reported outcome measurements are becoming 
increasingly important for the design of any future prevention or treatment trials. There is a 
need for a better understanding of long-term outcomes including quality of life, cognitive, 
adaptive behavioural and functional skills, neuropsychiatric symptoms, and treatment 
effects for children presenting with CNS inflammatory demyelination. I have hence designed 
a cohort study that ascertains patient and proxy reported generic and disease specific 
measures  (Figure 20).  
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Figure 20: Data and Outcome Collection Schedule Summary 
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Acquired demyelinating syndromes (ADS) and whether monophasic or relapsing can result in 
impairments in: motor function; bladder and bowel function; vision; cognition; and mood. 
The ADS are a group of heterogeneous disorders, with unpredictable natural history and of 
low incidence. Additionally these conditions usually have complex, overlapping symptoms, 
and co-morbidities that are important to measure. Measuring outcomes in children with ADS 
hence provides significant challenges in every day practice and research. At the time of 
writing, however, there are no agreed systems that allow monitoring of all areas of potential 
change, and are able to monitor symptoms, impact on family life and individual children’s 
quality of life and participation systematically. Measuring the impact of future therapies is 
hence challenging due to the additional barrier of a lack of nationally or internationally 
accepted core outcome measures. There is also the difficulty of using a multitude of paper 
based questionnaires (generic or disease specific) which are often labour intensive, not 
readily repeatable, and not designed to measure change. 
 
Ideally inclusion criteria for outcome measures should include: 
The ideal criteria to realise the study aims are: 
1. Measures that encompass the framework developed by the World Health Organisation’s 
International Classification of Functioning, Disability and Health (ICF). Measures should 
also reflect agreed definitions and standards.  
2. Suitability for longitudinal assessment into adulthood. 
3. Ease of administration and access for children, and families. Ideally allowing completion 
in child centred methods (including allowing self report) via secured internet access. 
Hence avoiding extra laborious paper based assessments to be sent by post, and 
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excessive Hospital visits. Parent reported (proxy completion) methods should also be 
available, with ideally good agreement with the child self report measures. 
4. Brief and minimal response burden for children and families, whilst allowing rapid 
analysis by staff. 
5. Normative data available for UK children 
6. As well as being clinically useful for this study population, scientific robustness is an 
important consideration, specifically relating to the tool’s psychometric properties: 
Reliability; Validity; Responsiveness; & Appropriateness 
7. Measures should include: 
- Objective as well as subjective analysis 
- Generic and Disease Specific items 
8. Measures should ideally be cross-culturally compatible. 
 
Option of using Disease Specific Questionnaire based on already established adult tool 
The lack of outcome tools in childhood ADS has been highlighted by the international 
paediatric demyelinating disease study group (166). There is a hence a need to consider the 
use of one or more disease specific measures previously designed for use in the adult 
population. In this case, these measures will require additional validation for use in children. 
There are however advantages to basing new measures of QoL for children on those 
previously developed for adults. These include: potential value in longitudinal studies where 
there is a need to determine changes in QoL across the life-span; and the opportunities to 
draw on established expertise of those working in adult disease specific QoL measures. It 
also costs less if some of the basic stages of item determination used in adult work can be 
assumed appropriate for use in children.   
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The disadvantages of this approach also need to be recognised. QoL is usually regarded as a 
multidimensional concept related to the ICF definitions of health proposed by the WHO 
(Error! Reference source not found.). In adapting adult QoL measures for children, a 
entral question relates to how well the domains assessed in adult measures are appropriate 
to assess QoL in children.  
 
The traditional domains, including physical QoL may not have the same meaning for children 
as adults. In adult work, there is an emphasis on attainment of everyday routine activities 
which may not fully reflect the range of physical activities typical of normal children. 
 
Adult measures may fail to tap the specific aspects of QoL that are important to the child. At 
the least, additional domains to tap autonomy, body image, cognitive skills and relationships 
with the family are needed. Failure to include these domains may limit understanding of the 
child in a social context and therefore does not provide a robust framework for the 
development of measures for children. Response scales, wording and format of adult 
measures may need modifying to account for children’s cognitive and language skills. 
 
To help address difficulties with administering questionnaires primarily designed for use in 
adults to children, I have chosen to use a novel biomedical informatics system (259) called 
Healthtracker®. This system allows children, parents, and professionals to use a web-based 
monitoring system to enable more effective treatments, better pathways of shared care, and 
more equitable and efficient service delivery for children. Healthtracker® is a sophisticated, 
user-friendly, UK, web-based assessment system launched with Department of Health 
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support in 2008. It comprises a suite of questionnaires and test games for children and their 
carers. Importantly, assessments can be accessed via home-based computer for convenience 
and lower costs. This helps circumvent the many practical difficulties associated with long-
term assessment of chronic diseases. Testing is encouraged fun through online computer 
games, animated characters asking questions, and children can track their own progress.  
 
Outcome choices 
The following tools have been selected after thorough review as they best fit the specified 
inclusion criteria. 
Health related Quality of Life (QOL) 
- Generic QOL: Paediatric Quality of Life Inventory TM; 
Generates physical, psychological, and total score. 
o Self report for ages 5-25 years. 
o Parent report for ages 2-25 years. 
- Disease specific QOL: Multiple Sclerosis Impact Scale-29 version 2 (MSIS-29 v2) 
Generates physical, and psychological scores. 
o Self report for children 5 years -adulthood 
o Parent report. 
Fatigue 
- Paediatric Quality of Life InventoryTM; Multidimensional Fatigue Scale 
o Self report for children 5-25 years 
o Parent report; for children 2- 25 years 
Neuropsychiatric Symptoms   
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- Profile Of Neuropsychiatric Symptoms (PONS)  
o Self report for children 5-16 years 
o Parent report 
Functioning ; Adaptive behavioural skills 
o Adaptive Behaviour Assessment System II (ABAS II).  
- Parent report for children 5 years –adulthood. Two out of the three domains will be 
used: 
(i) Conceptual skills: communication, functional academics, and self-direction skills 
areas 
(ii) Social skills: Social, and leisure skills areas 
Cognitive   
o Two Healthtracker online games played by children aged 5-16 years that aim to 
measure memory, attention and concentration. These are embedded in between 
questionnaires. 
o Online D2 test game for participants aged 9 years- 60 years. The D2 Test measures 
processing speed and quality of performance of individuals, allowing for a 
neuropsychological estimation of individual attention and concentration performance.  
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CONCLUSIONS 
The set up of the Paediatric UK Demyelinating Disease Longitudinal Study (PUDDLS), a 
prospective multicentre longitudinal observational study, will help to determine the natural 
history, predictors and outcomes of childhood acquired demyelinating syndromes. I also 
envisage that that by facilitating the establishment of a biological sample biobank (CSF, 
serum, and DNA), I will enable future hypothesis driven research. For example, the future 
discovery of a biomarker will allow validation within this dataset for the evaluation of novel 
biomarkers. In addition, establishing baseline detailed objective outcome, patient reported 
and proxy outcome measures will facilitate both primary secondary outcome measurement 
and power analyses for future clinical trials.  The study will also allow our group to 
collaborate internationally with the International Paediatric Multiple Sclerosis Study Group 
when future mutual studies are proposed. A paediatric population should reflect the 
vanguard of MS epidemiological changes and may reflect trends yet to be observed in adult 
MS cohorts. The restricted window between clinical expression of disease and exposure to 
environmental factors in children offers a unique research opportunity. Studying a paediatric 
population from the first demyelinating event will also allow us to investigate the changing 
epidemiology of MS, and may offer further valuable insights into the genetic and 
environmental interactions in the pathogenesis of MS.  
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4.2  Considerations in the design of paediatric MS and ADS clinical trials 
Background 
New MS drugs are emerging with reported better efficacy in adults than current injectables. 
European regulation and directives in 2007 have provided a framework with an obligation to 
perform paediatric studies on any new molecule. New drugs hence require a Paediatric 
Investigation Plan (PIP) aimed at ensuring that necessary robust data are obtained through 
studies in children to support authorisation by the European medicines agency (EMA).  To 
date eight new MS drugs have been granted PIP approval by the EMA (Table 52). PIPs 
initially approved often specify designs as in large adult randomised controlled trials (RCTs). 
Given there are no RCTs in MS children to date, this situation gives rise to unique but 
obvious practical and ethical dilemmas. 
Most data suggest that paediatric MS largely behaves like adult MS suggesting similar 
disease processes. For example, similar to adults, children: usually have a clinical relapsing 
remitting disease course with a clinically isolated syndrome as the first attack; are likely to 
have been previously infected with the Ebstein Barr virus; and have  positive CSF oligoclonal 
bands (5, 221). However, children probably have a higher MRI lesion load at onset and 
higher relapse rate than in adult MS, but slower accumulation of disability (11, 260, 261). In 
addition ADEM is more common in children than adults, and may be the first presentation of 
multiple sclerosis (76). Disease modifying treatments (DMT) have been used off-label after 
being approved in adults, thus there is no approved standard of care (166). In addition, in 
the UK, it often takes a considerable amount of time (up to 6 months) to obtain Primary Care 
Trust (PCT) funding for the drugs (mainly due to lack of RCT evidence and 
recommendations), which is not always guaranteed, hence creating inequalities in care. 
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Table 52: European Medical Agency Paediatric Investigation Plans for disease modifying therapies in paediatric multiple sclerosis 
Drug 
Decision 
date Administration Paediatric Investigation Plan 
Anti-BAFF 
monoclonal 
antibody 
Nov 
2010 Subcutaneous 
Multicentre open-label treatment randomised active comparator (Interferon beta-1a) controlled study to 
evaluate safety, tolerability, pharmacokinetics and efficacy of anti-BAFF monoclonal antibody in children (10-18 
years) with remitting relapsing multiple sclerosis. 
BAF 312 
July 
2010 Oral 
 
Open-label, randomised, multicentre, multiple dose, active controlled, parallel-group efficacy and safety study 
of BAF312 in children from 10 to less than 18 years of age with multiple sclerosis with relapsing remitting 
course. 
 
Follow up: Measures to address long term follow-up of potential safety and efficacy issues in relation to 
paediatric use. 
Fingolimod 
Dec 
2008 oral  
Open label, randomized, multicentre, multiple dose, active controlled (interferon beta-1a), parallel group trial 
to evaluate pharmacokinetics, safety and efficacy of Fingolimod using blinded MRI assessment in children from 
10 to less than 18 years of age followed by a long-term extension. 
Laquinimod 
sodium  
 
Jan 
2011 Oral 
Randomised, multicentre, parallel group, active controlled trial to evaluate safety, tolerability and effect of oral 
Laquinimod , compared to disease modifying treatment in children from 10 years to less than 18 years with 
relapsing remitting multiple sclerosis (RRMS) using blinded MRI assessment. 
Follow up: Measures to address long term follow-up of potential safety and efficacy issues in relation to 
paediatric use. 
 
Dimethyl 
fumarate 
(BG00012)  
 
Feb 
2011 Oral 
Open-label, randomised, multicentre, multiple dose, active controlled, parallel-group efficacy and safety study 
of Dimethyl fumarate in children from 10 to less than 18 years of age with relapsing-remitting multiple 
sclerosis. 
 
Measures to address long term follow-up of potential safety and efficacy issues in relation to paediatric use  
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Drug 
Decision 
date Administration Paediatric Investigation Plans 
Ocrelizumab 
May 
2011 Intravenous 
Randomised open label active-control parallel-group superiority study to evaluate safety and efficacy of 
ocrelizumab in comparison with active comparator (interferon beta-1a) in children from 10 to less than 18 
years old with relapsing remitting multiple sclerosis. 
 
Measures to address long term follow-up of potential safety and efficacy issues in 
relation to paediatric use. 
 
  
Teriflunomide 
 
July 
2011 Oral 
Open label, randomized, multicentre, active controlled (interferon beta 1a), parallel group trial to evaluate 
efficacy, safety/tolerability and pharmacokinetics of Teriflunomide in children and adolescents 10 to less than 
18 years of age with multiple sclerosis with relapses using brain MRI assessment followed by a 24 months long-
term extension.  
 
Follow up: Concerns on potential long term safety and efficacy issues in relation to paediatric use:  
 
Alemtuzumab 
Oct 
2011 Intravenous TBA 
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Challenges for paediatric clinical trials in paediatric ADS and multiple sclerosis: 
• There are small numbers of patients available for clinical trials 
• Immature immune and nervous system, hence possibly different side effect profiles 
• Ongoing growth/ development in children necessitating consideration of different doses 
• For younger children, especially those <10 years with regards diagnosis and monitoring:  
– may require sedation for MRI scans 
– the diagnosis of multiple sclerosis may be more challenging 
• It is also important to take into consideration the challenges and the expectations of the 
various parties involved in management of paediatric multiple sclerosis:  
– the community (including families, children, physicians, researchers)  
– regulatory agencies; the requirement by the EMEA for all new drugs to undergo a 
paediatric investigation plan in order to approve the drugs 
– the pharmaceutical companies, and competing commercial interests (there is an 
incentive for a 6 month extension of the label). 
Expectations for new paediatric dugs: 
• Safety: long-term vs short-term: is safety the same in children as adults?  Are there 
effects tolerated in adults that wouldn't be tolerated in children? 
– Example: in October 2004, the US Food and Drug Administration (FDA) 
directed manufacturers of antidepressants to include a warning stating that 
antidepressants may increase the risk of suicidal ideation and behaviour in 
children and adolescents.  
• Effectiveness: if drug is effective in adults, how much more evidence is needed in 
children (given there are no although there are no approved DMT for paediatric MS)? 
• Given lack of established evidence, should an active comparator or placebo be used. 
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• Dose finding studies in new drugs, due to BMI and metabolism differences, and the 
need to find the lowest safest dose. 
If one takes the view that there is no RCT standard treatment to compare to, one will never 
reliably (by Randomised Controlled Trial) define the standard treatment. According to 
regulatory agencies, given that active comparators do  not  have a  good  evidence  base 
(only case series conducted),  then  superiority  to  comparator or placebo will  be necessary 
using a clinically meaningful surrogate.  
One option with regards using new drug therapies in children which were only tested in 
adults is to use registries as they: 
- are easier to enrol to, and include patients requiring treatments, and potentially more 
‘mildly’ affected cases; 
- allow complete medical, parental and patient choice as opposed to limiting to the 
specific clinical trial protocol 
- have the potential to estimate health economic costs with longer term follow up 
- may supply important information on the natural course of disease and may help in the 
long term assessment of  effectiveness  vs  safety as the natural course of the disease is 
not very well known.  
Registries hence can help establish 'best standard care' and include patients who choose not 
to be treated.  
Historical controls and registries, however, have well known problems as they: 
- cannot eradicate biases due to other factors, aside from treatment, that may have 
changed over time; 
-   are unable to control for confounding of selection biases, treatments  
- there are often dropouts 
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An unbiased point estimate of treatment effect, even with wide uncertainty, is preferable to 
a point estimate with unquantifiable bias. There is potentially a window for clinical trial 
recruitment when identifying children at first attack who fulfil the new McDonald MS criteria 
at disease onset for treatment (see chapter 2.5), and are awaiting a relapse before a decision 
regarding treatment. 
Controlled  studies  with  low statistical power in case of an important treatment effect may 
indeed be preferable to no controlled studies. The following key points need to be 
considered: 
• Ideally  a  ‘hard’  and  clinically  relevant  endpoint  is  used.   
• Ideally,  I  wish  to  obtain  an  unbiased  estimate  of  the  effect  of  the  treatment  
being  investigated compared to placebo or to another active compound and, for this 
reason, every effort should be made to randomise patients. 
• Where a placebo control may not be possible, an appropriate control group may be 
‘best standard of care’. 
• As current active comparators do  not  have  their  own  good  evidence  base (beta 
interferons),  superiority  to  that  comparator  will  be necessary.  
Using adult trial data to inform decisions about clinical trials in children  
I might want to use adult trials to (262): 
- decide on sample sizes for paediatric trials 
- interpret the results of paediatric trials 
- estimate how close the results on the same outcomes from adult and paediatric trials 
might be  
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A Bayesian approach can be used (posterior probability = Likelihood x prior Probability). This 
is because paediatricians often believe drugs effective in adults will be effective in children. 
Bayesian approaches allow exploiting prior information for sample size calculation, which 
could minimise unnecessary paediatric experimentations. Small Trials, adaptive designs, 
futility trials all require: more up front planning; strong evidence to base decisions; and a 
willingness to stick with exact rules (Table 53). 
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Table 53: Possible issues which may arise from small, early stopping or adaptive trials 
 
Problem  Reason  
Lack of credibility  Small trials are not convincing  
Lack of realism  Dramatic treatment difference is implausible  
Imprecision  Wide confidence interval for treatment effect  
Bias  Trial is liable to stop on a random high or low  
Speed  Time spent and information yielded may be insufficient to allow 
consideration of overall balance of costs and benefits 
Stopping early can seem more important than completed trial  
Pressure  Unduly enthusiastic recommendation for practice may follow  
Mistakes  Risk exists for false-positive or false negative results  
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CLINICAL TRIAL DESIGNS- PRACTICAL EXAMPLES FOR FUTURE TRIALS 
 
(1) Using large phase adult 3 clinical trials to inform paediatric clinical trial design. 
In this section I aim to explore potential clinical trial designs, and calculate sample sizes for 
new MS oral drugs in children. 
 
Methods: 
In order to inform clinical trial design requirements for paediatric trials (including sample 
size) I conducted a secondary analysis of two relapsing-remitting adult MS Fingolimod trials: 
FREEDOMS (263), a 24-month, double-blind, randomised, placebo controlled- study, 
(n=1033); and TRANSFORMS (264), a 12-month, double-blind randomised active controlled 
study, (n=1153). Cochrane’s RevMan v5.1 and NQuery sample size software were used for 
the metanalysis and sample size estimations.  
 
Results: 
To conduct an active RCT as in TRANSFORMS and assuming a similar risk ratio (0.62) for 
relapse in the study period and a similar event number, a sample size (equal numbers in 
both arms) of 436 children is required (power 80% and alpha 5%).  Sample size for a placebo 
RCT with same assumptions is n=134. If the event rate is higher in children than in adults (eg. 
by 50%) the required sample size for an active RCT is n=248. Assuming that MS is the same in 
adults as in children so that adult data is considered replicable in children but additional 
paediatric data is collected to perform a planned metanalysis of the TRANSFORMS + 
FREEDOMS + paediatric RCT,  the calculated sample size is n=183 (121 experimental arm; 62 
active arm).  Appendix 0 details the metaanalysis, sample size calculations, and assumptions 
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used when extrapolating from the FREEDOMS and TRANSFORMS trials for the relapse rates 
and MRI outcome measures. 
Secondary outcomes (MRI findings and functional disability) are problematic in children, as 
cognitive function, schooling and quality of life need to be considered. 
 
(2) Using published paediatric relapse rates to calculate samples sizes for a clinical trial 
Published paediatric relapse rates (Table 9) make sample size calculations possible as relapse 
rates are accepted as the primary outcome measure in multiple sclerosis clinical trials. The 
negative binomial model is increasingly used to calculate sample sizes in multiple sclerosis 
clinical trials (265) due to the wide variability present in individual relapse rates.  Assuming a 
baseline relapse rate of 0.85/year and a new drug with 50% efficacy, a total sample size of 
n=804 would be required (power 80% alpha 0.05). Appendix 6 shows the sample size 
calculations for different relapse rates and power assumptions.  
 
(3) Designing a transverse myelitis treatment trial 
Background; the unmet clinical need and need for trials  
Transverse myelitis (TM) is a rare (incidence 3-7/million/year) immune-mediated disorder of 
the spinal cord affecting children and adults. In TM, spinal cord dysfunction presents 
acutely/subacutely with motor (weakness of the limbs), sensory, and sphincter disturbance 
which may be asymmetric with varied presentation and severity (50). MRI lesions do not 
always result in a corresponding clinical sensory level (45). Despite there being no biomarker 
available, TM is usually accompanied by changes in neuroimaging and a reactive cerebro-
spinal fluid analysis, which complements the clinical presentation in making a diagnosis of 
TM, as emphasised by the TM Consortium Working Group diagnostic criteria (Chapter 1.4).  
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Most children reach a nadir within the first 1-2 weeks of presentation. A ‘plateau’ phase 
typically lasts for approximately one week before ongoing recovery begins.  The initial 
recovery period may extend to several months after the initial insult. The widely accepted 
American Spinal Injury Association (ASIA) scale of myelopathy, rates patients according to 
severity: 
A = Complete: No motor or sensory function is preserved in the sacral segments S4-S5 
B = Incomplete: Sensory but not motor function is preserved below the neurological level 
and includes the sacral segments S4-S5. 
C = Incomplete: Motor function is preserved below the neurological level, and more than 
half of key muscles below the neurological level have a muscle grade less than 3. 
D = Incomplete: Motor function is preserved below the neurological level, and at least half of 
key muscles below the neurological level have a muscle grade of 3 or more. 
E = Normal: Motor and sensory function are normal. 
 
The disease leads to varying levels of permanent disability in a majority of children and 
adults.  Early recognition, diagnosis and treatment are considered vital to the management 
of this condition. Despite this, there currently remain no robust controlled trials for the 
treatment of TM, in children or adults, to inform on the optimal early treatment of TM. The 
current management recommendation is largely based on an evidence-based review 
commissioned by the American Academy of Neurology (266). Children and adults are now 
treated with high dose intravenous steroids for 3-7 days to reduce inflammation based on 
Class IV evidence. Plasma exchange (PLEX) is increasingly used in children and adults with 
acute fulminant central nervous system (CNS) demyelination including TM. The efficacy of 
PLEX was demonstrated in a small randomized controlled trial in adults with acute central 
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nervous system (CNS) demyelination (including 4 patients with TM) where steroids had 
failed to induce a remission of symptoms (160). Another promising potential early treatment 
for patients with TM is intravenous immunoglobulins (IVIg). In children who do not respond 
to steroids, intravenous immunoglobulin is often used, although supporting data are limited 
to small case series and single case reports (5, 42). IVIg is used increasingly in the 
management of a range of neurological conditions, and its efficacy has been established 
clearly in randomised controlled trials for some such as Guillain-Barre syndrome and chronic 
inflammatory demyelinating polyradiculoneuropathy (267). The relevant immune-
pathological mechanisms attenuated by IVIg in other neurological disease are likely to be 
present in TM (268), providing a strong rationale for its use in the management of acute TM. 
There is hence a need to design therapies for this devastating condition in order to 
ameliorate disability. In the next section I will consider considerations regarding sample size 
calculations in this rare disorder to conduct a trial to establish whether early treatment with 
IVIg is of extra benefit in acute TM when compared to intravenous steroids, the current 
standard therapy. 
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Considerations for study design, particularly sample size, for hypothetical TM trial 
The following treatment arms to be considered: 
- Arm 1: Control arm, high dose intravenous methylprednisolone (IVMP) 
- Arm 2: Intervention arm, high dose methylprednisolone with IV Immunoglobulin (IVIG).  
The proposed outcome measure will be the proportion of a 2 point improvement on the 
ASIA scale (classified A – E). The proposed inclusion criteria will be patients presenting with 
TM and an ASIA severity scale of A-C. 
 
The assumptions of the sample size calculation have been based on the conclusions of pilot 
data from a one centre retrospective cohort study (Birmingham Children’s Hospital). Twenty 
four patients were followed over a 6 month period; their progress was measured by 
classification on the ASIA scale.  Patients were given a range of treatments including (IVMP, 
IVIG, intravenous cyclophosphamide, and plasmapharesis).  The results of patents that were 
classified as C or above (n=19), in line with the inclusion criteria for the proposed RCT are 
shown in Table 54. This table demonstrates certain points I used in my decision surrounding 
the power calculation: 1) no patients showed any deterioration on the scale; 2) 50% of 
patients improved by 2 points or more. Thus I assumed that the proportion of participants 
showing a 2 point improvement (or greater) on the ASIA classification will be approximately 
0.5 (50%) in the control arm and a minimum of 0.75 (75%) in the intervention arm. I propose 
that the minimum clinically important difference in percentages between the intervention / 
control group will be 25% observable at 24 weeks post randomisation. I believe these 
estimates are realistic based on the existing data and given the measures in place to 
maintain retention in the trial. Attrition will be accounted for in the sample size, at 
estimated value of 10%.  
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Table 54: ASIA scale at onset and at 6 month follow up for n=19 children followed up at 
Birmingham Children’s Hospital 
 
Starting 
Classification  
N=19 0 point 
improvement  
1 point 
improvement  
2 point 
improvement  
3 point 
improvement  
A 8 1 3 2 2 
B 2 0 1 0 1 
C 9 0 5 4 - 
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Sample size and power analyses 
An overall sample size of 188 participants, 94 in each group, (randomised 1:1 to control arm: 
intervention arm) would provide 90% power to detect a 25% difference in the proportion of 
2 point improvement or greater on the ASIA scale for the control verses intervention 
comparisons. Appendix 6 provides details for the analysis plan. 
 
The main barrier to conducting this proposed trial is the sample size of 188. According to the 
national surveillance study I conducted, one expects n=26 children per year presenting with 
TM (Chapter 2.3). A potential solution would be to conduct a multicentre trial which includes 
both children and adults. This scenario is feasible as TM affects adults and children with a 
similar presentation, severity and primary outcomes. This means that clinical trial results 
could be applied across all ages, with post hoc subgroup and sensitivity analyses providing 
further information.   
 
CONCLUSIONS 
MS adult trial designs cannot be used as a template for paediatric studies as:  effects and the 
balance of benefit and harm may differ; outcome measures used in adults are problematic;   
small populations present challenges.  In this section I presented possible solutions including 
methodologies that borrow strength from adult studies; using primary outcome measures 
that are applicable across the ages to include children in future trials. Secondary outcome 
measures which are child specific and core outcome measures for this patient group will 
need to be refined and agreed internationally. 
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CHAPTER 5 THESIS CONCLUSIONS 
I report the highest surveillance incidence rates (approximately 1 per 100,000 children/ year) 
of childhood acquired demyelinating syndromes ADS to date and show that children of non-
white ethnicity are not underrepresented as expected from adult MS studies. I discuss 
several clinical features for example, that clinically isolated syndrome (CIS) presentations are 
twice more common than acute disseminated encephalomyelitis (ADEM); and that optic 
neuritis is more commonly unilateral than bilateral. This work also shows that in childhood 
ADS, sex ratios varied with age, with more females in older age groups. The observations 
regarding the demographics of childhood ADS support the hypothesis that changing 
environmental risk factors for MS may indeed be operating in childhood, hence having 
implications for future preventative studies (such as use of Vitamin D supplementation). This 
is also the first study which has applied the newly revised MS 2010 Macdonald diagnostic 
criteria in a prospective population based series.  I showed that a minimum 24% of first 
onset met criteria for being at high risk of MS diagnosis at first ADS presentation and hence 
were potentially eligible for early disease modifying treatment. The variable treatments 
given at first acute ADS presentation also highlights the need for future clinical trials for 
acute ADS therapies. 
The potential to diagnose MS at disease onset has implications for MRI protocols for children 
with suspected ADS, and individual patient treatment decisions. To date, eight new MS drugs 
have been recommended for a Paediatric Investigation Plan, hence earlier diagnosis may 
increase the eligible clinical trial population.   
In a one year follow up of the national surveillance study, I confirm that children presenting 
with a CIS are more likely to have a clinical relapse than those with ADEM over the course of 
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one year. This has important implications with regards monitoring and the requirement of 
repeating an MRI scan after an interval. Currently with the wide availability of MRI, an 
increasing number of children are having follow up scans. I have highlighted the wide 
differential diagnoses in a prospective national study, which supports the need for 
standardised guidelines, protocols, and education programmes. This is an important factor 
to consider when drawing up guidelines for childhood multiple sclerosis, and relapsing 
inflammatory demyelinating diseases. I showed that children with ADEM have several MRI 
features on initial presentation that additionally appear to distinguish them from polyfocal 
CIS. The new McDonald 2010 MS criteria appear to have good overall specificity and 
sensitivity (over 80%) for children presenting with CIS. However, on univariate analysis there 
were other factors (besides MRI) that were important to take into account when predicting 
outcome such as age; and particularly CSF oligoclonal bands. Previous international studies 
(this is the first study of its kind in the UK) have tended to focus on clinical features, MRI 
features and CSF oligoclonal bands in isolation. By combining these factors in a clinical 
algorithm, I have shown that more useful models could be devised. These findings need to 
be validated in collaboration with other groups internationally. 
In this thesis work I also describe a series of longitudinal retrospective case series delineating 
prognostic risk factors. In a retrospective analysis of 38 childhood onset MS cases from three 
UK demyelination clinics was conducted, I showed that at first MRI scan, the 2010 McDonald 
MRI criteria hence appeared more sensitive than the recommended 2007 IPMSSG and may 
allow MS diagnosis at first presentation of CIS in at least a half of cases. In another 
multicentre longitudinal retrospective case series including 44 children I show that childhood 
optic neuritis is associated with severe visual deficit with good recovery. An initial abnormal 
MRI brain scan or relapsing optic neuritis should were strong predictors for to MS or NMO 
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diagnosis. In another population based study involving intensive care units I show that ADEM 
is potentially a severe disorder and may result in death. In another study I described a 
historical neuromyelitis optica (NMO) longitudinal cohort (n=22) with known aquaporin-4 
antibody (AQP4-ab) status and compare it to a contemporary incident national cohort 
sample.  As in other adult and paediatric series, NMO predominantly affects females. This 
cohort confirms that brain involvement is common in paediatric NMO with nearly two thirds 
having an abnormal MRI brain scan compared with adult NMO (25%). It is important to 
recognise the spectrum of brain abnormalities in NMO as the occurrence of such lesions and 
sometimes the presence of encephalopathy and polyfocal neurological deficits may 
resemble ADEM, with misleading implications as to prognosis and therapy. In addition I 
showed thatAQP4-Ab positivity is associated with early recurrence and visual disability.  
The set up of the Paediatric UK Demyelinating Disease Longitudinal Study (PUDDLS), a 
prospective multicentre longitudinal observational study, will help to determine the natural 
history, predictors and outcomes of childhood acquired demyelinating syndromes. I also 
envisage that that by facilitating the establishment of a biological sample biobank (CSF, 
serum, and DNA), I will enable future hypothesis driven research. For example, the future 
discovery of a biomarker will allow validation within this dataset for the evaluation of novel 
biomarkers. In addition, establishing baseline detailed objective outcome, patient reported 
and proxy outcome measures will facilitate both primary secondary outcome measurement 
and power analyses for future clinical trials.  The restricted window between clinical 
expression of disease and exposure to environmental factors in children offers a unique 
research opportunity. Longitudinally studying a paediatric population from the first 
demyelinating event will also allow us to investigate the changing epidemiology of MS, and 
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may offer further valuable insights into the genetic and environmental interactions in the 
pathogenesis of MS.  
I described key concepts important for the design of the first future clinical trials and 
preventative studies in ADS and MS. The potential to diagnose MS at disease onset has 
implications for MRI protocols for children with suspected ADS, and individual patient 
treatment decisions. This observation may be particularly important as new MS drugs are 
emerging with reported better efficacy in adults than current injectables, and the 
simultaneous requirement for new drugs to undergo testing in children with the aim of 
ensuring robust evidence to support authorisation by the European Medicines Agency. To 
date, eight new MS drugs have been recommended for a Paediatric Investigation Plan, 
hence earlier diagnosis may increase the eligible clinical trial population.  Allowing children 
to enter these studies at an earlier stage might optimise outcomes but also would involve 
attendant burdens and potential risk. I presented possible solutions including methodologies 
that borrow strength from adult studies; using primary outcome measures that are 
applicable across the ages to include children in future trials. Secondary outcome measures 
which are child specific and core outcome measures for this patient group will need to be 
refined and agreed internationally. MS adult trial designs cannot be used as a template for 
paediatric studies as:  effects and the balance of benefit and harm may differ; outcome 
measures used in adults are problematic;   small populations present challenges.   
 
The detailed study of ADS presented in this work I hope will help to inform future clinical 
service delivery and clinical trial design. 
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APPENDICES 
1. Surveillance Case Notification Questionnaire 
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2. Surveillance Outcome Questionnaire 
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3. Surveillance Data Storage procedures 
 
System Details  
 
1. The System shall be known as  Inflammatory Demyelinating Disease (IDD) study 
 
2. The System’s responsible owner shall be Dr Michael Absoud 
 
3. The System’s Caldicott Guardian or Data Controller shall be Mrs Carolyn Pike, Data 
Protection officer, University of Birmingham. 
 
 
System Security  
 
4. Security of the system shall be governed by the corporate security policy of …  
 
University of Birmingham 
http://www.it.bham.ac.uk/policy/documents/UoBInformationSecurityPolicy.pdf  
 
 
5. The System’s responsible security manager shall be Mr Peter Scott, Information 
Security   
      Manager, University of Birmingham.  
 
6. The security manager duties shall include: 
 
 Accrediting the system’s security implementation 
 Maintenance of the IT network including firewall and virus protection  
 Security sign-off/accreditation   
 Staff security and training 
 
Specifically, computer and network use at the ICH is bound by University of Birmingham 
policies. These cover data protection, connection to the network, appointment of 
custodians of computer systems and network administrators as well as computer 
security incident reporting procedures. Additionally, local policies exist covering 
computer accounts, disposal of equipment holding sensitive information and security of 
data. The ICH is protected by University of Birmingham’s institutional firewall, which 
limits external access to computers on the ICH network. The Information Systems Unit is 
in regular contact with University of Birmingham’s computer security teams who oversee 
IT security throughout the organisation. 
 
7. The System shall incorporate the following security countermeasures: 
 
The System comprises: 
 
- Desktop computer holding electronic research data (clinical data sheets of 
questionnaire) 
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- Paper records consisting of the front and clinical data sheets of the questionnaire. 
Front and clinical data sheets are stored separately in locked cabinets with restricted 
access and linked by a unique British Paediatric Surveillance Unit (BPSU) case code 
and a unique study code. 
 
i. Password protected desktop computer holding electronic research data (anonymised 
clinical data sheets of questionnaire). The data will be stored in a specified protected 
and restricted area (with advantage of regular back-up and less vulnerable to theft of 
hard drive). The database will be encrypted with a password only accessible to the 
study team.  
ii. Paper records consisting of the front and clinical data sheets of the questionnaire. 
Front and clinical data sheets are stored separately in locked cabinets with restricted 
access and linked by a unique BPSU case code and a unique study code. Anonymised 
MRIs will be stored with the clinical data sheets. 
iii. All information (paper and electronic) will be stored in a locked office, in a locked 
section of the building with swipe card protected access. 
iv. Paper records will be permanently destroyed by shredding.  
v. The University of Birmingham IT disposal and security policy will be complied with. 
vi. Confidentiality clauses are included in the staffs’ terms of employment and training is 
given in data protection. Investigators are members of professional organisations and 
adhere to the principles of confidentiality laid down by the General Medical Council. 
Staff are given training in data protection as part of their initial induction process. 
They are notified of changes to policies within University of Birmingham and the 
Birmingham Children's NHS Trust. 
 
 
System Management 
 
8. The System shall be developed / provided by Dr Michael Absoud 
 
9. The System shall be implemented by: the BPSU study applicants. In accordance with 
Medical Research Council (MRC) guidance, paper records i.e. front and clinical data 
sheets will be held for a total of 20 years1 to allow adequate time for review or 
reappraisal and to allow any concerns about the conduct or consequences of the 
study to be resolved. Paper records will then be permanently destroyed by 
shredding. The exception to retention of paper records is patient identifiable 
information collected for the purposes of case verification and de-duplication. This is 
destroyed once this process has been completed (usually within 12 months). 
 
10. The System shall be shared or used by the following organisations…… 
 
Institute of Child Health (University of Birmingham) 
Birmingham, Children’s Hospital 
Steelhouse Lane 
Birmingham 
                                               
1 Medical Research Council. Personal Information in Medical Research. Available at 
http://www.mrc.ac.uk/Utilities/Documentrecord/index.htm?d=MRC002452  
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B4 6NH 
 
 
System Design  
 
11. The System shall comprise:   
 
The IDD study complies with British Paediatric Surveillance Unit (BPSU) policy on data 
handling and data storage 
(http://www.bpsu.inopsu.com/about/Guidance%20for%20BPSU%20investigators%20on%20
patient%20confidentiality.doc ).  
 
 
 The British Paediatric Surveillance Unit (BPSU) office receives an ‘orange card’ indicating 
that a case of IDD has been seen by a clinician 
 BPSU office informs the study applicants – Dr Michael Absoud (Principal Investigator), Dr 
Evangeline Wassmer, Dr Carole Cummins - that a case of IDD has been notified to them 
by a clinician. The study applicants send a questionnaire to the relevant clinician for 
completion. 
 On receipt of completed questionnaire the study applicants detach the front sheet of 
questionnaire (containing patient identifiable information) from the clinical data sheets 
of the questionnaire (containing research data). 
 The front sheet and the clinical data sheets have a code assigned to the case it represents 
(BPSU Case code). 
 Front sheet and clinical data sheets are stored separately in secure locked cabinets and 
accessed only by the nominated study applicants. 
 
 Clinical data sheets contain research data only – they are linked to the corresponding 
front sheet (which contains patient identifiable information essential for the identification 
of duplicates and case verification) by means of the unique BPSU Case Code. 
 Patient identifiable information essential for the identification of duplicates and case 
verification will be removed from the front sheet once the process of case verification and 
de-duplication has been completed. 
 Research data held on the clinical information sheets, including that required for de-
duplication, are entered on computer. 
 
 
The Figure below summarises the data storage processes in the system. 
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The System Level Security Policy (SLSP) for the IDD study has been developed through a 
formal process of risk assessment by the study applicants. It covers security and management 
procedures in place throughout for data collection, data handling, data storage, data 
analysis and data destruction. It details the lines of accountability within the Institute of Child 
Health and University of Birmingham who may legitimately use it. It references external 
security documentation and standards, including the University of Birmingham corporate 
security policy. 
 
 
 
Operational Processes 
 
12. The patient identifiable / sensitive data will be collected via the system which will 
process: 
 
i. Patient identifiers consisting of initials, date of birth, sex, NHS/CHI number and first 
four figures of the current post code, which are stored separately to clinical research 
data and linked by a unique BPSU and study codes. 
ii. Anonymised clinical research data which are entered onto computer 
iii. Patient identifiable information collected for the purposes of case verification and 
de-duplication, destroyed once this process has been completed. 
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iv. Paper records consisting of the front and clinical data sheets of the questionnaire, 
stored separately in two locked cabinets and linked only by unique BPSU and study 
case codes. 
 
Anonymised notifications are provided to the BPSU office by members of the RCPCH 
using BPSU methodology i.e. the orange card. The BPSU informs the lead investigator, or 
their nominated staff, of the notifying member's details so the investigators can request 
further details.  Members notifying cases subsequently submit patient data to the 
investigator. Patient data are not held by the BPSU. 
  
Specific aims of the project are to: 
 
- Determine the incidence of childhood acquired demyelinating disease and MS in the 
UK and Ireland 
- To report clinical features, and distribution by age, sex and ethnic group. 
- To identify the frequency of proposed predictors (clinical and radiological) for MS in 
children. 
- To establish short term outcomes and recurrence after a first demyelinating event in 
children. 
- Determine whether these children can be classified according to the new 
international classification and further characterise those that cannot. 
- Increase awareness amongst Paediatricians and describe current practices and 
treatments offered in the UK and Ireland. 
 
 
 
 
 
 
 
13. The data will be stored via the following methods:  
 
The system is networked to the University of Birmingham network. However, only 
anonymised clinical research data will be held on computer systems. This has the 
advantage of regular backup. The database will be stored in a password protected 
area of the network. The database will additionally be password encrypted. 
 
 
14. The data will be processed via a system which has the following security measures in 
place:  
 
i. Firewall 
ii. Virus protection  
iii. Password protection 
iv. Locked rooms/cabinets 
v. IT disposal policy: 
http://www.it.bham.ac.uk/policy/documents/UoBInformationSecurityPolicy.pdf  
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The Code of Practice on Access to Computing Facilities will be used. Microsoft 2007 
encryption software will be used. It is to the required industry standard. In Access 2007, 
database passwords and encoding the database have been combined to create a 
stronger protection measure for ACCDB format files. When a database password is 
added in Access 2007, Access encrypts the database, with the encryption key being 
derived from the password. Fortunately, the password is not retained in the file so the 
file becomes more secure. This style of encryption is common across all 2007 Office 
system programs. After Access applies the password encryption, the database file can be 
opened only after the user enters the password. 
 
15. The System’s authorised users shall be The BPSU, Michael Absoud, Evangeline 
Wassmer, Carole Cummins. 
 
 
16. When the system or its data has completed its purpose / has become redundant or 
is no longer needed, the following methods will be adopted to dispose of 
equipment, back-up media or other stored data: 
 
i. Patient identifiable information, essential only for the process of de-duplication and case 
verification will be permanently destroyed once this process has been completed. 
ii. Data entered on computer will be permanently wiped from the hard drive. As part of the 
University computer standard build an application called Eraser is installed specifically for 
this purpose. Eraser is an open-source and the latest version can be downloaded from here: 
http://sourceforge.net/projects/eraser . The ‘erase’ functions deletes the data and wipes the 
disk space occupied by that data rendering any attempts to recover the information 
impossible. When a PC is due to be disposed of by IT Services it is securely stored until 
handed over to an authorised disposal firm, the hard drive is removed in a secure 
environment and physically shredded to remove any and all data. 
 
 
 
System Audit 
 
17. The System shall benefit from the following internal / external audit arrangements: 
 
The system shall be risk assessed on an annual basis by Michael Absoud using an 
audit checklist. Any deficiencies, including security or confidentiality matters, 
identified will be discussed with Peter Scott (information security officer) and 
solutions implemented.  
 
 
18. The System shall be risk assessed every 12 months  
18.1 - By using a system audit checklist.  
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18.2 - A risk management / security improvement plan shall be established to 
address all unacceptable risks.  
 
 
System Protection 
 
19. The System shall benefit from the following resilience / contingency / disaster 
recovery arrangements: 
- Electronic research data are backed up daily on the network 
- Paper records consisting of the front and clinical data sheets of the questionnaire 
are stored separately in locked cabinets with restricted access and linked only by 
unique BPSU and study case codes.  
 
20. In the event of serious disruption or total system failure, business continuity shall 
be provided by the following means: 
- Electronic research data may be retrieved from the daily back up on the network 
- Paper records consisting of clinical data sheets of the questionnaire stored 
separately in locked cabinets can also be used to retrieve the data. 
 
21. In the event of a security or confidentiality breach occurring the following 
procedure shall be followed: 
 
Any deficiencies, including security or confidentiality matters, identified will be 
discussed with the study team and Mr Peter Scott (information security officer) and 
solutions implemented.  
 
 
System Level Security Policy Ownership 
 
22. This SLSP shall be the responsibility of Dr Michael Absoud  
22.1 – It shall be reviewed on an annual basis for its completeness and for relevant 
update.  
 
23. The SLSP shall be available to Michael Absoud, Carole Cummins, Evangeline 
Wassmer, Mrs Carolyn Pike, Mr Peter Scott and the BPSU. 
 
 
Data Protection Registration 
 
24. Please confirm that your organisation has Data Protection Registration to cover the 
purposes of analysis and for the classes of data requested.  
 
The data protection Policy number for the University of Birmingham is: Z6195856 
The data protection policy can be viewed on: 
http://www.legalservices.bham.ac.uk/documents/Data_Protection_Policy._Dec_200
7.pdf   
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4. Paediatric UK demyelinating disease longitudinal study (PUDDLS) PROTOCOL 
 
 
 
ABSTRACT 
 
Background: There is evidence that at least 5% of Multiple sclerosis (MS) cases manifest in 
childhood. Children with MS present with a demyelinating episode involving single or 
multiple symptoms prior to developing a second event (usually within two years) to then 
meet criteria for diagnosis.  There is evidence from adult cohorts that the incidence and sex 
ratios of MS are changing and that children of immigrants have a higher risk for developing 
MS. A paediatric population should reflect the vanguard of such changes and may reflect 
trends yet to be observed in adult cohorts. Studying a paediatric population from the first 
demyelinating event will allow us to test these hypotheses, and may offer further valuable 
insights into the genetic and environmental interactions in the pathogenesis of MS. 
 
Methods/Design: The Paediatric UK Demyelinating Disease Longitudinal Study (PUDDLS) is a 
prospective longitudinal observational study which aims to determine the natural history, 
predictors and outcomes of childhood CNS inflammatory demyelinating diseases. PUDDLS 
will involve centres in the UK, and will establish a cohort of children affected with a first CNS 
inflammatory demyelinating event for long-term follow up by recruiting for approximately 5 
years. PUDDLS will also establish a biological sample archive (CSF, serum, and DNA), allowing 
future hypothesis driven research.  For example, the future discovery of a biomarker will 
allow validation within this dataset for the evaluation of novel biomarkers. Patients will also 
be requested to consent to be contacted in the future. A secondary aim is to collaborate 
internationally with the International Paediatric Multiple Sclerosis Study Group when future 
collaborative studies are proposed, whilst sharing a minimal anonymised dataset. PUDDLS is 
the second of two jointly funded studies. The first (UCID-SS) is an epidemiological 
surveillance study that already received ethical approvals, and started on the 1st September 
2009. There is no direct patient involvement, and UCID-SS aims to determine the UK and 
Ireland incidence of CNS inflammatory demyelinating disorders in children under 16 years. 
 
Discussion: A paediatric population should reflect the vanguard of MS epidemiological 
changes and may reflect trends yet to be observed in adult MS cohorts. The restricted 
window between clinical expression of disease and exposure to environmental factors in 
children offers a unique research opportunity. Studying a paediatric population from the first 
demyelinating event will allow us to investigate the changing epidemiology of MS, and may 
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offer further valuable insights into the genetic and environmental interactions in the 
pathogenesis of MS. 
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BACKGROUND 
 
Introduction 
CNS inflammatory demyelinating diseases (CIDD) are rare childhood disorders but may 
culminate in physical and cognitive disability or ultimately be diagnosed as Multiple Sclerosis 
(MS). MS is a chronic inflammatory demyelinating disease of the CNS characterized by 
myelin loss, axonal degeneration and, often, progressive neurological dysfunction, that is 
usually relapsing remitting at onset. The incidence of childhood CIDD is unknown, and the 
UK and Ireland Childhood Inflammatory Demyelination Surveillance Study (UCID-SS) is 
already underway to determine this. At the first presentation of a CNS inflammatory 
demyelinating event, children are diagnosed with either an acute disseminated 
encephalomyelitis (ADEM), optic neuritis, transverse myelitis, or another clinically isolated 
episode (CIS). Children who present with a CNS inflammatory demyelinating episode 
involving single or multiple symptoms may later present with a second event (majority 
usually within two years) to then meet criteria for MS diagnosis(6). There is evidence that at 
least 5% of MS cases manifest in childhood(269). It is not clear at the first onset of symptoms 
which children will go on to develop MS. 
 
Prospective studies are required 
The available literature on paediatric MS, is primarily limited to smaller case series and larger 
retrospective reviews of established adult MS populations(11, 26, 31, 39, 77, 83, 176, 221, 
251-256).  The International Paediatric MS Study Group, (www.ipmssg.org) have recently 
published consensus definitions of paediatric CNS inflammatory demyelinating disorders and 
MS to help facilitate uniformity in future research(12). Evidence for differences in natural 
history of childhood onset MS(5) are also primarily derived from retrospective cohorts, as 
are studies linking environmental factors (EBV infections or Vitamin D deficiency) with 
possible MS development(257). The risk of relapse in children and hence the risk of 
developing MS may be geographically different(6). There is hence an urgent need for 
prospective population based studies to further understand clinical, radiological, and 
pathobiological features as well as outcome of childhood onset inflammatory demyelinating 
disease. 
 
Paediatric cohort may reveal new trends 
Various new trends in adult MS have been reported (reviewed in ref (2)), which include 
geographic rising rate of MS, and a rising female to male sex ratio by year of birth (3). There 
is evidence that Indian and Pakistani immigrants who entered England younger than 15 had 
a higher risk of developing MS than those that entered after this age(1). The vanguard of any 
change in trends in the epidemiology of MS is likely to be evident in a paediatric population. 
Genetic epidemiology to date supports the dual role of “nature and nurture” in MS 
pathobiology(2). As such paediatric cohorts can also offer further valuable insights into the 
genetic and environmental interactions in the pathogenesis of MS. The corner stone of 
cohorts that are likely to be able to address complex disorders such as MS, depend on the 
availability of biological sample with comprehensive databases with clinical information.  
 
New criteria for diagnosis for paediatric MS require evaluation 
At first presentation of CIDD, children are diagnosed with optic neuritis, transverse myelitis, 
other clinically isolated episodes (CIS) or acute disseminated encephalomyelitis (ADEM). The 
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newly proposed consensus definitions(12) for CIDD are operational and require evaluation in 
prospectively followed up cohorts. For isolated monophasic syndromes, normal MRI and 
cerebrospinal fluid (CSF) are thought to predict a very low risk for development of MS in 
adults (86). However the same may not be true for children. In addition the differential 
diagnosis for childhood demyelinating disease and MS (documented in exclusion criteria) is 
much wider than that in adults. Furthermore, MRI criteria used in adults to diagnose MS e.g. 
MRI McDonald criteria may not be valid in children (24, 91, 224). The utilisation of revised 
McDonald criteria(67) and others including the KIDMUS MRI criteria (77) for paediatric MS 
need to be validated in new cohorts.  
 
McDonald et al. (67) criteria: 
Three of: 1) ≥9 white matter lesions or 1 gadolinium enhancing lesion, 2) ≥3 periventricular 
lesions, 3) 1 juxtacortical lesion, 4) an infratentorial lesion. 
 
KIDMUS (77) criteria: 
All of:  ≥1 lesion perpendicular to long axis of corpus callosum; sole presence of well defined 
lesions 
 
No available biomarker for MS 
In line with adult based studies (258), there is no currently available biomarker that fulfils 
the criteria of a surrogate endpoint in MS in children. Current routine tests including CSF 
oligoclonal bands, lack sensitivity and specificity in individuals presenting with a first CNS 
inflammatory demyelinating event. A precondition for the identification of biomarkers is a 
well described and prospectively followed clinical cohort and the availability of stored tissue 
linked to relevant clinical information.  
 
Early diagnosis allows for early treatment 
For relapses or attacks of MS, corticosteroids are the mainstay of treatment. Early initiation 
of “disease modifying agents”, such as beta interferon and glatiramer acetate appears to be 
of benefit in adults. Thus, it is more critical than ever to accurately diagnose MS as early as 
possible. However, very little is published on the use of interferon in children (161-165). The 
determination of the longitudinal outcome of the first CNS inflammatory demyelinating 
episode in children is an essential pre-requisite for the design of any prevention or 
treatment trials. Prediction of outcome at an early stage is critical to quantify the risk to 
benefit ratio of any intervention.   
 
The need to know the extent of disease burden 
Furthermore, identifying the natural history and outcomes of paediatric MS in the UK has 
major implications when planning service provisions, where there is evolving evidence of 
lack of awareness, and patchy service provision. At the Paediatric MS meeting, London 
November 2007 (attended by families and multidisciplinary professionals) there was a call 
for a better understanding of long-term outcomes including quality of life, cognitive, 
adaptive behavioural and functional skills, neuropsychiatric symptoms, and treatment 
effects for children presenting with CNS inflammatory demyelination. 
 
 
 
  
262 
 
Context of study in relation to current practice 
Children with CNS inflammatory demyelination are most often routinely seen by a Paediatric 
Neurologist as part of clinical care in order to provide expert advice and management. In line 
with guidelines by the International Paediatric MS Group, demyelination clinics have been 
set up in several Tertiary Centres by paediatric neurologists with an interest in these 
conditions. This led to the UK and Ireland Paediatric CNS Inflammatory Demyelination 
Working Group being set up, providing a steering committee for future collaborative studies, 
networking, future direction, writing clinical guidelines and future grant applications.  As a 
result, the majority of these children are seen in these specialist centres where they will be 
recruited. 
 
Study aims and objectives 
PUDDLS aims to establish if prognostic factors for relapse of CNS inflammatory 
demyelination (and hence risk of progression to MS) can be identified for UK children (Figure 
1). PUDDLS is a prospective UK based study with the following objectives to:  
 
1. Identify features (clinical, epidemiological, imaging, pathophysiolgical tests such as 
oligoclonal bands) that may predict which children are more likely to relapse and 
develop MS, whilst assessing the validity and utility of the new consensus definitions for 
childhood CNS inflammatory demyelination and of proposed MRI criteria. 
2. Establish outcomes for children, for an initial period of up to five years depending on 
when the case was recruited (minimum 6 months follow up). 
3. Describe disease modifying therapy usage, efficacy, and adverse effects. 
4. Provide a platform for future a) identification of biological markers in MS, b) genetic 
studies and c) hypothesis driven biological studies; by storing blood  and CSF samples 
already taken at the time of first demyelinating event  (currently in 7 participating 
centres). 
5. Ensure that long term outcomes of childhood demyelinating disease are as complete as 
possible by flagging patients with their consent with the NHS Information Centre 
[Medical Research Information Service (MRIS)] which will allow them to be traced in 
future via their G.P.s (currently in 7 selected centres). 
 
Specific Hypotheses: 
We wish to test the following hypotheses (as suggested by the IPMSSG [17]): 
(i) Children who present with CIS are more likely to develop MS than children who 
present with ADEM 
(ii) ADEM Children with prolonged steroid– dependent events (≥3 months) are more 
likely to develop MS than children with rapid recovery ADEM 
(iii) Children with multiphasic ADEM compared to children with recurrent ADEM are 
more likely to develop MS. 
(iv) Children with recurrent ADEM are more likely to develop MS than children with 
monophasic ADEM. 
(v) MRI criteria (McDonald, KIDMUS) can be validated to distinguish between ADEM, 
ADEM variants, CIS, and MS 
(vi) Identified future biomarkers with suggested prognostic significance, can be tested 
against PUDDLS outcomes 
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(vii) Early treatment with disease modifying therapy in relapsing CNS Inflammatory 
Demyelination, reduces relapse rate and slows neurological disability progress. 
(viii) Environmental risk factors can be identified for children with first episode CNS 
inflammatory demyelination and MS. 
 
New hypotheses will be added if suggested by publications by other centres prior to data 
analysis 
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METHODS/ DESIGN 
 
Case Definitions and Inclusion Criteria:  
 
Children (younger than 16 years) experiencing first episode of clinical neurological events 
consistent with site specific inflammatory CNS demyelination and except in Optic Neuritis 
confirmed with white matter changes on MRI (table 1). 
 
 
Table 55: Summarised definitions for CNS Inflammatory Demyelinating Disease  
 
 
Condition Definition 
Acute 
Disseminat
ed 
Encephalo-
myelitis 
(ADEM)  
A polysymptomatic clinical event with acute/subacute onset that must 
include encephalopathy (behavioural change or altered consciousness). (2) 
MRI Brain shows multifocal (usually diffuse bilateral lesions), predominantly 
involving white matter. 
 
• Relapsing ADEM: symptoms or signs within 3 months of initial onset of 
ADEM. 
IF a new event occurs ≥3 months later and ≥1 month after completing 
steroid treatment, it is defined as: 
• Recurrent ADEM: recurrence of initial symptoms without involvement of 
new clinical areas. 
• Multiphasic ADEM: New event, but involving new anatomical areas of the 
CNS. 
 
Clinically 
Isolated 
Syndrome 
(CIS)  
A first acute-clinical episode of CNS symptoms which may either be 
monofocal or multifocal, but does not include encephalopathy (except in 
brainstem syndromes). The MRI will show area of white matter 
demyelination. These include: 
Transverse myelitis: weakness and/or numbness of both legs +/- arms, 
usually with maximal deficits 1 week after symptom onset supported by 
demyelination on MRI spine. 
Brainstem, cerebellar, and/or hemispheric dysfunction, supported by 
demyelination on MRI. 
 
Optic 
Neuritis 
(ON) 
Acute or subacute loss of vision and ≥1 of: relative afferent pupillary defect 
(unilateral cases), visual field deficit or scotoma, impaired colour vision, 
optic disc oedema, or abnormal visual evoked potentials. MRI is not 
necessary for diagnosis. 
 
Neuro-
myelitis 
Optica 
(NMO)  
Must have: i. Optic neuritis and ii. Acute myelitis iii.  
Must have: Spinal MRI lesion extends over three or more segments OR iv. 
NMO antibody testing is positive. 
The brain MRI must not meet Multiple Sclerosis diagnosis criteria 
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Table 56: IPMSSG Multiple Sclerosis definition 
Multiple 
Sclerosis 
(MS)  
 
- Two or more non ADEM episodes of CNS demyelination separated in 
time (4 weeks) and space. For children aged >12 years:  
 
- Dissemination in space can be met if: MRI shows three of: 1) ≥ 9 white 
matter lesions or 1 gadolinium enhancing lesion, 2) ≥3  periventricular 
lesions, 3) One juxtacortical lesion, 4) an infratentorial lesion. 
  
OR abnormal CSF (oligoclonal bands or elevated IgG index) with 2 lesions 
on the MRI (one in the brain). 
 
- Dissemination in time can be met if: MRI shows new T2 or gadolinium 
enhancing lesions developing ≥3 months after initial event. 
 
 
 
Exclusion criteria: 
1. Leukodystrophies (e.g., metachromatic leukodystrophy, adrenoleukodystrophy) or 
mitochondrial disease 
2. Proven CNS infection (e.g. bacterial meningitis, herpes simplex encephalitis, Lyme disease, 
HIV) 
3. Radiation/chemotherapy associated white matter damage 
4. Condition fulfilling criteria for CNS connective tissue disease e.g. lupus, vasculitis. The sole 
presence of antibodies associated with CNS connective tissue diseases is not sufficient for 
exclusion. 
 
 
Relapses,  MS, and Progression 
A relapse is a new occurrence of neurological symptoms that lasted > 24 hours and stabilized 
or resolved either partially or completely. MS is defined in table 2 below. Progression of MS 
is a continuous worsening of symptoms and signs for > 6 months, ± superimposed relapses, 
either primarily (at onset of disease) or secondarily (after first relapse). 
 
 
Design 
PUDDLS is a observational cohort study with sample biobanking which will characterize the 
spectrum of CNS demyelinating syndromes, their outcomes, and possible progression to MS 
(Figure 2). Children will be recruited over a 4 year and 6 month study period and followed 
up. At recruitment an initial Case Report Form (CRF) will be completed by the PI/Research 
Nurse/Research Fellow. MRI copies and biological samples will be archived. An 
environmental questionnaire will be administered by telephone interview within three 
months of disease onset. Patient reported and proxy outcome questionnaires will be 
completed online at onset and at  specified time intervals (figure 3). At six months and one 
year from onset, and then at yearly intervals, a follow-up CRF will be completed in clinic. A 
telephone interview will also be conducted at the same frequency to ask if the patient has 
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had a clinical relapse or hospital admission and to provide an opportunity to ask questions. 
Any significant concerns will be referred back to the GP or clinician in charge. 
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Patient recruitment and consent 
Based on an expected incidence of 1-2/100,000 children, each Centre is expected to recruit 
approximately 10-15 cases/year over the 5 year length of the study, with a minimum of 6 
months follow up. Children with CNS Inflammatory Demyelination are seen by Paediatric 
Neurologists with an interest in CNS Demyelination to provide expertise in diagnosis and 
management. Patients usually present to Neurologists’ attention via the following routes: 
- Presentation directly to Tertiary Centre 
- Referral from Paediatric DGH Consultant for admission or an outpatients opinion 
- MRI scans referred to weekly Tertiary Centre Neuroradiology meeting for an opinion 
(permission to approach the clinician for referral will be obtained).   
- Shared care or outreach clinic 
 
Patients will be ascertained via these available methods, and given or sent information 
leaflets before being consented (minimum 24 hours) to take part in the study. A website 
(www.childdemyelination.org.uk ) is set up to provide newsletters and information regarding 
study progress, and up to date information on management directed at Paediatricians. If the 
patient or carer requests referral, normal clinical follow up patterns of care will be followed. 
 
Currently in 7 centres, PIs will obtain consent from families presenting to their centres. The 
Paediatric Research Nurse at each site (0.1 WTE at each site, except lead Centre 
[Birmingham] to have 0.3 WTE) or the Research Fellow (Dr M Absoud) may also approach 
families directly to obtain consent. Appropriate agreements and contracts will be in place for 
the Research Fellow and Nurse as recommended by the National Institute for Health 
Research. Patients will be asked to consent to: 
- Taking part in the study and longitudinal follow up via The National Health Service 
Information Centre [Medical Research Information Service (MRIS)] 
- Storage of Samples (CSF, DNA, serum) 
- Obtaining MRI copies and information from Hospital notes  
- Sharing an anonymised dataset with the International Paediatric Study MS Group. 
 
Data Collection and Outcome assessment 
 
Data collection will take place at recruitment, 6 months after initial event, annually after 
initial event, and during clinical relapses (see Figure 3). Clinical follow ups for patients 
affected with CNS inflammatory demyelinating diseases will be part of clinical care, and no 
extra hospital visits will be required. Children and parents/carers will be able to fill in 
questionnaires from a secure online programme (Healthtracker TM). Access to a computer 
with privacy will be made accessible if needed during clinic visits. The Research Nurse will 
make contact with the family at the designated follow up times, to ensure they understand 
the research, ask about any relapses or investigations the child might have had, and discuss 
further queries.  
 
The primary outcome measures will be (1) if the patient developed a clinical relapse, and (2) 
a diagnosis MS. Secondary outcome measures will include: Patient reported and proxy 
Quality of life, disease impact, neuropsychiatric & fatigue symptoms, conceptual & social 
adaptive behavioural functioning skills, MRI criteria, and objective EDSS disability scores (ie. 
EDSS>5.5, patient unable to walk without aid). 
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Case Report Forms (CRFs):  
 
The CRFs have been adapted with permission after consultation with the International 
Group. The initial CRF (first episode) will be completed by the PI, the Research Fellow, or the 
Research Nurse with assistance from the PI. A condition specific targeted neurological 
history (using a check box questionnaire) would take place at the time of first demyelinating 
event. The event would be classified as either ADEM, CIS, or MS (see case definition).  Data 
collected can broadly be categorised to: 
 
a. Basic demographic data (ethnicity, place of birth, current residence)  
b. Family history of MS or autoimmune disease 
c. Demyelinating symptoms and signs (using tick box table) 
d. Presence of behavioural disturbance or encephalopathy (to distinguish ADEM from 
CIS) at time of demyelinating event. 
e. Information which might predict the subsequent development of recurrent ADEM, 
multiphasic ADEM, or MS, like details of the anatomic distribution (optic nerve or 
spinal cord, monofocal or multifocal distribution), CSF findings, serological and 
neuroimaging results.  
f. Treatment (eg, steroids, immunoglobulins, intensive care) given.  
g. Information as to whether the risk of future MS was given to the family. 
h. Neurological examination, Kurtze EDSS scales, and functional status. 
 
For 6 month and annual outcome data, follow up information will be obtained on 
neurological function and further demyelinating events (if these have occurred). We aim to 
collect 90% data within a window period of one month on either side of the designated 
follow up periods. 
 
 
 
Healthtracker®; patient self report and proxy outcomes 
 
PUDDLS will use Healthtracker® which is a sophisticated, user-friendly, UK, and web-based 
assessment system launched with Department of Health support in 2008. It comprises a 
suite of questionnaires and test games for children and their carers, and not for investigator 
use. These allow accurate measures of change across a wide range of symptoms, side-
effects, psychological functions and quality of life. Assessments can be home-based for 
convenience and lower costs. This helps circumvent the many practical difficulties associated 
with long-term assessment of chronic diseases.  
 
Health related Quality of Life (QOL) 
- Generic QOL: Paediatric Quality of Life Inventory TM; 
Generates physical, psychological, and total score. 
o Self report for ages 5-25 years. 
o Parent report for ages 2-25 years. 
- Disease specific QOL: Multiple Sclerosis Impact Scale-29 version 2 (MSIS-29 v2) 
Generates physical, and psychological scores. 
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o Self report for children 5 years -adulthood 
o Parent report. 
 
Fatigue 
- Paediatric Quality of Life Inventory TM; Multidimensional Fatigue Scale 
o Self report for children 5-25 years 
o Parent report; for children 2- 25 years 
 
Neuropsychiatric Symptoms   
- Profile Of Neuropsychiatric Symptoms (PONS)  
o Self report for children 5-16 years 
o Parent report 
 
Functioning ; Adaptive behavioural skills 
o Adaptive Behaviour Assessment System II (ABAS II).  
- Parent report for children 5 years –adulthood. Two out of the three domains will be 
used: 
(iii) Conceptual skills: communication, functional academics, and self-
direction skills areas 
(iv) Social skills: Social, and leisure skills areas 
 
Cognitive   
o Two Healthtracker online games played by children aged 5-16 years that aim 
to measure memory, attention and concentration. These are embedded in 
between questionnaires. 
o Online D2 test game for participants aged 9 years- 60 years. The D2 Test 
measures processing speed and quality of performance of individuals, 
allowing for a neuropsychological estimation of individual attention and 
concentration performance.  
 
Environmental Questionnaire: 
 
One off telephone interview (30-45 minutes) with parent/carer to be conducted during 
study period within three months of disease onset if direct hospital contact whilst inpatient 
has not been achieved. Only once further funding is gained, case controls for administering 
only the environmental questionnaire will be ascertained via a 'buddy system' to the child 
who is age and sex matched. No other involvement of controls will be required. 
 
MRI criteria: 
 
Routine patient MRIs will be collected in order to apply proposed criteria (such as McDonald, 
KIDMUS) that the study team can validate against PUDDLS outcomes.  Data will be collected 
using a standardised data collection performa with agreed definitions designed by Neuro-
radiology collaborators (available on request). MRIs will be randomly evaluated by one of 
four Neuroradiologists blinded to presentation and clinical features. Inter-rater reliability will 
be assessed.  
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Biobank sample collection: 
 
Samples and Procedures: 
Additional informed consent will be obtained to store sera, DNA, and CSF collected during 
routine clinical care at first onset of a CNS demyelinating event, and then at future hospital 
visits if clinical relapses occur. This will be done in accordance with the Human Tissue Act 
(HTA, 2004). Currently designated laboratories in each of the seven establishments hold 
appropriate HTA licences and would be responsible for storage: 
(http://www.hta.gov.uk/licensingandinspections/listoflicensedestablishments.cfm ) 
1. Alder Hey Children’s NHS Foundation Trust 
2. Birmingham Children's Hospital 
3. Frenchay Hospital 
4. Great Ormond Street Hospital 
5. Guy's & St Thomas' Hospitals, Cellular Pathology 
6. John Radcliffe Hospital 
7. Nottingham University Hospitals NHS Trust 
Sample collection, transport and storage will be undertaken using standard SOPs and be 
based at collaborating centres as appropriate.  
 
There will be no additional venepuncture or lumbar puncture procedures for the child 
beyond those required for routine clinical care. Informed consent will be required, for extra 
volumes to be collected during these procedures for the study. Residues of CSF and blood 
already taken as part of the clinical management of the patient, will also be used for future 
research investigations and to supplement the specimen archive. For each patient at least 
one CSF sample and two blood samples will be required. Clinicians will be encouraged to 
follow existing guidelines for the investigation of CNS demyelinating disorders (17,18) and as 
updated in the future 
 
Confidentiality 
Samples will be stored pseudoanonymised in HTA approved labs, and linked with the clinical 
data by the unique PUDDLS number. Any information that is likely to identify participants 
(such as name, address, date of birth) will be removed from samples. Personal identifiers are 
kept separately under strict control with restricted access in secured cabinets, at the 
Institute of Child Health, Birmingham Children’s Hospital in a secure locked area. Access to 
data is limited to the Chief and Principal Investigators. The study administrator at 
Birmingham Children’s Hospital will ensure pseudo-anonymous tracking of the samples, 
solely for the purposes of linkage once they are collected as informed by the Principal 
Investigator. The location, nature and date of samples will be recorded on the database 
  
Future research 
Separate funding will be sought for the biological/genetic sample studies and a further five 
year longitudinal follow up, once sufficient samples and clinical data has been collected.  The 
details of the studies are beyond the scope of this protocol but we have identified future 
potential studies of sufficient scientific validity to ethically justify the storage of human 
samples. Collaborations with international experts and leaders in the field will maximise 
yield of investigations, and ensure a thorough review process: 
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The PUDDLS Biological Studies Steering Group will consider any future studies, and follow 
the agreed guidelines for study selection (available on request). Once studies are deemed of 
sufficient quality, and depending on the strand of study the group will collaborate with the 
experts in their fields and with the International Paediatric Multiple Sclerosis Study Group 
(IPMSSG) 
 
Expected Numbers:    
 
Based on an expected incidence of 1-2/100,00 children, the expected recruitment over the 
initial 5 year study period is 400-450 cases (12-13/year in every Centre). 
 
 
Statistics and data analysis 
  
Descriptive statistics (with confidence intervals where appropriate) will be used to 
summarise the key components of the database. Univariate associations between potential 
prognostics factors and potential confounders and with MS diagnosis or other CNS 
demyelinating episodes; outcomes. These associations will be further explored in logistic 
regression models that will allow for control of confounding factors. Factors associated with 
early occurrence of second episodes will also be explored and Cox models will be used if the 
proportional hazards assumption is met. Life table analysis methods will be used to calculate 
primary outcome time points. SPSS (v.17.0) statistical software will be used for data analysis. 
 
 
 
 
 
Research and development procedures 
 
Research & Development (R&D) approval from each participating NHS Trust will be obtained 
prior to recruitment. Principal investigators will follow rules of data protection ethics and 
confidentiality 
 
Longer term follow up: 
To ensure that long term outcomes of childhood demyelinating disease can be identified by 
flagging patients with their consent via the NHS Information Centre (MRIS) and NHS Central 
Register which will allow them to be traced in the future via their G.P.s. We will consent 
patients for long term follow-up. 
 
 
 
Data Handling and Integrity 
 
 Each patient enrolled will be assigned a unique PUDDLS study identification number. 
This number will be used in all future correspondence between the study centre and 
principal investigators. 
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 Principal investigators will be responsible for the security of data at each local site 
according to their employing authorities’ rules and regulations.  Investigators will 
ensure that the study is conducted and data are generated, documented and 
reported in compliance with the protocol, and applicable regulatory requirements. 
 
 Patient identifiable information (name and address) will be sent to the study office 
on only one occasion (initial case report form) by secure fax. The original signed 
consent form to participate in the study will be kept in the patient’s medical records 
unless required otherwise by local regulations, and a copy kept securely in the site 
file. 
 
 At the central study office (ICH, Birmingham Children’s Hospital), all patient 
identifiable study data will be stored in locked filing cabinets. Identifiable patient 
data will be separated from the clinical data and linked with a unique study code. 
Clinical data used for research may also include patient identifiable data, e.g. date of 
birth, sex, that are also important for the data analysis, linkage during follow up, and 
to answer the research questions. These cannot be removed from the questionnaire 
and will be stored for 30 years in secure archives (MRC guidelines). Only pseudo-
anonymised clinical data only will be entered into the electronic study database for 
analysis. Case report forms will be kept in the site file in a secured locked cabinet, 
and a copy will be sent to the Central study office at the Institute of Child Health, 
Birmingham Children’s Hospital.  
 
 Database Information 
(i)       Clinical Information 
The research nurse, data administrator, and/or the research fellow will enter and maintain 
the clinical information for all study participants from within the Institute of Child Health 
(ICH), Birmingham Children’s Hospital. The database will be anonymised. CRFs will be sent to 
the study team on paper. This has the added benefit of providing consistency of data entry, 
allowing for more complete and accurate set of data for long term analysis. This database 
will use the PUDDLS code only. The data base will be password protected, backed up by the 
ICH server backup daily, and encrypted for added protection. The database will be accessed 
according to Trust policies and procedures. 
 
(ii) Healthtracker TM  
Healthtracker is hosted with Rackspace on a single server running the Microsoft Windows 
Server 2003 Standard Edition operating system. Rackspace ensures the server is 
continuously updated and has all the latest service packs and security patches. The server 
itself houses a Dual-Core AMD Opteron processor running at 2.20 GHz with 4.0 GB of RAM. It 
has three 73GB SCSI hard drives in a RAID 5 configuration offering 140GB of usable storage. 
The server acts as both the web and database server running Internet Information Services 
(IIS) and SQL Server 2005 Standard Edition. 
 
Both the admin and non-admin websites use SSL 128bit encryption to ensure data is securely 
encrypted between requests. The websites are written in C# and run under the Microsoft 
.Net 2.0 framework. HTML and cascading style sheets are used in both sites to apply 
common styling. All database transactions are performed via stored procedures (there is no 
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in-line SQL). Flash is used to provide some questionnaire and game content to the child 
portion of the non-admin website. XML web services are used to send and receive 
information to and from these components. All data in the system is stored in a single SQL 
Server database and therefore can be exported in any format facilitated by SQL Server. 
Alternatively custom exports can be written. 
 
Healthtracker (HT) Results are generated in real time and can reflect symptom 
trends/treatment efficacy/or changes over time. The program has been designed with the 
ability to analyse large amounts of longitudinal data with inbuilt real-time Bayesian/Neural 
Net algorithms. This system allows testing of hypothesis as new data comes in. The online 
presentation of HealthTracker has already meant that rapid acquisition of data for norming, 
or comparing new measures with existing ones is possible. Non-linear mixed effects 
modelling will be used to generate estimates of expected recoveries. Data from HT will also 
be exported via an excel spreadsheet for the research team to analyse.  Item analysis of 
questionnaires will be via Rasch analysis, utilising the WINSTEPS TM statistical software. 
 
 
 Data protection, security and confidentiality will be implemented according to the UK 
Data Protection Act 1998 and each Trust's own Information Governance Policy.  
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LIST OF ABBREVIATIONS 
 
ADEM: Acute Disseminated Encephalomyelitis 
CNS: Central Nervous System 
CIDD: CNS Inflammatory Demyelinating Disease 
CRF: Case Report Form 
CSF: Cerebrospinal Fluid 
EDSS: Expanded Disability Status Scale 
Health Tracker®: A web-based assessment system which comprises a suite of questionnaires 
and test games for children. These allow accurate measures of change across a wide range of 
symptoms, side-effects, psychological functions and quality of life. Assessments can be 
home-based for convenience and lower costs. 
HTA: Human Tissue Act 2004  
(http://www.opsi.gov.uk/acts/acts2004/ukpga_20040030_en_1 ) 
IPMSSG: International Paediatric Multiple Sclerosis Study Group 
Life-H: Assessment of Life Habits Questionnaire 
MCRN: Medicines for Children Research Network 
MRIS: Medical research Information Service. 
MS: Multiple Sclerosis 
MSIS-29: The Multiple Sclerosis Impact Scale; Parent report version 
NIHR: National Institute for Health Research 
NMO: Neuro-myelitis Optica 
ON:  Optic Neuritis 
PedsQL: Paediatric Quality of Life Inventory TM 
PUDDLS: Paediatric UK Demyelinating Disease Longitudinal Study 
SDQ: Strengths and Difficulties Questionnaire 
SOP: Standard Operating Procedure  
TM:  Transverse Myelitis  
UCID-SS: UK and Ireland Childhood Inflammatory Demyelination Surveillance Study 
UKCRN: UK Clinical Research Network 
UKCNRC: UK Children's Neurological Research Campaign; Provides neurology network and 
study management support. 
WTCRF: Wellcome Trust Clinical Research Facility 
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5. Cochrane’s RevMan v5.1 and NQuery metanalysis and sample size estimations 
using data from the TRANSFORMS and FREEDOMS trials. 
 
TRANSFORMS 
Annualised relapse rate for Active Comparator= 0.33 (SD 0.9) n=431 
Annualised relapse rate for Fingolimod= 0.18 (SD 0.5) n=854 
FREEDOMS: 
Annualised relapse rate for Placebo= 0.40 (SD 0.8)   n=418  
Annualised relapse rate for Fingolimod=  0.17   (SD 0.5)   n=840 
 
Figure 1: To conduct an active RCT as in TRANSFORMS and assuming a similar risk ratio 
(0.62) for relapse in the study period and a similar event number, a sample size (equal 
numbers in both arms) of 436 children is required (power 80% and alpha 5%).   
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Figure 2:  
sample size for a placebo RCT with same assumptions is n=134 
 
 
 
Figure 3: If the event rate is higher in children than in adults (eg. by 50%) the required 
sample size for an active RCT is n=248 
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Figure 4: Assuming that MS is the same in adults as in children so that adult data is 
considered replicable in children but additional paediatric data is collected to perform a 
planned metanalysis of the TRANSFORMS + FREEDOMS + paediatric RCT,  the calculated 
sample size is n=183 (121 experimental arm; 62 active arm).   
 
 
 
 
Figure 5: Annualised relapse rate: Fingolimod vs Placebo and Avonex- Rate ratio (Generic 
inverse variance) 
 
 
 
 
Figure 6: Annualised relapse rate: Fingolimod vs Placebo and Avonex- Mean Difference 
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Figure 7: Disability Progression (3 months): Fingolimod vs Placebo and Avonex 
 
 
Figure 8: New or enlarged T2 lesions: Fingolimod vs Placebo and Avonex 
 
 
 
 
Figure 9: New T2 lesions mean difference
 
 
 
 
Figure 9: New GAD lesions: Fingolimod vs Placebo and Avonex 
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Figure 10: Brain Volume: Fingolimod 0.5 vs Placebo and Avonex 
 
 
 
 
 
 
Table 1: Sample size calculation based on MRI: 
 
Mean(SD) new or enlarged lesions on T2-weighted images for (TRANSFORMS data): 
Interferon B1a mean (SD): 2.6 (5.8)- n=431 
Fingolimod 0.5mg mean (SD): 1.7 (3.9)-  n=429 
Using a two group Satterthwaite t-test with two sided α of 0.050: 
Total estimated sample size=564 (282 in each group) will have 80% power to detect a 
difference in means of 0.9  
Using the negative binomial distribution assuming a relatively conservative inflation of the 
variance over the mean by a factor of 2 (dispersion parameter (k) of 2: 
A total estimated sample size=430 (215 in each group) will have 80% power to detect a 
difference in means of 0.9 new lesions. 
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6. Sample size calculations for childhood studies in multiple sclerosis and transverse 
myelitis 
 
Table 1:  RCT sample sizes based on relapse rate during the first year after CIS; data in 
Chapter 3.3. Sample sizes calculated using negative binomial model with an estimated 
dispersion Index (k) = 0.9 
 
Based 
on 
baseline 
relapse 
rate  
Number of 
new relapses 
in 1 year in 
active 
comparator 
(30% 
efficacy) 
Number of 
new 
relapses in 
1 year in 
oral drug 
(50% 
efficacy)  
Total 
sample 
size 
required 
for 80% 
power / 
binomial 
Total 
sample 
size 
required 
for 90% 
power/ 
binomial 
Total 
sample 
size 
required 
for 80% 
power / 
T-test 
Total 
sample 
size 
required 
for 90% 
power/ 
T-test 
1.15  0.805 0.575  658 886 594 796 
0.85 0.595 0.425 804 1082 1088 1456 
0.60 0.42 0.3 1036 1384 2182 2920 
 
 
Dispersion parameters (k) calculated manually using STATA v10 negative binomial distribution 
function. 
Study Data (n= sample 
size) 
Dispersion 
parameter (k) 
Lower 95% CI Upper 95% CI 
Absoud thesis (n=38) 0.68 0.38 1.21 
Fingolimod 0.5mg 
TRANSFORMS(n=429) 
0.80 0.24 2.70 
Avonex 
TRANSFORMS(n=431) 
1.13 0.66 1.93 
k - This is the estimate of the dispersion parameter. If the dispersion parameter equals zero, 
the data reduces to the simpler poisson distribution. If the dispersion parameter, k, is 
significantly greater than zero than the data are over dispersed.  
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Sample size and power analyses details for proposed TM trial 
The primary intention to treat analyses will compare the control arm verses the intervention 
arm at 24 weeks post-randomisation. Allowing for 10% attrition (n=18), an overall sample 
size of 188 participants, 94 in each group, (randomised 1:1 to control arm: intervention arm) 
would provide 90% power to detect a 25% difference in the proportion of 2 point 
improvement or greater on the ASIA scale for the control verses intervention comparisons.  
Note: this equates to an effect size of 0.500, as a secondary outcome I will consider the total 
motor score as a continuous measure (0-100). There will be 90% power to detect a 
difference between the control and treatment arms of a minimal effect size of 0.5.  The 
Fleiss with continuity correction formula and method was used to calculate sample size and 
assumptions (openepi software version 2·3·1, www.openepi.com) (201). There is little 
evidence in acute transverse myelitis to summarise this is terms of variance and mean 
location. As a working example I believe that a 20 point difference will be of clinical 
significance. This trial has 90% power to see a difference between the control and 
intervention arms of 20 points or great , considering a pooled standard deviation as variable 
as 40.  
The significance level will be 5% (2-sided) for main and secondary analyses. Estimates and 
confidence intervals will be needed for differences over treatment groups. Sensitivity 
analyses will assess the robustness of conclusions to missing outcome data and to 
departures from randomised treatment.  
Analyses of effectiveness will be pragmatic, based on the intention-to-treat sample, and 
utilising all available follow-up data from all randomized patients. The models will include 
covariates; treatment group (control or intervention) and the stratification factors site and 
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status (adult or child). Where outcome variables have a baseline measure, this will be 
controlled for in the associated outcome analyses to allow for pre treatment differences.  
 
All analysis will be repeated considering status (adult or child) as a moderator and interacted 
will treatment group (control or intervention), allowing estimates of treatment effect in the 
adult and child populations to be summarised. 
 
The main objective of the statistical analyses will be to assess the effect of the intervention 
model on the primary outcome. Herein I will dichotomise the participant population in to 
those who are responders (a 2 point improvement or great from baseline on the ASIA scale) 
and non-responders.  A generalised linear mixed-effects model will be utilised for the 
analyses, specifying a logistic regression.   
There is expected to be missing data in the post treatment outcomes variables, as 
participants discontinue treatment and drop out of the study (lost to follow- up). The LMM 
analyses are based on maximum likelihood and will provide valid inferences under the 
missingness mechanism; missing at random (MAR).  
Treatment effects on secondary outcomes will be also using a LLM, specified in the same 
way as the primary model, using generalisations of the linear mixed model to allow for non-
normal data where necessary.  
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